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Introduction. 
The epigenetic of human cancer has always been in the shadows of human cancer genetic but 
this area has become increasingly visible with a growing understanding of specific epigenetic 
mechanism.  
If the disruption of the balance of epigenetic networks can cause several major pathologies, 
including cancer and syndromes involving chromosomal instabilities and mental retardation, 
great potential lies in the development of “epigenetic therapies”: several inhibitors of enzymes 
controlling epigenetic modifications, specifically histone deacetylases, have shown promising 
anti-tumorogenic effects for some malignancies. 
 
 1. Epigenetics. 
Many phenomena suggest that gene expression is not determined solely by the DNA code 
itself. Instead, as it is now well known by cell and molecular biologists, this activity also 
depends on a host of so-called epigenetic phenomena-defined as any gene-regulating activity 
that does not involve changes to the DNA code and that can persist through one or more 
generations. Specifically, the most current interpretation of epigenetics combines the concept 
of changes in gene expression and the implication of mitotic inheritance with the use of DNA 
as a reference point and the implication of generational, including meiotic, inheritance to give 
rise to the current, and most widely accepted definition: the study of changes in gene function 
that are mitotically and/or meiotically heritable and that do not entail a change in DNA 
sequence.1,2 
Although the mechanismof inheritance for epigenetic modifications has yet to be identified, 
themost important difference between an epigenetic mechanism and a genetic mechanism is 
that the epigenetic changes can be reversed by chemical agents.3 Over the past 10 years, 
researchers have shown that gene activity is influenced by the proteins that package 
theDNAinto chromatin, the protein–DNAcomplex that helps the genome fit nicely into the 
nucleus; by enzymes that modify both those proteins and the DNA itself; and even by RNAs.4 
As we will see in detail below, the two major mechanisms, sometimes strictly interdependent, 
in the epigenetic regulation of genes involve changes in the structure (remodeling) of 
chromatin, through covalent modifications of histone proteins and DNA methylation. These 
mechanisms have an important role in biological research and affect many different areas of 
study including cancer biology,5,6 viral latency,7–10 activity of mobile elements,11 somatic 
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gene therapy,12–17 cloning and transgenic technologies, shutting down of one copy of the X 
chromosome that occurs in female mammals,18 genomic parental ‘‘imprinting’’ (in which a 
gene’s activity depends 
on whether it is inherited from the mother or the father),19 and developmental abnormalities.19 
Now, some researchers are beginning to investigate whether subtle modifications to the 
genome that do not alter its DNA sequence (i.e., epigenetic changes) may also underline 
common diseases such as diabetes, obesity, heart disease, and a host of psychiatric disorders 
like manic depression and schizophrenia. Many features of these conditions, such as the 
differences between pairs of twins in which only one suffers from schizophrenia,20 cannot be 
explained readily by DNA-sequence variation. Although some psychiatric disorders seem to 
run in families, the chance of succumbing depends in some cases on whether this story is on 
the mother’s or the father’s side, suggesting that parental imprinting is involved. Moreover, in 
the mentioned case of twins, substantial differences in their patterns of DNA methylation 
have been found.20 Some factors, such as lifestyle and diet, undoubtedly influence human 
susceptibility to disease and there is mounting speculation that they leave a trail of epigenetic 
footprints across human genome.21 Furthermore, some researchers argue that changes in diet 
could activate certain biochemical pathways that leave an epigenetic imprint that is passed to 
the next generation too.22,23 Now, the emerging evidence that epigenetic changes can be 
inherited, make it possible to argue that similar modifications, and not just mutations in DNA 
sequence, could lie at the root of inherited diseases.24,25 
 
2. DNA methylation. 
The best-known epigenetic signal is DNA methylation, which tags cytosine, one of the four 
chemical bases that make up the genetic code, with a methyl group at C5-pyrimidine position. 
Recent advances have led to the cloning and preliminary characterization of the three known 
active DNA cytosine methyltransferases (DNMT 1, 3a and 3b).26,27  
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 Figure 1. A methylating enzyme binds to its target site on DNA. 
 
This post-synthetic addition’s reaction alters the appearance of the major groove of DNA to 
which the DNA binding proteins bind. These epigenetic ‘‘markers’’ on DNA can be copied 
after DNA synthesis, resulting in heritable changes in chromatin structure. The sites of almost 
all methylation in mammals are the so-called CpG islands, regions of DNA where the bases 
cytosine and guanine alternate with one another (Fig. 1). These islands are often found in 
association with genes, most often in the promoters and first exons but also in regions more 
toward the 3’ end.28 Methylation of CpG-rich promoters is used by mammals to prevent 
transcriptional initiation and to ensure the silencing of genes on the inactive X chromosome, 
imprinted genes and in the long-term silencing of non-coding DNA in the genome, which 
contains a very substantial portion of repetitive elements (parasitic DNAs). The potential role 
of methylation in tissue-specific gene expression or in the regulation of CpG-poor promoters 
is less well established. There is also tantalizing evidence that normal chromosome structure 
may be affected by methylation and that human diseases, including cancer, are caused and 
impacted by abnormal methylation. Although it is often said that ‘‘methylation blocks gene 
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expression,’’ this statement is an oversimplification. Methylation changes the interactions 
between proteins and DNA, which leads to alterations in chromatin structure and either a 
decrease or an increase in the rate of transcription, depending on whether positive or negative 
regulatory elements of the genes are involved. Especially, methylation of a promoter CpG 
island leads to binding of several proteins (methylated CpG binding proteins MBD 1, 2, 3, 
and methylated DNA binding protein MECP 2), which can recruit HDACs and other 
transcriptional repressors to form tightly condensed chromatin structures and so to block the 
transcription initiation because the transcription factors (TFs), which normally regulate gene 
expression, are not able to access the promoter.29,30 On the other hand, methylation of 
silencer31,32 or insulator33 elements blocks the binding of the cognate binding proteins, 
potentially abolishing their repressive activities on gene expression. Cytosine methylation is a 
major contributor to the generation of disease-causing germline mutations34 and somatic 
mutations that cause cancer.35 Moreover, recent works have shown that the abnormal 
methylation of the promoters of regulatory genes causes their silencing or overexpression, and 
it is a substantial pathway to cancer development and of comparable importance to gene 
mutations for the initiation and propagation of carcinogenesis. Many tumor suppressor genes, 
that are inactivated in particular tumor types, have highly methylated promoters; under normal 
conditions, the promoter regions are unmethylated and the relative genes are transcribed.36–42 
Some studies have also shown low DNAmethylation of proto-oncogenes in various human 
cancer cells.43–46 As underlined above, the integration of DNA methylation with chromatin 
organization and the regulation of histone acetylation and deacetylation may be an important 
part of the overall carcinogenic effect. The links between DNA methylation and histone 
modifications have encouraged some researchers to investigate about dual therapies 
combining DNA methylation inhibitors (i.e., 5-azacitidine) with HDAC inhibitors (see 
below).47–50 The molecular mechanisms of how hypermethylation of promoter regions 
participate in gene silencing and how loss of methylation alters chromosome structure are not 
fully elucidated yet. However, these epigenetic changes are potentially good therapeutic 
targets because of their reversibility and as tumor biomarkers may also be very useful for 
monitoring of the onset and progression of cancer.51 
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3. Chromatin remodelling. 
Another very important mechanism in the epigenetic regulation of gene expression is the 
chromatin remodelling.  
Indeed, all of the human genome is packaged into chromatin, which is a dynamic 
macromolecular complex that consists of DNA, histones and non-histone proteins.52 
Distinct levels of chromatin organization are dependent on the dynamic higher order 
structuring of nucleosomes, which represent the basic repeating units of chromatin.  
In each nucleosome, roughly two super-helical turns of DNA containing about 146 base pairs 
wrap around an octamer of core histone proteins formed by four histone partners: an H3-H4 
tetramer and two H2A-H2B dimers.53  
 
 
Figure 2. Nucleosomes. 
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Figure 3. DNA wrapped around histones H3 
and H4 (a), H2A and H2B (b). 
 
Histones are small basic proteins consisting of a globular domain and a more flexible and 
charged NH2-terminus (so called histone ‘tail’) protruding from the nucleosome.  
How the nucleosomal arrays containing the linker-histone H1 could twist and fold this 
chromatin fiber into increasingly more compacted filaments, leading to defined higher-order 
structures, is still unclear. 
Certainly, H1 plays an important role in determining the level of DNA condensation, 
stabilizing the higher-order folding by electrostatic neutralization of the linker DNA segments 
through a positively charged carboxy-terminal domain.  
So, this dynamic higher-order structure of nucleosomes defines distinct levels of chromatin 
organization and, subsequently, gene activity . 
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In general, condensed chromatin (also called “heterochromatin”) mediates transcriptional 
repression, whereas transcriptionally active genes are in areas of open chromatin (so called 
“euchromatin”).54  
 
 
Figure 4. Heterochromatin (condensed or closed chromatin) and 
euchromatin (open chromatin). 
 
An oversimplified view is that trans-acting, DNA-binding transcription factors have greater 
access to naked DNA in an open chromatin conformation compared with a condensed 
conformation.  
However, it is important to remember that nucleosomes are not static, and their dynamic 
nature, allowing nucleosomal DNA to transiently unwrap and rebind the histone octamer, can 
give transcription factor access to DNA, albeit at various rates. 
Nuclear histones, once thought as static, non-participating structural elements, are now known 
as integral and dynamic components of the machinery responsible for regulating not only 
gene transcription, but also other DNA-templated processes such as replication, repair, 
recombination and chromosome segregation.  
An extensive literature shows an elaborate collection of post-translational modifications 
including acetylation, phosphorylation, methylation, ubiquitylation and ADP-ribosylation that 
take place on the ‘tail’ domains of histones.54-56  
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Figure 5. Covalent modifications of amino-terminal tails of 
core histones. A, acetyl; C, carboxyl terminus; E, glutamic 
acid; M, methyl; N, aminoterminus; P, phosphate; S, 
serine;Ub, ubiquitin. 
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Figure 6. Reversible status of histone modifications. 
 
These tails, which protrude from the surface of the chromatin polymer and are protease 
sensitive, comprise ~25-30% of the mass of individual histones,57 thus providing an exposed 
surface for potential interactions with other proteins.58,59 
Specifically, the tail of histone H4 appears to extend into the adjacent nucleosome to interact 
with the H2A-H2B complex, thereby indicating that the histone tails might regulate higher-
order chromatin structure.53  
Histone tails of H3 and H4 particularly are targeted for the mentioned covalent modifications.  
These modifications performed by histone acetyltransferases (HATs), deacetylases (HDACs), 
methyltransferases (HMTs) and kinases (HKs) offer a mechanism by which upstream 
signalling pathways can converge on common targets to regulate gene expression.  
Infact, it has been proposed that there is a ‘histone code’ or ‘epigenetic code’ defined by the 
modifications that regulate the transcriptional activity of specific genes.60-63  
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The hypothesis is that the multiprotein complexes of transcription factors that activate or 
repress gene expression ‘read the code’.  
Specifically, there are mounting evidences that distinct histone amino-terminal modifications, 
on one or more tails, can act sequentially or in combination and generate synergistic or 
antagonistic interaction affinities for chromatin-associated proteins, which in turn dictate 
dynamic transitions between transcriptionally active (euchromatic) or silent (heterochromatic) 
chromatin states. 
The combinatorial nature of these modifications seems to reveal that the histone code 
considerably extends the information potential of the genetic (DNA) code.  
In the attempt to understand rules and consequences of this novel code, it is of capital 
importance to identify and to characterize the enzyme systems that add or subtract these 
modifications. 
 
4. Histone phosphorylation. 
Histone phosphorylation involving Ser-10 of histone H3 (the reaction is catalyzed by Aurora 
B kinase) has also emerged as an important modification, both in transcriptional activation 
and in chromosome condensation during mitosis.  
As chromosome condensation and transcription are expected to involve opposing physical 
alterations of chromatin (i.e. closing of chromatin during mitosis and opening during 
transcription), the finding that the same modification is involved in both processes is 
circumstantial support for considering these modifications as binding surfaces rather than 
direct alteration of chromatin. 
In fact as the outcome of histone modifications has been examined, two non-exclusive models 
have emerged. One is that histone modifications affect chromatin structure directly.  
The second model is that modifications present a special surface for interaction with other 
proteins. Either model can be reconciled with the “histone code hypothesis”, both may operate 
simultaneously, and both have great explanatory power regarding the relationship between 
histone modification and gene control. 
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5. Histone ubiquitylation. 
Two recent developments indicate that histone ubiquitylation is joining the ranks of important 
modifications.  
First, in S.cerevisiae lysine 123 within the H2B carboxy-terminal tail is a substrate for the 
Rad6 ubiquitin ligase. This modification is critical to mitotic and meiotic growth, although it 
is not yet clear whether it is involved in transcription.  
Second, TAFII250 in the TBP-associated complex TFIID has been shown to posses histone 
H1 ubiquitylation activity, adding to its long list of enzymatic activities (kinase and HAT 
ativities), which may be involved in transcription. 
 
Figure 7. Control of chromatin by ubiquitin. 
The ubiquitin (Ub)-conjugating enzyme Rad6 
ubiquitylates lysine 123 (K123) in the core of 
histone H2B. Through an unknown mechanism, 
this modification promotes the methylation of 
another histone, H3, at two positions, lysine 4 
(K4) and lysine 79 (K79). These H3 
modifications, in turn, are required for 
telomeric-gene silencing. In addition, TAFII250, 
which is a component of the general 
transcription factor TFIID, can ubiquitylate the 
linker histone H1; the significance of this 
ubiquitylation is unknown, but it might relate to 
the role of this TATA-binding protein (TBP)-
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associated factor (TAF) in transcriptional 
activation. 
 
6. Histone acetylation status and gene expression. 
Among post-traslational histones mofication, acetylation has been the most studied and 
appreciated.64 The acetylation status of core histones is controlled by the competitive 
activities of HAT and HDAC superfamilies of enzymes.65,66The ε-amino groups of lysine 
residues in the N-terminal regions of histones are substrates for HATs and HDACs.  
 
 
NH3+
S
CH3
O
SH
NH
O
CH3
Histone -Lys-
Coenzyme -A
HAT
Coenzyme -A
Histone -Lys-
HDAC
H20CH3COOH  
Figure 8.  Acetylation/deacetylation reactions on lysine ε-amino groups. 
 
Generally, transcriptionally active genes are associated with highly acetylated core histones 
whereas transcriptional repression is associated with low levels of histone acetylation. Within 
the nucleosome, positively charged hypoacetylated histones are tightly bound to the 
phosphate backbone of DNA, maintaining chromatin in a transcriptionally silent state.  
Acetylation neutralizes the positive charge on histones, disrupting higher-order structures in 
chromatin, thereby enhancing access of transcription factors, transcriptional regulatory 
complexes and RNA polymerases to promoter regions of DNA.  
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Histone deacetylation restores a positive charge on lysine residues of core histones, allowing 
chromatin to condense into a tightly supercoiled, transcriptionally silent conformation.67,68  
Nevertheless, in some cases histone acetylation is involved in transcriptional repression but 
not surprisingly: indeed the ‘histone code’ hypothesis itself offers a possible explanation for 
these situations.69-70 
 
 
 
 
Figure 9.  HAT/HDAC and transcriptional regulation. 
 
 
6.1. Histone acetyltransferase. 
It has been over three decades since Allfrey and coworkers proposed that the acetylation state 
of histones within chromatin influence gene expression. 71 
Despite the time since these initial studies, the enzymes that mediate histone acetylation and 
deacetylation have been identified and characterized only over the past few years. A 
breakthrough came with the cloning of a HAT enzyme from Tetrahymena71, which turned out 
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to be a homologue of the previously identified Gcn5 transcriptional co-activator/adaptor from 
yeast. 
Subsequently, a flurry of studies led to the discovery of numerous HATs that were previously 
identified as transcriptional co-activators, such as the global regulator of transcription, the 
CREB (cyclic AMP response element binding protein)-binding protein (CBP)/p300 (a 300-
kDa protein homologous to CBP), and the TAFII250 TBP-associated factor of the TFIID 
general transcription factor complex. 72 
Proteins that contain HAT modules fall into distinct families. There is high sequence 
similarity within these families, but poor to no sequence similarity between them.The HAT 
families are found in eukaryotes from yeast to humans and include the Gcn5/PCAF 
(p300/CBP-associated factor), CBP/p300, TAFII250/TAFII130, and the steroid-receptor co-
activator (SRC) families, among others. 73 
The size of the HAT module differs between families, and HAT modules themselves occur in 
the context of other conserved protein modules. Moreover, different HAT families seem to 
elicit distinct biological activities. 
For example, the Gcn5/PCAF (p300/CBP-associated factor) HAT family are co-activators for 
a subset of genes, whereas members of the CBP/p300 HAT family are more global activators 
of gene expression. By contrast, some members of the MYST (MOZ, YBF2/SAS3, SAS2, 
Tip60) family of HATs are involved in gene silencing. 
Finally, different HAT families have specific and distinct histone substrate specificities. For 
example, recombinant Gcn5/PCAF family members will preferentially acetylate lysine 14 on 
histone H3, whereas the MYST family members have a preference for several lysines on 
histone H4.  
As well as catalysing histone acetylation, several HATs, including CBP/p300 and PCAF, have 
intrinsic transcription-factor acetyltransferase activity and, in many of these cases, acetylation 
enhances the DNA-binding affinity of the affected protein.  
Despite the differences between the various HAT families, there are some unifying themes.  
First, all of the HAT proteins that have been characterized in vivo are associated with large 
multiprotein complexes. For example, Gcn5 is part of at least two multiprotein complexes, 
Ada and SAGA51, and Esa1, a member of the MYST family of proteins, is the catalytic 
subunit of the histone H4–specific NuA4 (nucleosome acetyltransferase of histone H4) HAT 
complex.  
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Second, although the recombinant proteins can acetylate free histones, nucleosomal 
acetylation occurs only in the context of in vivo HAT complexes, and substrate specificity is 
modulated in the context of these complexes. For example, recombinant Gcn5 preferentially 
acetylates Lys14 on histone H3, but it will also acetylate (to a lesser extent) Lys8 and Lys16 
of histone H4.  
Insights into the histone-binding properties of HAT proteins were revealed in the recent 
structure determinations of the Gcn5/PCAF and Esa1 HAT domains in various ligand-bound 
forms. 73 
A comparison of the HAT domains from the Gcn5/PCAF family, the MYST family (for 
example, Esa1) and the nucleosome-deposition-related HAT, HAT1, reveals structural 
homology within a central core domain that is important for acetyl-coenzyme-A cofactor 
binding and catalysis. Overall, protein regions amino- and carboxyterminal to this core 
domain show structural divergence. 
However, despite the overall structural differences within the amino- and carboxy-terminal 
segments of the three HAT proteins, an α-helix–loop region just amino-terminal to the core 
domain and an α-helix–loop region just carboxy-terminal to the core domain superimpose 
well, indicating a related mode for histone substrate binding. 
The structure of Tetrahymena Gcn5, in complex with CoA and a histone H3 peptide, reveals 
that these structurally conserved regions are indeed important for histone substrate binding. 
Specifically, the structure shows that the 11-amino-acid histone H3 peptide (centred around 
the Lys14 target of histone H3) adopts a random coil structure and is bound in a pronounced 
protein cleft of the Gcn5 protein above the core domain, and flanked on opposite sites by the 
amino- and carboxy-terminal protein segments (figure 10).  
An extrapolation of this result suggests that the core histone-binding scaffold for other more 
sequence-divergent HAT modules might be structurally conserved, whereas the sequence 
divergence within this scaffold might mediate histone substrate binding specificity. 
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Figure 10. Overall structure of HAT domain module. a: Structure of 
the Tetrahymena Gcn5–CoA–histone-H3 peptide complex. The CoA 
cofactor is shown in red and the histone H3 peptide is shown in green. 
The central core domain responsible for CoA binding and catalysis is 
blue. b: Structure of the MYST HAT family member yeast Esa1, bound 
to CoA. Colour coding is the same as in (a). 
 
6.2. Histone deacetylase. 
Eighteen mammalian deacetylase enzymes have been identified to date, and these can be 
divided into two families: the histone deacetylase, properly named HDACs, and the ySir2-like 
deacetylases, or sirtuins (also named class III HDACs).  
The HDAC family members can be divided into two classes based on their primary structure, 
size and similarity to Saccharomyces cerevisiae histone deacetylases: those with homology to 
the yeast’s transcriptional regulator Rpd3 (reduced potassium dependency 3), or class I 
HDACs (HDAC1-3,8,11), and those with greater similarity to Hda1, or class II HDACs 
(HDAC 4-7,9,10).74,75,76  
All of these enzymes possess a highly conserved catalytic domain of approximately 390 
amino acids, and appear deacetylate their substrates by the same Zn2+-dependent mechanism, 
but the class II proteins are two to three times larger in size than the class I proteins (120-130 
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kDa and 42-55 kDa, respectively) and there are certain conserved sequence motifs in the 
catalytic domain that differ between the two classes.150 In addition, based on sequence 
homology among their deacetylase domains, class II can be further divided into two 
subclasses, namely IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and IIb (HDAC6, 
containing as unique feature two homologous deacetylase domains, and HDAC10, more 
similar to HDAC6 than to HDAC4-7 and HDAC9).75-77  
 
     HDAC families. 
HDAC CLASS INTERACTIONS CELLULAR LOCALIZZATION 
 
TISSUE 
EXPRESSION 
 
HDAC1 I 
DNMT1, ATM, BRCA1, 
MECP2, MYOD, p53, pRb, 
NF-kB 
nuclear ubiquit. 
HDAC2 I DNMT1, BRCA1, pRb, NF-kB, GATA2 nuclear ubiquit. 
HDAC3 I pRb, NF-kB nucl/cytopls ubiquit. 
HDAC8 I a-SMA nucl/cytopls ubiquit. 
HDAC11 IV HDAC6 nuclear ubiquit. 
HDAC4 IIa 14-3-3, MEF2, calmodulin shuttling n/c heart, muscle, brain 
HDAC5 IIa 14-3-3, MEF2, calmodulin shuttling n/c heart, muscle, brain 
HDAC6 IIb tubulin, PP1, dynactin, HDAC11 nucl/cytopls testis 
HDAC7 IIa 14-3-3, MEF2, calmodulin shuttling n/c CD4/CD8++thymocytes 
HDAC9 IIa 14-3-3, MEF2, calmodulin shuttling n/c heart, muscle, brain 
HDAC10 IIb PP1, LcoR nucl/cytopls liver, spleen, kidney 
SIRT1 III FOXO, p53, p300 nuclear ND 
SIRT2 III tubulin cytoplasmic ND 
SIRT3 III ND mithocondr. ND 
SIRT4 III ND ND ND 
SIRT5 III ND ND ND 
SIRT6 III ND ND ND 
SIRT7 III ND ND ND 
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Like the class I HDACs, members of class II HDACs function in the context of other protein 
subunits in vivo, and are sensitive to inhibition by TSA, SAHA, and related compounds. 
However, class II proteins appear to interact with a different set of proteins in vivo than class I 
proteins. Indeed, class II HDACs are not part of the above mentioned Sin3-HDAC and 
NuRD-Mi2-NRD complexes, but interact with one or more DNA-binding transcription factors 
including MEF2, BCL6, PLZF and TR2; with transcriptional co-repressors such as N-CoR, 
SMRT, B-CoR, and CtBP, and with the methyllysine-binding protein HP1.78,79 Among these 
interactions, the most studied is that with myocyte enhancer factor 2 (MEF2). Class IIa 
HDACs inhibit MEF2-dependent transcription in reporter gene assay and regulate myogenesis 
in muscle differentiation models in vitro.78-80 Moreover, in HDAC9 nude mice the 
development of age-dependent cardiac hypertrophy has been observed, strongly implicating 
class IIa members as important regulators of myogenesis.81 In addition, class II HDACs differ 
from class I proteins depending on their tissue expression, subcellular localization and 
consequently biological roles. 
Class I HDACs are ubiquitously expressed, whereas class II enzymes display tissue-specific 
expression in humans and mice (for example, human HDAC4 is the most abundant in skeletal 
muscle, modest in brain, heart and ovary, but not detectable in liver, lung, spleen and 
placenta, and HDAC5 is expressed in mouse heart, brain, liver and skeletal muscle but not in 
spleen).78-80 In contrast to class I HDACs, which are mainly nuclear enzymes (except 
HDAC3),82 under different cellular conditions class II HDACs localize either to the cell 
nucleus or to the cytoplasm, depending on their phosphorylation extent and subsequent 
binding of 14-3-3 chaperone proteins. For example, HDAC4 is actively shuttled between the 
nucleus and the cytoplasm in vivo, and phosphorylation and/or overexpression of 14-3-3 
chaperons promote its cytoplasmic accumulation.80  
S. cerevisiae has five sirtuins, including the founding member, Sir2, and four homologues, 
Hst1-4 (homologue of Sir two). Seven sirtuins (SIRT1-7) have been identified in humans. The 
sirtuins family can be divided into five classes, based on their primary structure.83 All the five 
yeast sirtuins are class I proteins, as well as the human SIRT1-3. SIRT4 is a class II sirtuin, 
SIRT5 is in class III, and SIRT6 and SIRT7 are class IV proteins. The sirtuin deacetylases 
contain a conserved 275 amino acids catalytic domain, which is unrelated to that of HDACs 
(classes I and II), and operate by a very different mechanism that requires NAD+ as 
cosubstrate.84 
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Despite these structural and mechanistic differences, proteins from both families have been 
shown to silence transcription at specific promoters or chromosomal domains by localized 
histone deacetylation and function in other cellular processes with non-histone substrates. To 
date, cellular functions have been assigned to only human SIRT1 that has been shown to 
deacetylate p53 at the carboxy terminus and inhibit p53-mediated transcriptional activation 
and apoptosis.85,86 Their subcellular localization is not fully understood but seems that some 
of them are prevalently nuclear and others cytoplasmic.83,87  
6.3. Histone deacetylase family: class I. 
HDAC1 and HDAC2 are highly similar enzymes, with an overall sequence identity of approx. 
82%. The catalytic domain on the N-terminus forms the major part of the protein.  
HDAC1 and HDAC2 are inactive when produced by recombinant techniques, implying that 
cofactors are necessary for HDAC activity to occur. These complexes consist of proteins 
necessary for modulating their deacetylase activity and for binding DNA, together with 
proteins that mediate the recruitment of HDACs to the promoters of genes.  
Three protein complexes have been characterized that contain both HDAC1 and HDAC2: 
Sin3, NuRD (nucleosoma remodelling and deacetylating) and Co-REST. Both the Sin3 
complex (named after its characteristic element mSin3A) and the NuRD complex consist of a 
core complex containing HDAC1, HDAC2, Rb-associated protein 48 (RbAp48, which binds 
histone H4 directly) and RbAp46. In addition to functioning through these complexes, 
HDAC1 and HDAC2 can also bind directly to DNA binding proteins such as YY1 (Yin and 
Yang 1, a cellular nuclear matrix regulatory protein), Rb binding protein-1 and Sp1. 88-92 
In addition to the regulation of HDAC1 and HDAC2 activity by the availability of co-
repressors, a second means of regulating activity is via post-translational modifications. Both 
activity and complex-formation are regulated by phosphorylation. HDAC1 and HDAC2 are 
phosphorylated at a low steady-state level in resting cells. Hyperphosphorylation of HDAC1 
and HDAC2 leads to a slight but significant increase in deacetylase activity, and at the same 
time to disruption of complex-formation between HDAC1 and HDAC2 and between HDAC1 
and mSin3A/YY1. 
When hypophosphorylation of HDAC1 and HDAC2 occurs, the activity of HDAC1 and 
HDAC2 decreases, but complex formation is increased. The apparently contradictory 
consequences of phosphorylation maintain HDAC activity at a certain optimal level. 
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Mutational analysis of HDAC1 shows that Ser-421 and Ser-423 are crucial phosphorylation 
sites; when they are mutated, complex-formation is hampered and HDAC activity is 
decreased.93 
HDAC3 is evolutionarily most closely related to HDAC8, with 34% overall sequence 
identity, and HDAC3 has the same domain structure as all class I HDACs.  
In HDAC1 and HDAC2, the regions that correspond to amino acids 181-333 of HDAC3 are 
very similar to each other (93% identity). However, the corresponding region in HDAC3 has 
only 68% identity with HDAC1 and HDAC2. Surprisingly, the non-conserved C-terminal 
region of HDAC3 is required for both deacetylase activity and transcriptional repression. In 
addition to the nuclear localization signal (NLS) that other class I HDACs possess, a NES 
(nuclear export signal) is also present in HDAC3 (amino acids 180-313).  
The balance between these two signals is probably dependent on cell type and on 
environmental conditions. HDAC3 shares structural and functional features with other class I 
HDACs, but it exists in multisubunit complexes that are different from other known HDAC 
complexes. This could imply that individual HDACs have distinct functions due to their 
complex specificity. 
SMRT (silencing mediator for retinoic acid and thyroid hormone receptors) and N-CoR 
(nuclear receptor co-repressor) are necessary factors for HDAC3 activity. 94 
N-CoR and SMRT are two distinct, but highly related, proteins that share similar domain 
structure and function. Both act as co-repressors, both have a conserved deacetylase-
activating domain for HDAC3 activation. 94 
Of all the class I HDACs, HDAC8 is most similar to HDAC3 (34%identity). HDAC8 consists 
largely of the catalytic domain with an NLS in the centre. 95 Due to its very recent discovery, 
it is not yet known whether HDAC8 function is regulated by a co-repressor complex of 
proteins.  
Recently the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor 
was reported by Vannini et al. 96 Similar to bacterial HDAC-like protein, HDAC8 folds in a 
single α/β domain. The inhibitor and the zinc-binding sites are similar in both proteins. 
However, significant differences are observed in the length and structure of the loops 
surrounding the active site, including the presence of two potassium ions in HDAC8 structure, 
one of which interacts with key catalytic residues. CD data suggest a direct role of potassium 
in the fold stabilization of HDAC8. 
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Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and 
cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell 
proliferation.  
 
 
Figure 11. Ribbon diagram of human 
HDAC8 monomer with α-helices and β-
strands labeled and colored yellow and 
indigo, respectively. The inhibitor is 
drawn in stick representation (Vannini et 
al 96).  
 
From the phylogenetic analysis, it appears that HDAC11 is most closely related to HDAC3 
and HDAC8, suggesting that it might be more closely related to the class I HDACs than to the 
class II HDACs (but in general its overall sequence identity with the other HDACs is limited). 
HDAC11 contains a catalytic domain situated at the N-terminus, with proven HDAC activity 
that can be inhibited by trapoxin (a TSA analogue). HDAC11 was found not to reside in any 
of the known HDAC complexes (Sin3, N-CoR/SMRT), possibly indicating a biochemically 
distinct function of HDAC11. 
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6.4. Histone deacetylase family: class II. 
HDAC4, HDAC5 and HDAC7 are found in the same region of the phylogenetic tree, and 
represent a subgroup within the class II HDACs. HDAC4 and HDAC5 are most similar to 
each other (overall similarity 70%), but HDAC7 is also closely related (58 and 57% overall 
similarity respectively).  
All three HDACs have their catalytic domain on the C-terminal half of the protein, and the 
NLS is situated close to the N-terminus. Binding domains for C-terminal binding protein 
(CtBP), myocyte enhancer factor 2 (MEF2) and 14-3-3 proteins are conserved in all three 
HDACs on the N-terminus.  
Furthermore, HDAC5 has a NES within the catalytic domain, suggesting nuclear/cytoplasmic 
trafficking. HDAC4, HDAC5 and HDAC7 are able to interact with SMRT/N-CoR, and the 
co-repressors BCoR (Bcl-6-interacting co-repressor) and CtBP. The N-termini of HDAC4, 
HDAC5 and HDAC7 interact specifically with and repress the myogenic transcription factor 
MEF2. MEF2 plays an essential role, as a DNA binding transcription factor, in muscle 
differentiation.  
When MEF2 is associated with HDAC4, 5 or 7, the function of MEF2 as a transcription factor 
is inhibited, thus blocking muscle cell differentiation. CaMK activity overcomes this 
inhibition by dissociating the MEF2/HDAC complex due to phosphorylation of HDAC4/5/7.  
Subsequently, transport (along with the cellular export factor CRM1) of the HDAC out of the 
nucleus can occur, illustrating another type of regulation of HDAC activity. Interestingly, 
HDAC4, 5 and 7 associate with HDAC3 in vivo via co-recruitment to the SMRT/N-CoR 
factors in the nucleus, with an absence of HDAC3 leading to inactivity. This suggests that 
HDAC4, 5, and 7 function as a link between DNA-binding recruiters and the HDAC3-
containing HDAC complex. 91 
The subcellular localization of HDAC5 and HDAC7 differs from that of HDAC4 at the 
different stages of muscle cell differentiation. These HDACs might complement each other in 
order to control the differential regulation of gene expression during the various stages of 
differentiation in muscle cells.  
These three HDACs are able to “fine tune” the repression of gene expression due to the need 
for co-repressors for their activity, and even more intriguingly via their ability to change 
localization in response to a specific signal, thus providing a carefully regulated sequence of 
changes in gene expression during differentiation. 91 
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Figure 12. Interaction partners of class IIa histone deacetylases (HDACs). 
Class IIa HDACs interact with several partners through distinct domains. 
The N-terminal domain is used primarily as a targeting domain for distinct 
promoters by the MEF2 transcription factors. Interaction of class IIa 
HDACs with HP1, CtBP and the SMRT/N-CoR and B-CoR co-repressor 
complexes mediates the transcriptional repressive activities of class II 
HDACs. 
 
The phylogenetic tree shows that HDAC9 splice variants are clustered as a separate group 
related to HDAC4/5/7 within class II of the classical HDAC family. The HDAC9 catalytic 
domain is located on the N-terminus, as for the class I HDACs. 97 
There are three known splice variants, HDAC9a, HDAC9b and HDRP/HDAC9c, but more 
variants are suspected. HDAC9c/HDRP lacks the catalytic domain and is 50% similar to the 
N-terminus of HDAC4 and HDAC5. 
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By analogy with HDAC4/5/7, HDRP is able to recruit HDAC3, thus circumventing the lack 
of a catalytic domain. In addition, HDAC9 is also able to interact with MEF2, CaMK, 14-3-3 
proteins, indicating that HDAC9 may have an important function in muscle differentiation. 
The alternative splicing might also represent another way of fine-tuning HDAC activity. 
Certain cell types might express one isoform, while others express the other. 97 
The phylogenetic tree shows that HDAC6 is evolutionarily most closely related to HDAC10. 
In general the identity of HDAC6 with other human HDACs is low, with some resemblance 
to yeast HDA1 indicating an early separation from the other HDACs in evolution.  
HDAC6 is a rather unique enzyme within the classical family of HDACs, because it contains 
two catalytic domains arranged in tandem. Another unique feature of HDAC6 is the presence 
of a HUB (HDAC6-, USP3-, and Brap2-related zinc finger motif) domain on the C-terminus.  
This domain is a signal for ubiquitylation, suggesting that this HDAC is particularly prone to 
degradation. 98 The catalytic domains of HDAC6 are most similar to the catalytic domain of 
HDAC9. HDAC6 functions as a tubulin deacetylase, regulating microtubule-dependent cell 
motility. 
In 2003 Schreiber et al. used a multidimensional, chemical genetic screen of 7.392 small 
molecules to discover ‘‘tubacin’’ which inhibits α-tubulin deacetylation in mammalian cells. 
99  
Tubacin does not affect the level of histone acetylation, gene-expression patterns, or cell-
cycle progression. They evidenced that class II histone deacetylase is the intracellular target 
of tubacin.  
Only one of the two catalytic domains of HDAC6 possesses tubulin deacetylase activity, and 
only this domain is bound by tubacin. These results highlight the role of α -tubulin acetylation 
in mediating the localization of microtubule associated proteins and the effect on cell motility. 
Given the dependence of metastasis and angiogenesis on cell movement, increasing α-tubulin 
acetylation may be an important component to the antimetastatic and antiangiogenic 
properties of HDAC inhibitors.  
Conversely, decreasing α-tubulin acetylation by HDAC6 overexpression may be the cause of 
the reduced α-tubulin acetylation levels observed in neurodegenerative disorders such as 
Alzheimer’s disease.  
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In addition, both suberoylanilide hydroxamic acid (SAHA) and butyrate, HDAC inhibitors 
used to suppress neurotoxicity in polyglutamine-repeat disorders, also inhibit α-tubulin 
deacetylation. 
Besides altering the expression levels of genes important for neuronal viability, the 
therapeutic effect of HDAC inhibitors in neurodegenerative disorders may involve increased 
α-tubulin acetylation. By uncoupling the effects of deacetylase inhibitors on the cytoskeleton 
and chromatin, tubacin allows new applications of deacetylase inhibitors and improved 
versions of current ones having increased selectivity to be envisioned. 
HDAC10 is the most recently discovered member of the class II HDACs. Two mRNA 
species, with a slight difference in length, have been found, suggesting the existence of two 
splice variants of HDAC10. Analysis of protein sequence identity shows that HDAC10 is 
most closely related (37% overall similarity) to HDAC6. 100 
HDAC10 has a catalytic domain on its N-terminus, and a NES and a putative second catalytic 
domain on the C-terminus. Also, two putative Rb binding domains have been found on 
HDAC10, suggesting a role in regulation of the cell cycle. Furthermore, HDAC10 is found to 
interact with HDACs 1, 2 and 3 (and/or SMRT) and HDACs 4, 5 and 7, but not with HDAC6, 
although some contradictory results are presented in the literature. 100 The fact that HDAC10 
is able to associate with many other HDACs indicates that it might function as a recruiter 
rather than as a deacetylase. 
6.5. Biological role of histone deacetylases class IIa: MEF2 interaction. 
The many interactions between class IIa HDACs and transcriptional regulators suggest a wide 
variety of potential biological roles. However, most of these interactions have not been 
examined in a biological context.  
By contrast, the importance of interactions between MEF2 and class IIa HDACs has been 
demonstrated in several tissue culture and animal models. MEF2 plays a significant 
transcriptional regulatory role in myogenesis, in negative selection of developing thymocytes, 
and in the transcriptional regulation of Epstein–Barr virus (EBV).  
The striking similarity of MEF2 regulation in neurons and its role in neuronal resistance to 
excitotoxicity suggests that class IIa HDACs also play a significant role in neurons. 
Class IIa HDACs inhibit myogenesis by binding to MEF2 at several promoters critical for the 
muscle differentiation program. Members of the MyoD family of basic helix-loop-helix 
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(bHLH) proteins as MyoD, Myf5, myogenin, and MRF4 act at multiple steps in the myogenic 
pathway to control the establishment of the myogenic lineage and the activation of 
differentiation genes. Recent studies have revealed that myogenic bHLH and MEF2 proteins 
control the activation and repression of muscle-specific genes by associating with HATs and 
HDACs, respectively, which act in an opposing manner to control the acetylation state of 
nucleosomal histones. 101 
It is now clear that HDAC4, -5, and -7 associate with MEF2 and act as potent inhibitors of 
MEF2-dependent transcription. Binding of these HDACs to MEF2 is mediated by 18 
conserved amino acids in the amino-terminal extensions of HDAC4, -5, and -7. 
Class I HDACs lack this domain and fail to directly associate with or regulate the activity of 
MEF2.  
McKinsey et al. reported that when early muscle cells are encouraged to differentiate by the 
removal of serum from their culture medium, histone deacetylase-5 (HDAC5) exits the 
nucleus. MEF2 is left behind, where it promotes the transcription of genes essential for 
muscle differentiation. 101 This response is thought to be mediated largely by Ca2+ signals 
generated at the cell surface: in fact two Ca2+/calmodulin-dependent protein kinases (CaMKI 
and CaMKIV) are known to induce the export of added histone deacetylase 4/5 from the 
nucleus. 
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Figure 13.  Muscle cells differentiation and HDAC5 shuttling. 
 
All these data suggest how the pathway in early muscle cells might work: binding of an 
extracellular molecule to its receptor on the cell surface leads to an increase in cellular Ca2+. 
This then activates Ca2+/calmodulin-dependent kinases, which in turn phosphorylate histone 
deacetylase-4 and -5. These enzymes then detach themselves from MEF2, exposing their 
nuclear export signal. This signal consists of a sequence of amino acids that acts as an address 
label, allowing the proteins to be sent out of the nucleus. Alone in the nucleus, MEF2 works 
together with muscle-specific transcription factors to enhance the expression of muscle 
specific genes, allowing differentiation of the cell into a muscle fibre. 
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6.6. Regulation of histone deacetylase activities. 
The activity of HDACs can be separated into two areas, enzymatic activity (the ability to 
deacetylate histones or other non-histone protein substrates), and functional activity (the 
ability to regulate transcription, for example). As expected with proteins that occupy an 
essential physiological role, the activities of the HDAC proteins are highly regulated by 
multiple distinct mechanisms. 
A first regulation mechanism is through protein complex formation: several HDACs exist as a 
component in stable large multi-subunit complexes, and most if not all HDACs interact with 
other cellular proteins. 
Results from many studies in different laboratories suggest that with the exceptions of yeast 
HOS3 and mammalian HDAC8, most purified recombinant HDACs are enzymatically 
inactive. Any protein that associates with HDACs, therefore, has the potential to activate or 
inhibit the enzymatic activity of HDACs. Likewise, HDACs, in general, have no DNA 
binding activity, therefore, any DNA-binding protein that targets HDACs to DNA or to 
histones potentially can affect HDAC function. 
For example, as we underlined before, human HDAC1 and HDAC2 exist together in at least 
three distinct multi-protein complexes: Sin3, the NuRD/NRD/Mi2, and the CoREST 
complexes.  
Perhaps the best example of HDAC regulation by protein–protein interaction emanated from 
studies of HDAC3. Data from early studies suggested that nuclear receptor corepressors, 
silencing mediator of retinoid and thyroid receptor (SMRT) and nuclear receptor corepressor 
(N-CoR), function as platforms for recruitment of HDACs.  
Surprisingly however, the interaction between HDAC3 and SMRT/N-CoR resulted in the 
stimulation of HDAC3 enzymatic activity. No enhancement of  HDAC3 activity was seen 
with an N-CoR mutant that did not bind HDAC3. Thus, it appears that the enzymatic activity 
of HDAC3 is specifically regulated by the availability of interacting SMRT/N-CoR. The 
activation of HDAC3 is mediated by a deacetylase-activating domain (DAD) present in 
SMRT and N-CoR. This domain was found to be necessary and sufficient for HDAC3 
enzymatic activation in reconstitution experiments using purified components.  
Phosphorylation is a leading post-translational mechanism for controlling many enzyme 
activities.  
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All mammalian HDACs possess potential phosphorylation sites and many of them have been 
found to be phosphorylated in vitro and in vivo. In one study, hHDAC1was analyzed by ion 
trap mass spectrometry, and two phosphorylated residues, Ser421 and Ser423, located in the 
protein’s C-terminal, were identified. 102 
Site directed mutations of Ser-421 and Ser-423 to alanine in HDAC1 reduced enzymatic as 
well as transcriptional repression activity, and similar results were obtained with a C-terminal 
deletion mutant of HDAC1.102 Importantly, complex formation, including association with 
RbAp48, MTA-2, mSin3A, and CoREST, is severely impaired in these mutants.  
There are two non-mutually exclusive possibilities to explain how phosphorylation can affect 
HDAC activity. Conceivably, phosphorylation of HDAC1 can alter its conformation into a 
more favorable enzymatically active form. Alternatively, phosphorylation might increase the 
ability of HDAC1 to interact with proteins, such as MTA2 and SDS3, which can activate its 
activity and consequently enhance its enzymatic activity. 
Besides phosphorylation, another post-translational modification that has been shown to 
regulate HDAC activity and function is the conjugation of small ubiquitin-related modifier 
(SUMO-1). Unlike the protein degradation effects of ubiquitylation, SUMO-1 modification 
exerts varied effects on the target protein, including subcellular localization, protein–protein 
interaction, and enzymatic activity modulation. 
Two independent studies identified HDAC1 as a substrate for SUMO-1 modification in vitro 
and in vivo at Lys444 and Lys476.103,104  
In order to deacetylate histones and to repress transcription, HDACs must reside in the 
nucleus. Therefore, signals that enhance HDAC nuclear localization positively regulate 
HDAC activities. In contrast, signals that increase cytoplasmic localization of HDACs 
negatively regulate their activities. HDAC1, 2, and 8 are predominantly nuclear proteins, and 
at this time, it appears that these three class I HDACs are not regulated by subcellular 
localization.  
In contrast, HDAC3 can be found both in the nucleus and cytoplasm and the 
nuclear/cytoplasmic ratio depends on cell types and stimuli. 
In response to IL-1β signaling, the N-CoR/ TAB2/HDAC3 corepressor complex undergoes 
nuclear to cytoplasmic translocation, resulting in derepression of a specific subset of NF-kB 
regulated genes. 
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Class II HDACs 4, 5, 7, and 9 shuttle between the nucleus and the cytoplasm. The binding of 
HDACs to 14-3-3 is absolutely dependent on phosphorylation of conserved N-terminal serine 
residues of HDACs, and the association results in sequestration of HDACs to the 
cytoplasm.101 
The nuclear export sequences of HDACs 4, 5, and 7 are signal-responsive and are activated 
upon CaMK-dependent binding of 14-3-3 proteins to the N-terminal phospho-serine residues 
of class II HDACs.  
Unlike class I and II HDACs, the SIR2-like enzymes that comprise class III HDACs require 
the coenzyme NAD+ for catalytic activity.  
In this reaction, nicotinamide is liberated from NAD+ while the acetyl group of the substrate 
is transferred to cleaved NAD+, generating O-acetyl-ADP-ribose.  
The exact physiological regulator of the SIR2 enzymes has not been confirmed as yet. 
However, studies have suggested two alternative models of SIR2 activation: (i) increasing the 
NAD+/NADH ratio by increasing NAD+ or by reducing the level of NADH, a competitive 
inhibitor of SIR2,105 or (ii) decreasing the level of nicotinamide, an inhibitory product of 
SIR2.106 Whatever the case, the requirement of NAD+ for SIR2 activity provides a unique 
mechanism for regulating class III HDACs in response to the metabolic status of the cell. 
 
7. Histone deacetylase and cancer. 
It is now well documented that the aberrant transcription (ie epigenetic modulation) of genes 
that regulate cellular differentiation, cell cycle, and apoptosis is due to altered expression or 
mutation of genes that encode HATs, HDACs, or their binding and recruiting partners. Such 
modifications are key events in the tumour onset and progression.107-110 Cell development and 
differentiation is governed by a hierarchical order of sequential gene activation, which is 
controlled at the level of chromatin structure.111 The removal of cells from the cell cycle and 
regulation of apoptosis are integrated into the differentiation programme. So, disruptions in 
chromatin remodelling leading to aberrant gene expression can disrupt this highly-ordered 
process, and induce the proliferation of undifferentiated cells and cancer. 
HATs and HDACs are involved in acetylation and deacetylation not only of chromatin 
proteins which can lead to altered regulation of transcription of genes but also of non-histone 
proteins themselves controlling cell cycle progression, differentiation and/or apoptosis. It has 
become increasingly clear that there is ‘cross-talk’ between the epigenetic regulation of gene 
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expression and the post-translational modifications of cell cycle proteins, and that HDACs 
and HATs play an important role at both levels of regulation of cell proliferation.112-115 
Specifically, genes encoding HATs have been found translocated, amplified, overexpressed 
and/or mutated in different human cancers, both epithelial and haematological. Mutations in 
the p300 gene, either missense or encoding truncated p300, have been identified in colorectal 
and primary gastric tumours and other epithelial cancers.116,117  
Mutations in the transcriptional co-activator CBP are present in Rubinstein-Taybi syndrome, 
which has an increased risk of cancer development.118 Inactivation of HATs due to the 
inhibitory action of viral proteins is associated with cancer too.119 Infact, oncogenic viral 
proteins, such as adenovirus E1A and the SV40 T-antigen, can bind p300, CBP and PCAF, 
antagonizing in this manner the expression of cellular genes that are normally activated by 
p300 or CBP, either by directly inhibiting HAT activity or by blocking the interaction of the 
co-activators with DNA-binding proteins or basal transcription factors.119 Translocations 
resulting in in-frame fusions of the p300 or CBP genes with other genes are well described in 
several haematological malignancies.116  
Such translocations can have dual effect. First, they can inactivate the wild-type function of 
HAT, thereby disrupting the transcription of genes that are regulated by that particular HAT. 
In addiction, fusion of HAT to a DNA-binding protein result in aberrant transcriptional 
activation of genes, that otherwise might not be expressed. 
Whilst specific alterations in HDAC genes have not been reported in human cancers, there are 
associations between HDACs and well-characterized oncogenes or tumour suppressor 
genes.120,121 For example, the retinoblastoma tumour suppressor protein recruits 
HDAC1,122,123 p53 protein complexes with Sin3-HDAC124 and BRCA1, the breast cancer 
susceptibility protein, associates with HDAC1 and 2.125  
There are several examples in which HDACs are functionally involved in oncogenic 
translocation products in specific forms of leukaemia and lymphoma.126,127 The link between 
altered HDAC activity and tumorigenesis is best shown in acute promyelocytic leukaemia 
(APL) that serves as a model for several other haematological malignancies.  
The retinoic acid (RA) receptor (RAR) is a transcriptional regulator that is important for 
myeloid differentiation. RARα and its heterodimerization partner RXR bind to retinoic-acid 
response elements (RAREs), and, in the absence of retinoids, repress transcription by 
recruiting Sin3/HDAC through N-CoR and SMRT.  
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Addition of endogenous ligand releases the HDAC complexes from RARα-RXR, and allows 
subsequent binding of HATs, such as TIF2 and CBP, to activate transcription.108-110 So, the 
coordinated activation and repression of genes that contain functional RAREs is important for 
myeloid-cell normal differentiation and development. In APL, chromosomal translocations 
produce fusion proteins that contain RARα and PML (promyelocytic-leukaemia protein) 
[t(15;17)], and RARα and PLZF (promyelocytic zinc finger) [t(11;17)].  
These aberrant proteins bind to RAREs, recruit HDACs with high affinity, are not responsive 
to physiological concentrations of retinoids, and behave like constitutive transcriptional 
repressors of RAR-targeted genes, blocking normal promyelocytes’ differentiation and 
leading to APL.  
It is not known yet which RAR-targeted genes are sufficient and/or necessary to regulate 
myeloid differentiation, or whether RARα-containing fusion proteins target a different subset 
of genes compared with wild-type RARα. However, as discussed below, addition of HDAC 
inhibitors can restore sensitivity of APL cells to RA, indicating that aberrant histone 
deacetylation is a key process in leukaemogenesis (figure 14). 
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Figure 14.  In APL, chromosomal 
translocations produce fusion 
proteins that contain RARα and 
PML (a) and RARα and PLZF (b). 
These aberrant proteins bind to 
retinoic-acid response elements 
(RAREs), recruit HDACs with high 
affinity, are not responsive to 
physiological concentrations of 
retinoids (RA), and behave like 
constitutive transcriptional 
repressors of RAR-targeted genes. 
Addition of HDAC inhibitors can 
restore sensitivity of APL cells to 
RA. 
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Transformed cells, characterized by inappropriate cell proliferation, do not necessarily lose 
the capacity to undergo growth arrest under certain stimuli.128,129  
To date, several inhibitors of HDACs with different chemical features have been reported 
active both in vitro and in vivo in arresting cancer cell growth, with little toxicity.  
 
 
Figure 15. Biochemical effect of HDAC inhibitors. 
 
These compounds have been shown to inhibit the activity of partially purified HDACs, to 
cause reversion of transformed morphology and inhibition of cell proliferation by induction of 
cell cycle arrest in G1 and/or G2 phase, terminal differentiation and/or apoptosis of 
transformed cells in culture for a large range of transformed cell types including solid tumour 
and haematological neoplastic cell lines.  
Moreover, they inhibit the growth of several types of cancers in tumour bearing models, being 
some of them actually in clinical trials.129-132 The anticancer potential of HDAC inhibitors 
stems from their ability to affect several cellular processes, that are dysregulated in neoplastic 
cells. 
For the most part, activation of differentiation programmes, inhibition of the cell cycle, and 
induction of apoptosis are the key antitumour activities of HDAC inhibitors. In addition, 
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activation of the host immune response and inhibition of angiogenesis might also have 
important roles in HDAC-inhibitor mediated tumour regression in vivo (figure 16). 
 
 
Figure 16. Regulation of cell growth and survival by HDAC inhibitors. 
 
The treatment of normal and tumour cells with HDAC inhibitors causes a similar 
accumulation of acetylated histones H4, H3, H2A and H2B.129,131,132  
Nevertheless, tumour cells appear to be much more sensitive to the growth inhibition and 
apoptotic effects of these agents than normal cells.133-136 In clinical trials the accumulation of 
acetylated histone in normal and tumour tissue may be used as a marker of biological activity. 
Another important characteristic of HDAC inhibitors is their selectivity in altering gene 
expression in transformed cells.137-139  
These compounds induce accumulation of hyperacetylated histones in most regions of 
chromatin, but only a small subset of expressed genes show a change in transcription patterns. 
Initial studies using differential display techniques estimate that less than 2% of genes are 
affected; however more recent analyses using DNA microarrays put this number closer to 
10%.139 The basis of this selectivity is not fully elucidated. It appears that specific sequences, 
such as NFY or Sp1 sites in the promoter region of genes may be required for these effects.140-
141  
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In addition, this selectivity might relate to other covalent modifications of  histone tails that 
can similarly affect gene expression, confirming in this way the ‘histone code’ hypothesis.142 
In particular, histone methylation, which proceeds after deacetylation of histone tails, can 
induce heterochromatin and euchromatin gene silencing.  
In this case, the addition of HDAC inhibitors would not be sufficient to reactivate the silenced 
gene.142  
Among the genes whose expression is increased by different HDAC inhibitors in several 
transformed cell lines, there is the CDK-NIA gene which encodes the cyclin-dependent kinase 
inhibitor WAF (p21).136,143  
This tumour suppressor protein binds and inhibits the activity of CDKs, leading to 
hypophosphorylation of pocket proteins pRb, p107 and p130, suppression of cell 
proliferation, and cell cycle  arrest in G1 phase. 
Among other genes whose transcription is selectively altered there is the thioredoxin-binding 
protein 2 (TBP2). Its expression is low in a number of human cancers.144 Suberoylanilide 
hydroxamic acid (SAHA), a well known HDAC inhibitor, selectively increases the expression 
of TBP2, which in turn binds reduced thioredoxin and inactivates this important cellular redox 
regulatory protein, increasing sensitivity to oxidative stress and apoptosis.144  
The activation of TBP2 and probably other genes repressed in tumour cells by HDAC 
inhibitors could contribute to cell growth arrest, terminal differentiation and/or apoptosis 
caused by these agents. HDAC inhibitors induce transcriptional activation of a subset of genes 
such as p21WAF but does not necessarily account for maximal activation.  
Furthermore, these compounds induce repression of an equal or larger number of genes such 
as cyclins A and D. The mechanism of gene repression is poorly understood and may be the 
result of recruitment and/or activation of co-repressors and/or acetylation of non-histone 
protein substrates. The latter event has varying functional effects and may also explain tumour 
growth arrest caused by HDAC inhibitors through mechanisms, in addition to affecting gene 
expression.145  
These agents can cause accumulation of acetylated proteins that are important regulators of 
cell cycle progression, for example, pRb, transcription factors, such as p53, and hormone 
receptors, such as glucocorticoid and thyroid hormone receptors.  
The exact contribution to anticancer activity of such HDAC inhibitors’ different effects, as 
well as that exerted by other effects still to be discovered, require further investigation. In 
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addition to directly affecting cancer-cell growth and survival, HDAC inhibitors might have 
supplementary activities that indirectly affect tumour development. These agents can 
transcriptionally activate major histocompatibility complex (MHC) class I and II proteins, the 
co-stimulatory molecules CD40, CD80 and CD86, the intercellular adhesion molecule 
ICAM1, and type I and II interferons, to potentially augment immune-cell recognition and 
activation.145,146  
In support of this hypothesis, addition of HDAC inhibitors sensitizes tumour cells for 
destruction in an allogeneic mixed-leukocyte reaction.147 Moreover, the growth and survival 
of rapidly expanding solid tumours requires a continuous oxygen and nutrient supply to be 
maintained by the tumour neovasculature.  
Trichostatin A (TSA) can inhibit hypoxia-induced expression of vascular endothelial growth 
factor (VEGF) and suppress angiogenesis, both in vitro and in vivo.148-150 So, augmentation of 
the host immune response and inhibition of tumour angiogenesis might markedly suppress the 
growth of primary tumours and impede metastasis. 
 
8. HDAC inhibitors in epigenetics: not only for cancer diseases. 
Besides angiogenesis, it is now emerging that the histone proteins and the enzymes that 
regulate their acetylation’s state are important for chemotherapy too. In fact, the histones that 
are present in abundance, are antigenic and may have a role to play in the pathology of the 
parasitosis.151 
The histones of P. falciparum have recently been proposed as targets for drug treatment of 
blood stage parasites.151 They also play important role in chromatin remodelling in 
trypanosomatids, which include leishmania and trypanosomes.153 Apicidin itself, a cyclic 
tetrapeptide isolated from Fusarium spp, was firstly reported as reversible inhibitor of in vitro 
development of Apicomplexan parasites, acting by inhibition of parasite (including 
Plasmodium species) HDAC enzyme,152 and only later showed antiproliferative and 
cytodifferentiating effects on mammalian cells.154  
To date, there are some reports that highlight the potential use of HDAC inhibitors with 
selective toxicity for protozoan parasites, and also as a new class of antimalarial agents.155  
Epigenetic phenomena are also involved in many psychiatric disorders. For example, HDAC 
inhibitors have recently been proposed as therapeutic agents in mitigating vulnerability to 
schizophrenia among high-risk individuals.  
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More in detail, in the adult mammalian brain GABAergic interneurons release a protein 
named reelin (RELN) into the extracellular matrix. In this site RELN binds with high affinity 
to the integrin receptors, and likely plays a role in synaptic plasticity.  
Because there is a great deficit (∼50%) in the RELN content in specific areas of brains from 
schizophrenic individuals156, and this protein is normally operational during embryonic 
corticogenesis and throughout the patient’s lifespan, the morbidity risk of schizophrenia has 
been proposed arising as a consequence of compromised reelin expression. This is totally in 
accordance with the suggestion that embryonic factors contribute to the etiology of 
schizophrenia.157  
The deregulation of the RELN gene might well result from hypermethylation of the promoter 
and, because in heterozygous reeler mice (haploinsufficient in RELN) HDAC inhibitors 
increase DNA demethylase activity and restore RELN expression, they have been proposed 
for the treatment of schizophrenia.158 Furthermore, HDACs and their inhibitors are involved 
in mental retardation159 and neurodegeneration in Drosophila, respectively.160 
Recent evidence points out that HDACs are involved in the ageing too. Indeed, it has been 
identified a senescence-specific form of HDAC2.161 Furthermore, it has been reported that 
these enzymes regulate the lifespan in some animal models.162 
Last but not least, nicotinamide, an inhibitor of class III deacetylases (sirtuins), is often used 
to self-treat anxiety, osteoarthritis, psychosis, and is in clinical trials for treatment of some 
cancers and type I diabetes.163 
 
9. TSA/HDLP complex: mechanism of deacetylation. 
In 1999, the X-ray crystal structure of a deacetylase protein from the hyperthermophilic 
bacterium Aquifex aeolicus with sequence homology to the class I and II HDACs (termed 
histone deacetylase-like protein, HDLP) has been determined alone and in complex with two 
inhibitors, (R)-TSA and SAHA (figure 17).164  
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Figure 17. Computational representation of TSA in the 
active-site pocket of HDLP.164 
 
These crystal structures have suggested a mechanism for the deacetylation reaction (figure 
18).164 The carbonyl oxygen of the N-acetylamide bond is thought to coordinate to the zinc 
cation and to thereby position it closely to a bound water molecule and activate it for a 
nucleophilic attack by the water.  
The nucleophilicity of the water molecule, in turn, could be enhanced by an interaction with 
the negative charge of the buried Asp166-His131 charge-relay system to which the water is 
hydrogen bonded.  
The attack of the water molecule on the carbonyl carbon would produce an oxy-anion 
intermediate, stabilized by the zinc ion, and by hydrogen bond to Tyr297. The collapse of this 
intermediate would result in cleavage of the carbon-nitrogen bond, with the nitrogen 
accepting a proton from the His132 residue, and would thereby produce the observed acetate 
and lysine products.164 
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Figure 18. Proposed mechanism for HDAC deacetylation. 
 
The NAD+-dependent mechanism of deacetylation performed by sirtuins involves the 
cleavage of the nicotinamide-ribose glycosidic bond of NAD+, joined with the transfer of the 
acetyl group of acetyllysine to the ADP-ribose molecule: the result is the production of an O-
acetyl-ADP-ribose together with the free Lys residue (figure 19).  
The formation of a labile 1'-acetylated-ADP-ribose, which is in turn converted into the 2'-O-
acetyl-ADP-ribose, has been observed during the enzyme-catalyzed reaction.  
This product subsequently equilibrates with the 3'-acetylated-isomer in solution, through a 
nonenzymatic intramolecular transesterification reaction.84  
Although the physiological role of O-acetyl-ADP-ribose is still unclear, microinjection of 
such product results in delay/block in oocyte maturation, and in a delay/block of embryo cell 
division,165 providing further evidence for its important function in cell signalling or 
metabolism.  
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This unusual mechanism, proposed respect yeast Sir2 protein, reveals that NAD+ serves as a 
true stoichiometric cofactor rather than as a component of the catalytic machinery or as an 
allosteric regulator of the enzyme.  
Indeed, only one acetyl-lysine residue can be deacetylated for each NAD+ molecule, and 
hence the amount of Sir2 activity would be tightly linked to the cellular NAD+ concentrations 
and to the metabolic state of the cell. With this mechanism, Sir2 and likely the other sirtuins 
truly would function as ‘sensors’ of the metabolic conditions of the cell. 
 
Figure 19. Proposed mechanism for sirtuin deacetylation. 
 
 
10. Histone methylation. 
Although acetylation/deacetilation remain the most studied post-translational histone 
modification, in the last years it is emerging new regulators of protein function: HMT (histone 
methyltransferase) that methylate arginine residues (PRMTs) and lysine residues (HKMTs) 
on the histone tails. 
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10.1. Arginine methylation.  
Methylation of arginine residues is catalyzed by Type I and Type II Protein arginine N-
methyltransferases (PRMTs), both types catalyze the formation of 
monomethylarginine(MMA) as an intermediate, but Type I facilitate the formation of 
asymmetric ω-NG,NG-dimethylarginine (aDMA) residues, and Type II enzymes generate 
symmetric ω-NG,NG-dimethylarginine (sDMA) residues.166  
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Figure 20 . The Protein Arginine Methyltransferase Family. 
(A) There are currently eight mammalian members of the PRMT family, which harbor 
signature motifs I; post I, post II, and post III; and the conserved THW loop (in black). 
PRMT7 has a duplication of these motifs. PRMT2 and PRMT3 have an SH3 domain and 
a Zn2+ finger, respectively, which likely facilitate substrate recognition. The accession 
numbers for the PRMTs are as follows: AAF62893 for hPRMT1, AAH00727 for 
hPRMT2, AAC39837 for hPRMT3, NP_954592 for CARM1, AAF04502 for hPRMT5, 
Q96LA8 for hPRMT6, NP_061896 for hPRMT7, and DAA01382 for mPRMT8. The 
number of residues is indicated at the C terminus of the PRMTs. (B) Type I and type II 
PRMTs generate monomethylarginine. The generation of asymmetri dimethylarginine is 
catalyzed by type I, and the production of symmetric dimethylarginine is catalyzed by the 
type II enzymes. 
 
 
Currently, known mammalian Type I enzymes include PRMT1,167,168 the zinc finger-
containing enzyme PRMT3,169 the coactivator-associated arginine methyltransferase 
PRMT4/CARM1,170 and the nuclear enzyme PRMT6.171 Methyltransferases catalyze the 
addition of methyl groups to nitrogen, carbon, sulfur, and oxygen atoms of small molecules, 
lipids, protein, and nucleic acids. Currently, eight mammalian protein arginine 
methyltransferases (PRMT) have been identified. Six have been shown to catalyze the transfer 
of a methyl group from S-adenosylmethionine (AdoMet) to a guanidino nitrogen of arginine, 
resulting in S-adenosylhomocysteine (AdoHcy) and methylarginine. No activity has been 
demonstrated for PRMT2 and PRMT8. The PRMTs are ubiquitously expressed enzymes, and 
they may achieve a degree of tissue specificity by alternative splicing.172 Little data exist 
about the regulation of the expression or the stability of the PRMTs. 
It has long been known that proteins that harbor glycine and arginine-rich (GAR) motifs are 
often targets for PRMTs.173 Three enzymes that methylate GAR motifs have been 
crystallized, and their core structures have proven very similar.174-176  The crystal structure of 
PRMT1 in complex with the re-action product AdoHcy and a GAR motif has been 
described,175 and it reveals three different peptide binding channels, possibly reflecting 
alternate docking orientations for different GAR motif-containing substrates. RNA binding 
proteins (RBPs) represent major targets for PRMTs, but also histone H3, H4, p300/CBP, 
ILF3, HIV tat are known PRMT substrates. It was proposed that arginine methylation might 
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serve as a maturation signal.177 It was recognized early on that histones were substrates of 
methyltransferases,178 and it is now known that histones are substrates of PRMT1, CARM1, 
and PRMT5.179,180 The posttranslational modification of histones is known to regulate gene 
expression and contribute to the histone code.181  
Protein arginine N-methyltransferases (PRMTs) have been implicated in a variety of 
processes, including nuclear receptor-regulated transcription and protein trafficking.182 
There are numerous transcription factors, including p53,183 YY1,184 and NF-kB,185 that 
contribute to the recruitment of the PRMTs to promoters.186 In addition to the histones, 
PRMTs have been shown to methylate coactivators including CBP/p300.187,188 Signaling is 
governed by posttranslational modifications that alter protein function in part by altering 
protein-protein interactions. Methylated arginines have been shown to block some interactions 
and to promote others.179 
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Figure 21. Cellular Processes Regulated by Arginine Methylation. 
PRMTs have been implicated in a number of basic cellular actions, 
including RNA processing, transcriptional regulation, signal transduction, 
and DNA repair. Methylarginines are denoted by a red dot. 
 
 
There are several pathways that have been shown to utilize arginine methylation as a tag for 
signal transduction downstream of the interferon receptor, the T cell receptor, cytokine 
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receptors, and nerve growth factor (NGF) receptor. In addition, many cell surface receptors 
and signaling proteins were identified by proteomic analysis.189 PRMT1 was the first enzyme 
in this family to be linked to signal transduction, with the finding that it binds the cytoplasmic 
region of the type I interferon receptor,190 while binding of the tumor suppressor DAL-1 to 
PRMT3 acts as an inhibitor of enzyme activity, both in in vitro reactions and in cell lines.191  
Two well-studied enzymes, PRMT1 and PRMT4/CARM1, methylate histones H3,192,170,193,194 
H4,195,196 and H2B,183 in addition to many other substrates. Histone arginine methylation is a 
component of the histone code that directs a variety of processes involving chromatin.197,198 
For example, methylation of Arg-3 of histone H4 by PRMT1 facilitates H4 acetylation and 
enhances transcriptional activation by nuclear hormone receptors synergistically with 
CARM1,188,196,199,200 in that CARM1 prefers acetylated histone tails in generating H3 Arg-17 
methylation.196,200  
PRMT1 is the predominant type I PRMT in mammalian cells, accounting for 85% of cellular 
PRMT activity.201 It is essential for early postimplantation development, the expression is 
highest in developing neural structures in embryos202 and PRMT1 has been implicated in 
neuronal differentiation.203 The best-known substrates for PRMT1 are RNA-binding proteins 
involved in various aspects of RNA processing and/or transport, such as hnRNPs, fibrillarin, 
nucleolin,166 and poly(A)-binding protein II.204 A growing number of other proteins were 
found to be substrates of PRMT1, including high-molecular-weight fibroblast growth factor-2 
(HMWFGF-2), a nuclear growth factor;205 interleukin enhancer-binding factor 3 (ILF3);201 
STAT1, a transcription factor activated by extracellular signals;206  SPT5, a regulator of 
transcriptional elongation;207 and histones H4195,196 and H2B.183 PRMT4 was discovered as a 
transcriptional coactivator-associated arginine (R) MTase (CARM1).170  CARM1 enhances 
gene activation by nuclear receptors in a synergistic collaboration with two other classes of 
coactivators: the p160 coactivators and the protein acetyltransferases p300/CBP.170,199 
CARM1 can methylate specific arginine residues in the N-terminal tail of histone H3.170,192-194 
Both CARM1 as well as PRMT1 act in concert with the acetyltransferase CBP/p300, along 
with the p160 coactivator family to enhance transcription from hormone-responsive 
promoters.208,209 Similarly, CARM1 and PRMT1 act as coactivators in the tumor suppressor 
protein p53-mediated transcription, via direct interactions with p53 and its associated 
coactivator partner p300.183 Three crystal structures of PRMTs are currently available: rat 
PRMT1,175 the rat PRMT3 catalytic core176  and yeast RMT1/Hmt1.174 These structures 
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reflect a striking structural conservation of the PRMT catalytic core. The overall monomeric 
structure of the PRMT core can be divided into three parts: an MTase domain, a β -barrel, and 
a dimerization arm. The MTase domain has the consensus fold conserved in a class-I 
AdoMet-dependent MTase that harbors an AdoMet-binding site.210,211 The β-barrel domain is 
unique to the PRMT family.176 An identical hydrophobic dimer interface is observed in 
PRMT1,175 the PRMT3 core,176 and yeast RMT1/Hmt1,174 despite different crystallization 
conditions, space groups, and cell dimensions. This observation supports the notion that dimer 
formation is a conserved feature in the PRMT family.176  
It is conceivable that dimerization is required to engage the residues in the AdoMet-binding 
site in a manner in which they can interact with AdoMet properly. Interestingly, the higher 
order oligomerization of PRMT1168,175 does not occur in the absence of dimerization.175 
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Figure 22. Structure of PRMT1. 
(A) Two views (top and bottom panels) of monomer structure. The 
N-terminal helix αY is shown in red, and the AdoMet binding 
domain in green. The bound AdoHcy is shown in a stick model 
with the sulfur atom (where the transferable methyl group would 
be attached in AdoMet) shown in yellow. The β-barrel structure is 
shown in yellow, and the dimerization arm (which is inserted into 
the β-barrel) is in light blue. The bound arginine (blue) in the S14-
AdoHcy-R3 ternary complex defines the active site, located 
between the AdoMet binding domain (green) and the β-barrel 
(yellow). 
(B) Superposition of PRMT1 (residues 41–353) and PRMT3 core 
(residues 208–528, in gray). Besides deletion or insertion (located 
in loops between β-10 and β-11 and between β-14 and β-15), the 
two structures can be superimposed with less than 1 A° of root-
mean-square deviation between them. 
The target arginine is situated in a deep pocket between the 
AdoMet binding domain and the β-barrel domain. The residues 
that make up the active site are conserved across the PRMT 
family, and form a hairpin, that is called the “double-E loop” 
because it contains two invariant glutamates (E144 and E153;).  
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Figure 23. Active Sites of PRMT1 and PRMT3. 
(A) PRMT1 active site with bound Arg in stereo. The annealed omit electron density map, 
contoured at 5.0σ of the arginine, is shown as an insert. 
(B) Superimposition of PRMT1 and PRMT3 (PDB ID code 1F3J) active sites in stereo. 
Only the PRMT3 residues are labeled. The arrow indicates transfer of the methyl group 
(attached to AdoHcy) to the bound Arg. 
(C) pH dependence of PRMT1 and PRMT3 activities. Reactions (20 µl) contained 5 µM of 
purified hnRNP A1 or 100 µM of R3 peptide, 10µg/ml of PRMT1 or 50 µg/ml of 
PRMT3∆200, 40 µM [methyl-3H]AdoMet (0.5 µCi) in 100 mM buffer, 200 mM NaCl, 2 
mM EDTA, and 1 mM dithiothreitol. The buffers used were sodium acetate (pH 4 and 5), 
MES (pH 6.0, 6.3, 6.5, and 6.8), HEPES (pH 7.0 and 7.5), Tris (pH 8.0 and 8.5), and 
glycine (pH 9.0, 9.5, and 10.0). After incubating at 37°C for 15 min, 2.5 µl of 100 mg/ml 
BSA was added, followed by 0.5 ml of 20% TCA. The samples were filtered and washed 
three times with 20% TCA through a GF/F filter (Millipore), dried, and subjected to 
liquid scintillation counting. 
 
 
The hydrophobic methylene groups of the target arginine lie parallel to the plane of the Y148 
aromatic ring, while the side chain of E144 and the main chain carbonyl oxygen of E153 
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hydrogen bond the guanidino group. Surprisingly, the side chain of E153 points away from, 
rather than toward, the bound guanidino group in the active site. It is noted that all three forms 
of PRMT1 were crystallized at low pH (~4.7); under this condition PRMT1 is inactive, 
perhaps due to protonation of one or both Glu side chains.176  
10.2. Lysine methylation. 
Another substrate of methyltransferases is represented by histone lysine that is methylated by 
histone lysine (K) methyltransferases (HKMTs). This enzyme contains a SET domain that 
was originally identified in three Drosophila genes involved in epigenetic processes, the 
suppressor of position-effect variegation 3–9, Su(var)3–9; an enhancer of the eye color mutant 
zeste, En(zeste); and the homeotic gene regulator Trithorax.212 Mammalian homologues of 
Drosophila Su(var) 3–9 were the first HKMTs identified, and they specifically methylate H3 
at Lys-9.213  
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Figure 24.  SET domain HKMTs.  
(a) Domain structure of SET HKMT families. (b) DIM-5 protein (one of the smallest 
members of the SUV family) contains four segments: a weakly conserved N-terminal 
region, a pre-SET domain containing nine invariant cysteines, the SET region containing 
four signature motifs, and the post-SET domain containing three invariant cysteines. (c) 
Illustration of pre-SET Zn3Cys9 triangular zinc cluster (left panel); ribbon diagram of 
DIM-5 SET domain, with arrows indicating locations of conserved motifs, the cofactor 
binding and substrate histone H3 peptide, and the pseudo knot formed by motifs III and 
IV (middle panel); and post-SET zinc center (right panel). 
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So far, SET containing HKMTs that methylate Lys-4, -9, -27, or -36 of histone H3 and Lys-
20 of histone H4 have been identified. HKMTs can be classified according to the presence or 
absence and the nature of sequences surrounding the SET domain that are conserved within 
families.197,214 Representatives of the major families include SUV, SET1, SET2, EZ, and RIZ. 
The SET7/9 and SET8 proteins do not fit into these families. The SUV family includes the 
greatest number of HKMTs. The tertiary structure of SET proteins shows that these conserved 
residues are clustered together and involved in one of the three steps in the methylation 
reaction: AdoMet binding, catalysis of methyl transfer and formation of the hydrophobic 
target lysine-binding channel.  
Currently known structures of SET proteins include the crystal structures of two SUV family 
proteins, Neurospora crassa DIM-5215,216 and Schizosaccharomyces pombe Clr4;217  four 
human SET7/9 structures in various configurations.218-.221 SET7/9 in a ternary complex with a 
peptide containing histone H3 Lys-4221 revealed the target lysine is inserted into a narrow 
channel so that the target nitrogen lies in close proximity to the methyldonor AdoMet at the 
opposite end of the channel. At the bottom of the channel, the terminal ε-amino group of the 
substrate lysine hydrogen bonds the hydroxyl of catalytic Tyr of SET domain.  
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Figure 25. Active site of SET domain.  
(a) H3 peptide-binding site in DIM-5 with the target Lys-9 
inserted into a channel (PDB 1PEG) (left panel), and the 
AdoHcybinding site in SET7/9, located at the opposite end of 
the target lysine-binding channel (PDB 1O9S) (right panel). 
(b) The active sites in DIM-5 (PDB 1PEG) (left panel) and 
SET7/9 (PDB 1MT6) (right panel). The arrow indicates the 
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movement of the methyl group transferred from the AdoMet 
methylsulfonium group to the target amino group. (c) 
Structural comparison of active sites in DIM-5 and SET7/9: 
either two tyrosines and one phenylalanine (DIM-5) or three 
tyrosines (SET7/9) surrounds the target lysine. 
 
 
HKMTs differ both in their substrate specificity for the various acceptor lysines and in their 
product specificity for the number of methyl groups (one, two or three) they transfer. The 
Saccharomyces cerevisiae SET1 protein can catalyze di- and trimethylation of H3 Lys-4, and 
trimethylation of Lys-4 is thought to be present exclusively in active genes.222 Human SET7/9 
protein, on the other hand, generates exclusively monomethyl Lys-4 of H3.216,221 Considering 
that different methylation products might have different signaling properties,222-224 it is 
important to understand the structural basis for this product specificity.216 
A very important factor is that SET-domain-containing HKMTs such as DIM-5 and SET7, 
which have a narrower pH range (active at pH 8 or higher) and an unusually high pH 
optimum (~10).215,225 At pH 10, the amino group of the target lysine should be partially 
deprotonated. Only the deprotonated target lysine has a free lone pair of electrons capable of 
nucleophilic attack on the AdoMet methyl group, this is probably a necessary condition for 
catalytic activity. 
 
11. Possible Arginine Demethylation by Amine Oxidases. 
Recently, it was demonstrated that a common component of a number of corepressor 
complexes possesses lysine demethylase activity226. The enzyme responsible for this activity, 
LSD1, is an amine oxidase that can specifically remove the methyl groups from dimethylated 
H3-K4. Although not yet confirmed, members within this family of enzymes may also be able 
to demethylate arginine residues These enzymes are very likely the long sought after, bona 
fide lysine and arginine demethylases. 
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12.Histone Methyltransferases and Cancer. 
Prostate and breast cancers are common tumors that are often hormone dependent. The fact 
that PRMTs are known coactivators for nuclear receptors makes them likely candidates to be 
overexpressed in these cancer types. Indeed, it has been found that increased expression of 
CARM1 correlates with androgen independence in human prostate carcinoma.227 Importantly, 
small molecules that inhibit both PRMT1 and CARM1 can suppress estrogen and androgen 
receptor-mediated transcriptional activation,228 and, in mouse embryonic fibroblast cell lines 
derived from Carm1 null embryos, estrogen receptor-mediated transactivation is dramatically 
attenuated.229 In addition, the ability of PRMT5, when over-expressed, to promote anchorage-
independent cell growth also points to this enzyme as a candidate for deregulation in 
transformed cellular states.230 PRMT5 may achieve this task by inhibiting the expression of 
tumor suppressors. Although the PRMTs have not been convincingly identified as oncogenes 
or tumor suppressors, a precedent has been set by the lysine methyltransferases for the 
involvement of protein methylation in transformation.231,232 Moreover, the involvement of 
arginine methylation in the DNA damage response may identify examples of cancer in which 
there is genomic instability caused by the deregulation of arginine methylation. 
Cellular differentiation is governed by changes in gene expression, but at the same time, a 
cell’s identity needs to be maintained through multiple cell divisions during maturation. In 
myeloid cell lines, retinoids induce gene expression and a well-characterized two-step 
lineage-specific differentiation. To identify mechanisms that contribute to cellular 
transcriptional memory, some researchers studied the epigenetic changes taking place on 
regulatory regions of tissue transglutaminase, a gene whose expression is tightly linked to 
retinoid-induced differentiation. They reported that the induction of an intermediary or 
“primed” state of myeloid differentiation is associated with increased H4 arginine 3 and 
decreased H3 lysine 4 methylation. These modifications occur before transcription and appear 
to prime the chromatin for subsequent hormone-regulated transcription. Moreover, inhibition 
of methyltransferase activity, preacetylation, attenuated retinoid-regulated gene expression, 
while overexpression of PRMT1, a methyltransferase, enhanced retinoid responsiveness. 
Taken together, our results suggest that H4 arginine 3 methylation is a bona fide positive 
epigenetic marker and regulator of transcriptional responsiveness as well as a signal 
integration mechanism during cell differentiation and, as such, may provide epigenetic 
memory.233 
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The tumor suppressor DAL-1/4.1B, which suppresses growth in multiple cell types, interacts 
with PRMT5 and modifies its ability, either positively or negatively, to methylate cellular 
substrates in vitro and in cultured cells. How the PRMT5/DAL-1/4.1B interaction directly or 
indirectly relates to DAL-1/4.1B growth suppression may partially be explained through the 
altered methylation of known cellular substrates including the splicing-related Sm proteins 
and/or cyclin E1 as well as other cellular proteins as yet identified, regulating their ability to 
function in pathways important in controlling cell growth. This would be a unique mechanism 
for such tumor suppressor gene function in mammalian cells.234 
Despite recent advances in identifying MTases, we still know little about what regulates their 
activities or determines their specificity. This is evident by a recent report that SET7/9 activity 
is not limited to histones; it also methylates the tumor suppressor p53.235 With the increasing 
interest in protein (histone) methylation as a mechanism for gene regulation, we will 
undoubtedly discover other exciting roles for MTases and the cellular processes that they 
direct. 
 
13. HDAC inhibitors: mechanism of inhibition and pharmacophore model. 
As we have underlined above, the HDLP deacetylase core X-ray structure, together with the 
resolution of HDLP/TSA and HDLP/SAHA complexes, have revealed the active site of the 
enzyme but have also elucidated the mechanism of HDAC inhibition by hydroxamic-acid 
based inhibitors.164  
HDLP has a single domain structure related to the open α/β class of folds. It contains a central 
eight-stranded parallel β sheet, with four α helices packed on either face. Eight additional α 
helices and large loops in the β sheet further extend the structure and result in the formation of 
a deep, narrow pocket with an adjacent internal cavity. Concisely, the catalytic core has an 
α/β motif and the active site consists of a tubular pocket with a zinc-binding site and two 
Asp-His charge-relay systems (His 131/Asp 166 and His132/Asp173) that facilitate the acetyl 
cleavage of substrate by weakening the amide bond.  
The zinc cation required for the enzymatic activity is positioned near the bottom of the pocket 
and is coordinated by several histidine and aspartate residues too. Hydrophobic residues 
surround the channel leading to the bottom of the pocket, which is presumably where the 
aliphatic chain of the acetyl-lysine residue is nestled. TSA and SAHA act as substrate mimics; 
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the aliphatic chain and hydroxamic acid of each inhibitor are analogous to the lysine side 
chain and acetyl group of the substrate, respectively.  
These inhibitors bind inside the pocket by inserting the aliphatic chain into the tube, making 
contact with the residues at the rim, walls and at the bottom of the pocket. Specifically, TSA 
contains a cap group, an aliphatic chain and a terminal hydroxamic acid functional group. 
  
 
Figure 26. HDLP residues that interact with  TSA in the tubular pocket. 
 
The hydroxamic acid coordinates the zinc cation in a bidentate fashion (through CO and OH 
groups) and also contacts active-site residues (forming two hydrogen-bonds between its NH 
and OH groups and the two charge-relay systems His131/Asp166 and His132/Asp173, and 
another one between its CO and the Tyr297 hydroxyl group).  
Moreover, hydroxamic acid function replaces the zinc-bound water molecule of the active 
structure with its OH group.236 Fitting snugly into the channel, the aliphatic chain makes 
several Van der Waals contacts with the channel residues.  
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Figure 27. TSA binds inside the pocket making 
contacts to residues at the rim, walls and bottom 
of the pocket. 
 
The dimethylaminophenyl group acts as a cap to pack the inhibitor at the rim of the tubular 
pocket-like active site.  
Indeed, this cap group contacts the residues of Pro22 and Tyr91 on the rim of the pocket and 
possibly mimics the amino acids adjacent to the acetylated lysine residue in the histone.  
The binding of TSA causes a conformational change in a tyrosine residue on this rim (Tyr91) 
and thereby allows tighter packing of the cap group. It has been postulated that this insertion 
and binding in the catalytic site blocks substrate access to the active zinc ion and, thereby, 
inhibits the deacetylase activity.  
Conservation of the amino acid sequences of the loops that form the active site pocket among 
HDLP and class I and II mammalian HDACs strongly suggests that the catalytic reaction and 
mechanism of inhibition by TSA and SAHA are the same in HDACs as HDLP.236  
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The catalytic domains of the known class I and II human HDACs are very well conserved, but 
there are certain differences that may allow for the production of specific inhibitors.  
Most of the residues that are seen in the HDLP structure to interact directly with TSA are 
completely conserved among all of the HDACs, but there is less conservation in the 
surrounding residues, with significant differences apparent between the class I and class II 
HDACs.237 Notably, there is a striking divergence in the region of Tyr91 of HDLP, and this 
tyrosine residue itself is very poorly conserved among the human HDACs.  
This is particularly interesting in that Tyr91 is positioned on the rim of the channel and 
interacts directly with the cap group of TSA, and it is the only residue that shifts its 
conformation upon TSA binding.236  
Thus, the considerably diversity in the region of the protein suggests that it would be possible 
to develop more potent and/or specific inhibitors by altering the structure of this cap group. 
From the TSA/HDLP complex data, we can elaborate a structural model (common 
pharmacophore) for class I/II HDAC inhibition. This pharmacophore consists of a metal 
binding domain, which interacts with the active site, a linker domain, which occupies the 
channel, and a surface recognition domain, which interacts with residues on the rim of the 
active site.  
Indeed, in all known natural or synthetic inhibitors it is possible to see an extremely variable 
cap group.  
This moiety contacts residues on the rim of the catalytic pocket and is generally connected to 
an electronegative group (connection unit, CU) that is able to interact by hydrogen bond with 
other residues. 
Such CU portion is bound to an hydrocarbon linker interacting with the channel residues of 
the active site of the enzyme and finishing with the enzyme inhibiting group (EIG), that in 
many cases chelate the zinc cation near the bottom of the catalytic pocket.  
The cap groups can be, for example, represented by substituted benzene rings, pyridine, 
pyridylmethyl groups, a portion of tricyclic systems or of cyclic tetrapeptides. The 
electronegative group is generally a ketone, an amide, a reverse amide, a carbamate, or a 
sulfonamide.  
The linker is a saturated or unsaturated aliphatic chain, which mimics that of the lysine 
substrate, with an optimal length of 4-6 carbon residues. In some cases, it is possible to find 
an aromatic or heteroaromatic ring inserted into the hydrocarbon chain.  
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To date, the most useful EIG is the hydroxamic acid moiety but also ethyl ketone, 
trifluoromethyl ketone, α-ketoamide, 2-aminoanilide, thiol and its acetyl derivative (which in 
vivo is rapidly hydrolyzed) are effectively able to chelate the zinc ion.  
The epoxyketone and epoxy groups of some natural inhibitors seem to react irreversibly with 
some nucleophilic residues of the catalytic pocket of the HDAC enzymes, but the ketone 
group can also interact in its hydrate form as ligand with the metal ion (figure 28). 
 
 
 
 
 
  
 
 
 
 
 
 
             Figure 28.  Pharmacophore model for HDAC inhibitors. 
 
 
14. HDAC inhibitors. 
In the last ten years, a number of HDAC inhibitors have been reported as useful tools for the 
study of function of chromatin acetylation and deacetylation, and gene expression. These 
compounds can be natural or synthetic. Among former ones, TSA,238 a cyclic tetrapeptide 
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family including trapoxins A and B (TPX),239 chlamydocin,240 HC-toxin,236 Cyl-2,241 WF-
3161,242 apicidin,154 the more recent depsipeptide FK-228 (FR901228)243, and depudecin244 
have been isolated from cultures of fungal strains. Differently, sodium butyrate (NaB)245 is  a 
fiber-derived fermentation product generated by anaerobic bacteria in the lumen of intestine. 
On the other hand SAHA, its aza-analogue pyroxamide and the related second-generation 
hybrid polar compounds (HPCs),246 straight chain TSA- and SAHA-like analogues,247-249 1,4-
cyclohexylene- and 1,4-phenylene-N-hydroxycarboxamides,250 scriptaid,251 oxamflatin252 and 
related compounds,253 cyclic hydroxamic acid-containing peptides (CHAPs),254 NVP-
LAQ824 and related compounds,255 benzamide derivatives with MS-275 as lead 
compound,256 trifluoromethyl and other electrophilic ketones (α-ketoamides and heterocyclic 
ketones),257,258 and short chain and aromatic fatty acids (such as 4-phenylbutyrate259 and 
valproic acid260) were obtained by synthetic pathways. 
A useful classification of HDAC inhibitors could be made on the basis of the chemical 
structure that allow us to identify the different possibilities of the pharmacophore model.  
Seven main classe are described: 
 
1 small molecule hydroxamic acids,  
2 carboxylates,  
3 benzamides,  
4 electrophilic ketones,  
5 cyclic peptide inhibitors,  
6 thiol based inhibitors, 
7 miscellaneous. 
 
14.1. Small molecule hydroxamic acid. 
Hydroxamic acid based differentiating and antiproliferative agents were among the first 
compounds to be identified as histone deacetylase inhibitors, and these agents helped to 
define the pharmacophore model for HDAC inhibitors. The linker domain can consist of 
linear or cyclic structures, either saturated or unsaturated, and the surface recognition domain 
is generally a hydrophobic group, most often aromatic. Hydroxamic acids carrying cyclic 
peptide surface recognition domain structures are described in section 5. 
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TSA (2) and its glucopyranosyl derivative trichostatin C were first isolated from cultures of 
Streptomyces hygroscopicus as antifungal antibiotics active against Trichophyton 
species.261,262 
Many years later, the trichostatins were found to have potent antiproliferative and 
differentiating activity at nanomolar concentrations against Friend murine erythroleukemia 
cells in culture.263  
Whilst dimethylsulfoxide and sodium butyrate were previously known to induce 
differentiation in this cell line, TSA was orders of magnitude more potent.264 Stereoselective 
synthesis of the enantiomers of TSA and subsequent analysis showed that the natural 
configuration is (R)-TSA and (S)-TSA is 70-fold less potent as an inducer of Friend 
erythroleukemia cell differentiation.265  
The extremely potent biological activity and the chiral specificity of (R)-TSA suggested the 
binding of the molecule to a specific molecular target. In later studies, TSA was active in a 
number of normal and tumour cell lines, arresting the growth of rat fibroblast cells in G1 and 
G2 phases of the cell cycle.266  
Nuclear histones from cells treated with TSA were highly acetylated and on pulse-chase 
analysis this was not due to increased acetylation but rather, to decreased deacetylation.238 In 
experiments using partially purified mouse HDAC, TSA was a potent, reversible, non-
competitive inhibitor with Ki = 3.4 nM, closely related to the effective antiproliferative 
concentration in cell lines.  
Furthermore, the Ki was 10-fold higher for HDAC purified from a mutant cell line resistant to 
TSA, suggesting that HDAC was the likely primary target of TSA.238 
SAHA (1) is the prototype in a series of synthetic hydroxamic acid-based HPCs with 
nanomolar HDAC inhibitory potency also including pyroxamide.246  
Structure-activity studies of HPCs have shown that the hydroxamic acid is the crucial moiety 
to obtain high inhibiting activity, since substitution or modification at this site reduces their 
anti-HDAC effect.267 SAHA is in phase II development, and is reported to be active in 
patients with solid tumours and with Hodgkin’s disease at non-toxic doses.268  
Histone hyperacetylation was detected in tumour biopsies and in peripheral mononuclear cells 
after administration of SAHA at doses substantially below those at which antitumour efficacy 
was seen. SAHA also had good oral bioavailability and early phase clinical studies were 
reported to be ongoing in patients with both solid tumours and haematological cancers.268 In 
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phase I studies, the closely related compound pyroxamide was initially evaluated as a 
continuous intravenous infusion for 5-7 days, but severe fatigue and transient hepatic toxicity 
limit the dose. Shorter infusional schedules are now being investigated.268  
Hydroxamate SAHA analogues are represented by CBHA (3), pyroxamide (4) and 3-Cl-
UCHA (5). 269,270 These agents have been shown to be effective HDAC inhibitors and 
antiproliferative agents, both in vitro and in vivo. 
SAHA (1), TSA (2), and CBHA (3), which represent the paradigmatic hydroxamate HDAC 
inhibitors, have been instrumental in guiding the design of hydroxamate-derived HDAC 
inhibitors.  
Constituents of the hydroxamate class are herein divided into two categories based on the 
structures of their linkers:  
i      inhibitors with linear linkers (TSA and SAHA-like), 
ii     inhibitors with linkers consisting of carbo- or heterocycles (CBHA-like). 
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Inhibitors containing linear linker domain structures. In an effort to understand the 
importance of the methyl-substituted olefinic linker in TSA hybrids, the synthesis and 
evaluation of the compounds 7 and 8 has been performed.271 These agents, along with related 
analogue 6, demonstrate a highly sensitive and limited SAR profile. For example, the 
sequential addition of a methyl group (7) and two double bonds (8) caused a 2.3- and 33-fold 
reduction in activity, respectively, relative to the linear alkyl (6). 
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Oxamflatin (9) was prepared by researchers at Shionogi Laboratories in 1996.272,273  
Oxamflatin was found to be a potent HDAC inhibitor of partially purified mouse HDAC 
(IC50=15.7 nM), although it was found to be less potent than TSA (2) (IC50=1.44 nM) in the 
same assay. 
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Scriptaid (10), which was identified via highthroughput screening for transcriptional 
activators, was also found to inhibit HDAC and cause the induction of histone 
hyperacetylation.274 A series of tricyclic molecules related to scriptaid (10) and corresponding 
to the general formula 11 were recently reported. The most potent analogue, 12, has IC90=10 
nM.  
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Jung and co-workers synthesized a group of phenylalanine-containing SAHA analogues, 
including 13 and other derivatives.275,276 These agents were tested against both maize histone 
deacetylase (HD-2) and partially purified rat liver HDAC.  
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This series provides insight into the nature of inhibitor-enzyme interactions. The trends in 
activity against HD-2 are different from those observed in mammalian HDAC. 
For example SAHA (1) appears to be a poor inhibitor of HD-2; furthermore HD-2 does not 
discriminate between the five- and six-methylene linkers, while HDAC favors the six-
methylene linker. 
Compounds of this series with bulky hydrophobic residues (naphthyl or indolyl groups) in the 
side chains appear to be among the best inhibitors and differentiating agents. Finally, 
inversion of the phenylalanine chiral center did not affect inhibitor activity against the enzyme 
or in cells. 
The same group also reported reverse amide SAHA derivatives.277,278 This study confirmed 
the earlier observation that compounds with five- and six methylene spacers (6 and 14) are the 
most active. This series of compounds was expanded further to include scriptaid analogues 15 
and 16 and SAHA analogue 17. 
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 Biaryl ether hydroxamate 18 was identified by Glaser and co-workers as a mimic of 
transforming growth factor α (TGF-α) with proliferation inhibitory properties. This agent was 
further shown to inhibit a mixture containing human HDAC1, HDAC2, and HDAC3 (IC50= 9 
nM) and to cause histone hyperacetylation and p21 induction.279 
 
O NHOH
O
NC
18
 
 
In a more recent paper, Curtin and co-workers reported the synthesis and HDAC1 inhibitory 
activity of 21 and reaction byproduct succinimide 22, both of which contain a macrocyclic 
surface recognition domain.280 A related series of succinimide hydroxamic acids were 
prepared and assayed against human HDAC1. The number, identity, and disposition of 
macrocycle substituents appear to be critical for activity. The removal of the succinimide 
substituents or the phenylalanine side chain depresses activity. Replacement of the 
succinimide with a lactam or phthalimide also led to reduced activity. The length of the linker 
domain alkyl group was also found to be critical, with the five-methylene analogue showing 
maximal activity. 
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Schreiber and co-workers reported the synthesis of a library of SAHA-derived HDAC 
inhibitors including hydroxamates (23), benzamides, and carboxylates.281 This set of 
compounds was aimed at the exploration of the chemical space in the rim region of the 
HDAC enzymes. 
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Inhibitors containing cyclic linker domain substructures. One of the earliest papers reporting 
compounds with aromatic linkers presented the activity of compounds 24 and 25 together 
with compounds with linear linkers.275 These studies demonstrate the importance of the 
proper orientation of the linker, underscoring the importance of conformation and 
arrangement of substructures for HDAC inhibition. 
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The discovery of CBHA (3) as an HDAC inhibitor demonstrated toleration of aromatic rings 
in the linker domain.269,270 This observation, and the olefinmethyl arrangement found in TSA 
(2), suggests an isosteric relationship between these agents.  
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Oxamflatin-CBHA derived compounds have also been disclosed.282 Compounds containing 
cinnamic (26) and hydrocinnamic (27) linkers were determined to be the best in a series 
consisting of various lengths.  
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This result was interpreted in terms of effect of the chain length but could also stem from the 
geometries the compounds can assume, as seen for 24 and 25. The presence of the double 
bond has little effect on activity, while substitution R to the hydroxamate dramatically 
decreased activity. A 3-fold decrease in HDAC inhibitory activity was observed upon 
methylation of the sulfonamide nitrogen. 282 
Finally, screening of a compound library yielded CBHA derivative 28  which was found to 
inhibit HDAC, induce p21, and inhibit proliferation. A series of agents based on 28 led to 
NVP-LAQ824 (29)283 and SK-7041,284 that is in preclinical studies.   
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Hydroxamic acids constitute the largest class of HDAC inhibitors, with new examples being 
added at a rapid pace both in the literature and in patent disclosures. These agents are among 
the most potent HDAC inhibitors, with many examples of low nanomolar activity, and the 
search for even more potent compounds in this class will presumably continue for the 
foreseeable future. In addition, in vivo efficacy studies have demonstrated that the 
hydroxamate class has great therapeutic potential. There are currently two HDAC inhibitors 
from the hydroxamate class in clinical trials, the most advanced of which is SAHA 
(Vorinostat, phase III). 
14.2. Carboxylates. 
The study of the SAR of the carboxylate class285, which is defined as possessing a carboxylate 
in the metal binding domain, has been limited as a result of poor HDAC inhibitory activity. 
With some exceptions like a CHAP carboxylic acid analogue corresponding to trapoxin B 
(IC50=100 nM), these agents possess millimolar HDAC inhibitory activities. The activity of 
the CHAP carboxylic acid analogue illustrates the importance of the surface recognition 
domain to HDAC inhibitory activity. However, most carboxylates reported to date have been 
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limited to simple alkyl chains. Nonetheless, these agents are being studied in the clinic for the 
treatment of cancer, albeit at doses required to achieve high concentrations of drug.  
For example, butyric acid (BA, 30), a natural product generated in man by metabolism of 
fatty acids and bacterial fermentation of fiber in the colon, has long been known to be an 
antiproliferative and differentiating agent.285,286 The first report of anticancer activity of BA 
on solid tumors in 1933 was followed by the observation that it possesses differentiating 
activity at high micromolar concentrations on several cancer cell types.287 It was later 
determined that BA is a millimolar HDAC inhibitor, and this observation is thought to explain 
its mechanism of action. Other short-chain fatty acid analogues of BA, such as sodium 
phenylacetate (31), sodium phenylbutyrate (32), and the anticonvulsant valproic acid (33), 
have also been identified as antiproliferative agents and HDAC inhibitors.285 
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Despite poor enzymatic inhibitory activity, a number of carboxylates, including butyric (30) 
and phenylbutyric acid (31), are in clinical trials for cancer treatment alone and in 
combination with other agents.288 A combination of phenylbutyrate and all-trans retinoic acid 
(ATRA), for example, induced histone hyperacetylation and complete remission in a case of 
highly resistant promyelocytic leukemia before relapse occurred after 7 months.289 
The high concentration of BA and analogues needed for clinical use, coupled with poor 
bioavailabilty and rapid metabolic degradation, has led to the exploration of prodrugs such as 
34 and 35.290 Compound 34, also known as tributyrin, can deliver 3 equivalents of BA upon 
hydrolysis.  
Compound 36 is a prodrug of both BA and ATRA. These agents show better absorption and 
have a more favorable metabolic profile than the corresponding parent compounds.290 
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Overall, the carboxylate class possesses limited HDAC inhibitory activity. Advances in 
generating carboxylates with improved HDAC inhibitory potency have provided important 
insights into the field of HDAC inhibitor design. However, a great deal of work remains to be 
done before potent carboxylates can be routinely generated as HDAC inhibitors. Nonetheless, 
the clinical utility of modestly active constituents of the carboxylate class is under 
investigation and promising results have been obtained, thereby accentuating the validity of 
HDAC inhibition as a potential treatment for cancer. 
14.3. Benzamides. 
The benzamide class, which is generally less potent than the corresponding hydroxamate and 
cyclic tetrapeptide classes, includes MS-275291 (37) and CI-994292, 293(38).  
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In 1999, Suzuki and coworkers identified MS-275 (37) from a series of synthetic benzamide-
based HDAC inhibitors.291 The SAR of the benzanilide functionality revealed that a 2’-amino 
(37) or 2’-hydroxyl moiety is critical for inhibitory activity against partially purified histone 
deacetylase. 
Removing or repositioning the amino group on the aryl substitutent or capping with acetate 
generates inactive agents. 
Substitution at the 3’, 4’, and 5’ positions attenuated enzymatic activity, apparently because of 
increased steric interactions, given that electronic contributions of substituents at these 
positions appeared to have little effect. Additional evaluation of MS-275 demonstrated that it 
could inhibit partially purified human HDAC preparations and cause hyperacetylation of 
nuclear histones in various cell lines.294 When administered orally to nude mice implanted 
with tumor lines, seven out of eight lines were strongly inhibited.294 
Importantly, an inactive MS-275 structural analogue was devoid of both in vitro and in vivo 
activity, further suggesting that the beneficial biological effects are a result of HDAC 
inhibition. MS-275 is currently in phase II clinical trials. 
CI-99455 (38) is an acetylated derivative of dinaline initially developed as a potential 
anticonvulsive agent. The mechanism for the antitumor activity of CI-994 is currently unclear 
but may involve the modulation histone deacetylation, although no information on HDAC 
inhibitory activity has been published to date. Phase II trials for non-small-cell lung cancer 
revealed activity, and trials comparing gemcitabine alone to gemcitabine in combination with 
CI-994 have been initiated.295 
The benzamide moiety of MS-275 (37) was also explored in a library of SAHA derivatives 
related to 23 (generic formula 39). 
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These inhibitors, which were based on a 1,3-dioxane diversity structure, were synthesized on 
polystyrene beads and assayed for biological activity in a “one beadone 
stock solution format”.281 These elegant studies led to the identification of molecules that 
appear to selectively inhibit HDAC1 over HDAC6 .296 
The exact mechanism by which the benzamides exert their antiproliferative effects has not 
been fully elucidated. 
However, it has been clearly demonstrated that certain members of the benzamide class 
possess antitumor activity that correlates with HDAC inhibitory activity, although the nature 
of this activity appears to differ significantly from that of the small-molecule hydroxamates, 
as measured by changes in gene expression.  
Additional unanswered questions include whether benzamide-induced HDAC inhibition 
occurs at the active site, as demonstrated for hydroxamates, and if so, the exact nature of the 
benzamide moiety interaction with the active site zinc of the enzyme remains to be 
characterized. Additional studies will be required in order to understand the mechanistic 
differences between the benzamide and hydroxamic acid classes with regard to HDAC 
inhibition. 
14.4. Electrophilic ketones. 
Numerous electrophilic ketones are known inhibitors of proteases, including metal-dependent 
hydrolytic enzymes such as carboxypeptidase A and metallo-β-lactamase.297, 298 Studies have 
demonstrated that the hydrated form of the ketone acts as a transition-state analogue and 
coordinates the zinc ion in the active site of carboxypeptidase A.297 
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It seems likely that a similar mechanism is operative for HDAC inhibition by the electrophilic 
ketone class. The first constituent discovered in this newly defined class of HDAC inhibitors 
was trifluoromethyl ketone 40.278  
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The synthesis of various linear molecules based on this structure comprising an aromatic in 
the surface recognition domain, connected via ether or amide bonds to an aliphatic chain in 
the linker domain and carrying a trifluoromethyl ketone in the metal binding domain, was 
recently disclosed (generic formula 41, 42).299 
 
O
X CF3
O
N
H
CF3
O
O
R
41 42
 
These agents were tested against a mixture of HDAC1 and HDAC2 and showed inhibition at 
low micromolar/high nanomolar concentrations. These agents also possess antiproliferative 
activities in vitro and induce histone hyperacetylation and p21 gene expression.  
Both the five- and six-methylene linkers showed optimal activity in the ether series. 
Compounds carrying meta or para substituents were found to be significantly more potent 
than the corresponding ortho analogues (42 series), and an aromatic moiety can be 
accommodated in the linker. The trifluoromethyl ketone is essential for the inhibitory activity 
of these compounds.  
A simple ketone, a trifluoromethylcarbinol and a pentafluoroethyl ketone showed no 
inhibition up to 50 µM, although some simple ketones in the cyclic peptide class possess 
potent HDAC inhibitory properties. The trifluoromethyl ketones studied exhibit short half-
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lives both in vivo and in vitro by rapid reduction to the corresponding alcohol, which occurs in 
vitro in the presence of whole blood or cells. 
The same group recently presented R-ketoamides as HDAC inhibitors.300 The compounds of 
general structure 43 were chosen as the best candidates among other electrophilic ketones, 
including various R-ketoacids and ketoesters. Compound 44 is an HDAC inhibitor (IC50=9 
nM) that shows antiproliferative activity in vitro, as well as efficacy in a tumor model in vivo.  
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This series of compounds, as might be expected, was also rapidly metabolized to the 
corresponding alcohol both in vivo and in vitro in whole blood.  
The antiproliferative activity and in vivo efficacy of electrophilic ketones, despite their 
metabolic instability, were rationalized by the hypothesis that a brief exposure to HDAC 
inhibitors can induce a biological response.300 
The electrophilic ketone class represents a new design that has not yet been fully exploited. 
Current challenges include the need to develop additional structural variants in order to assess 
optimal design parameters and tolerances, as well as the application of the wealth of 
information available about the linker and surface recognition domains from other structural 
classes to the electrophilic ketone class. Nonetheless, the electrophilic ketone class contains 
potent inhibitors of HDAC that, despite apparent poor stability, possess antitumor effects in 
animal models. 
14.5. Cyclic peptide inhibitors. 
Cyclic peptide containing HDAC inhibitors, which constitute the most structurally complex 
class of HDACinhibitors, are herein divided into two subclasses: inhibitors bearing (S)-2-
amino-9,10-epoxy-8-oxodecanoic acid (L-Aoe), which contains an epoxy ketone, and 
inhibitors without the L-Aoe moiety.  
All of the agents from each subclass conform to the pharmacophore model for HDAC 
inhibitors and possess a macrocycle containing hydrophobic amino acids in the surface 
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recognition domain, an alkyl chain in the linker domain, and a functional group in the metal 
binding domain. 
Constituents of the cyclic peptide class typically possess nanomolar levels of HDAC 
inhibitory activity; however, their general utility in the treatment of cancer remains largely 
unproven, with the possible exception of FK-228 (45, aka depsipeptide, see below).301 
It is believed that cyclic peptide HDAC inhibitors bind to the HDAC enzyme in a manner 
consistent with the X-ray crystallographic findings with hydroxamates. By this model, the 
aliphatic linker passesdown the enzyme’s tubelike channel, positioning the binding moiety in 
proximity to the active site zinc, while the macrocyclic portion binds to the rim of the active 
site. However, the mechanism of action differs between the Aoe-containing inhibitors, which 
are typically classified as irreversible HDAC inhibitors, and those without the Aoe moiety, 
which are reversible inhibitors. 
However, the irreversible nature of Aoe-containing inhibitors is still in question and 
mechanistic possibilities include both direct covalent modification via nucleophilic attack on 
the reactive epoxy ketone in the active site and noncovalent binding with slow dissociation of 
the inhibitor from the active site. 302 
The first examples of the cyclic peptide class arose from screening natural products for 
antiparasitic or antiproliferation activity, with the Aoe-containing cyclic peptides being the 
first subclass isolated. These compounds include HC-toxins (46),303 trapoxin B (47),304 and 
chlamydocin (48)305.  
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46: HC-toxin 47: Trapoxin B
48: Chlamydomicin A  
The isosteric nature of the Aoe side chain with acetylated lysine suggests it mimics the natural 
substrate. Some Aoe-containing inhibitors appear to operate exclusively by an irreversible 
mechanism and require the epoxy ketone functionality for their effects. For example, the 9,10-
diol analogue of HC-toxin (46) is devoid of activity. Reduction of the C8-ketone of 
chlamydocin (48) to the alcohol or replacement of the epoxide with CH2=CH2, CH2CH3, or 
CH2CH2OH leads to reduced HDAC inhibitory activity.305 
Within the subclass of cyclic tetrapeptides classified as reversible inhibitors are active 
variants of the Aoe-containing natural products lacking the epoxy ketone functionality.  
These agents demonstrate that the potentially reactive epoxy ketone moiety is not required for 
HDAC inhibition. Apicidin (49), a fungal metabolite, contains an (S)-2-amino-8-oxodecanyl 
side chain lacking an epoxide.306  
It has broad spectrum activity (ranging from 4 to 125 ng/mL) against the apicomplexan family 
of parasites, presumably via inhibition of protozoan histone deacetylases (IC50=1-2 nM), and 
demonstrates efficacy against Plasmodium berghei malaria in mice. 
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A systematic study into side chain derivatives of apicidin revealed several picomolar HDAC 
inhibitors.307 These derivatives were tested for HDAC inhibition using partially purified 
extracts of both human HeLa cells and Eimeria tenella protozoa.  
Potent HDAC inhibitors maintaining a tetrapeptide macrocycle and linear linker, but 
incorporating the known zinc chelating ability of hydroxamic acids, have been explored 
extensively by Yoshida and co-workers. 308  
These synthetic hybrids of the hydroxamate and cyclic tetrapeptide classes, termed CHAPs 
(50), resulted in reversible inhibitors of HDAC1 that are active at low nanomolar 
concentrations. Studies of chain length between the macrocycle and the hydroxamic acid 
revealed that the optimal linker for HDAC1 inhibitory activity was five-methylene units, 
relative to four- and seven-methylene units. It is interesting to note that a CHAP carboxylic 
acid analogue corresponding to trapoxin B had significant activity (IC50=100 nM). 
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Other studies investigating the biological effects of synthetically modified macrocyclics have 
been performed.  In their efforts to identify parasite-selective HDAC inhibitors, Merck 
researchers generated indole-modified apidicin analogues possessing picomolar enzyme 
activity, as well as tryptophan-replacement analogues displaying 20- to 100-fold parasite 
selectivity.309 
FK228 (45) which was discovered from a fermentation broth of Chromobacterium violaceum, 
310 differs structurally from other constituents of the cyclic peptide class. FK228 contains a 
unique bicyclic structure with four amino acids and a β-hydroxyamide moiety, which 
collectively form a 16-membered lactone with a disulfide bridge. FK228 (Romidepsin) is 
currently the only member of the cyclic peptide class in clinical trials (phase III). 
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Cyclic peptides comprise a diverse class of HDAC inhibitors possessing modes of enzyme 
inactivation ranging from reversible to irreversible inhibition.  
This class of HDAC inhibitors has aided in the understanding of the factors governing HDAC 
inhibitor activity and selectivity. Further investigations probing binding interactions on the 
outer rim of the HDAC enzymes will hopefully lead to a greater understanding of essential 
inhibitor-enzyme contacts and ultimately to the identification of selective inhibitors with more 
druglike qualities. 
14.6. Thiol based inhibitors. 
In the search for a suitable hydroxamic acid replacement, thiols seemed to be reasonable 
targets, because they have been reported to inhibit zinc-dependent enzymes such as 
angiotensin converting enzyme (ACE) and matrix metalloproteinase (MMPs).  
Recently, Furumai et al. demonstrated that the disulfide bond of FK228  (45), a cyclic peptide 
HDAC inhibitor, is reduced in the cellular environment, releasing the free thiol analogue as 
the active species. 311   
Prompted by these data, T. Suzuki et al. synthesized thiol-based SAHA analogues. 312  
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Compound 51, in which the hydroxamic acid of SAHA was replaced by a thiol, was found to 
be as potent as SAHA.  
 
N
H
O
SH
             51
HDAC IC50=210nM  
 
They shown that the potency is related to chain length, and the amide and reversed amide 
were preferred as the group attaching the phenyl moiety. The conversion of the phenyl group 
of compound 51 to other aromatic groups led to the identification of inhibitors more potent 
than SAHA. The SAR results within the thiol series indicate that thiols inhibit HDACs in a 
manner similar to that of hydroxamates. 
 
15. Sirtuins’ Inhibitors. 
To date, only a few molecules have been discovered as inhibitors of sirtuins.  
Among them, the so called sirtinol (Sir two inhibitor naphtol) was identified by a high 
throughput phenotypic screening in cells.313  
The splitomicin was discovered by screening of other libraries,314 and last but not least the 
vitamin nicotinamide was recognized able to inhibit the sirtuins without competing with 
NAD+.163 
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         16. Research project. 
A large number of natural and synthetic class I/II HDAC inhibitors have been reported so far, 
and the majority of them do not discriminate between the different classes of enzymes.315-322 
The only exceptions are sodium valproate (VPA),323 some 2’-aminoanilides (such as MS-
275,324,325 histacin,326 and pimeloyl-anilide orthoaminoanilide (PAOA)326 a few cinnamyl 
hydroxamates (SK-7041 and SK-7068),327 and depsipeptide FK-228,328 which are class I-
selective HDAC inhibitors. Trapoxins (TPXs), cyclic hydroxamic acidcontaining peptide 1 
(CHAP1), and sodium butyrate (NaB) are ineffective in inhibiting HDAC6,329,330 whereas 
tubacin331-333 and some aryloxopropenyl-pyrrolyl hydroxyamides334 are class IIb- and class II 
(IIa)-selective HDAC inhibitors, respectively (Figure 28).  
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      Figure 28. Structures of known HDAC inhibitors. 
 
 
According to these findings, we undertook synthetic and biological efforts to improve the 
HDAC inhibitory activity of the aroyl-pyrrolyl hydroxyamides (APHAs) recently reported by 
us (Figure 29).335-339  
 
 
Design, synthesis and biological validation of epigenetic modulators of histone/protein deacetylation and 
methylation. 
 
 91
 
Figure 29. Structure–activity relationship (SAR) summary of 
aroyl-pyrrolyl hydroxyamides (APHAs). 
 
Starting from the first lead compound, 3-(4-benzoyl-1-methyl-1H-pyrrol-2-yl)-Nhydroxy-2-
propenamide (1) (Figure 30),335,336 we performed some chemical modifications on the 
structure of 1 to increase its anti-HDAC activity. Among the modifications described, only the 
insertion of a phenylacetyl/phenylpropionyl moiety at the C4 position of the pyrrole ring led 
to an improved anti-HDAC potency of the inhibitors, affording compounds 2 and 3 (Figure 
30).337,338 Furthermore, 2 and 3 were tested against maize HD1-B340,341 and HD1-A,342,343 two 
mammalian class I and class II HDAC homologues, to explore their potential class-selectivity. 
In these tests, 2 and 3 showed similar activities (2: IC50(HD1-B)= 150 nM, IC50(HD1-A)=50 
nM; 3: IC50(HD1-B)=120 nM, IC50(HD1-A)= 60 nM), with 2 having higher selectivity for 
class II than 3 (selectivity for class II HDACs: 2, 3-fold; 3, 2-fold). Compounds 2 and 3 
showed similar antiproliferative and cytodifferentiation properties in assays with Friends 
murine erythroleukemia (MEL) cells.338 
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Figure 30. APHA lead compounds 
and new designed derivatives. 
 
16.1. First lead optimizzation. 
As 2 and 3 showed similar behaviors both in vitro and in vivo, we chose the phenylacetyl-
pyrrolyl hydroxypropenamide template of 2 for chemical investigation. In particular, we 
introduced various substituents ranging between electron-donating and electron-withdrawing 
groups, in the ortho, meta, or para positions of the benzene ring (compounds 4, Figure 30). 
The influence of such insertions on the inhibitory activities toward HD2 as well as HD1-B 
and HD1-A was evaluated, and the potential class-selectivity of the novel derivatives was 
assessed. Selected title compounds 4b,k were tested against mouse HDAC1 in comparison 
with 2 and SAHA. Homology models, molecular modeling, and docking studies were 
performed on the most selective derivatives against HD1-B (compound 4u) and HD1-A 
(compound 4t), to gain insight about their binding mode. Finally, the most potent compound, 
4b, was evaluated as an antiproliferative and cytodifferentiation agent in human acute 
promyelocytic leukemia HL-60 cells. 
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16.2. Chemistry. 
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Scheme 1. a) Oxalyl chloride, DMF, RT; b) 1. R-Ph-CH2COCl, AlCl3, 1,2-dichloroethane, RT, 2. 
KOH, H2O, RT; c) (C2H5O)2OPCH2COOC2H5, K2CO3, C2H5OH, 80°C; d) 5b, SOCl2, AlCl3, 1,2-
dichloroethane, RT; e) NaHPO2, K2CO3, Pd/C, THF/H2O, RT; f) benzoyl chloride or benzenesulfonyl 
chloride, (C2H5)3N, dichloromethane, RT; g) 1. phenylboronic acid, Na2CO3, 
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tetrakis(triphenylphosphine) palladium, Ph-CH3/C2H5OH, 80°C, 2. KOH, H2O, RT; h) potassium 
peroxymonosulfate (oxone), NaCl, acetone/H2O, RT. 
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Scheme 2. a) KOH, C2H5OH, H2O, 70°C; b) LiOH, H2O, RT; c) ClCOOC2H5, (C2H5)3N, THF, 0°C; d) 
NH2OC(CH3)2OCH3, RT; e) Amberlyst 15, CH3OH, RT. 
 
 
Ethyl 3-[1-methyl-4-(substituted)phenylacetyl-1H-pyrrol-2-yl]-2-propenoates 7a–w, key 
intermediates for the synthesis of the hydroxamates 4, were prepared by the one-pot 
Vilsmeier–Haack/Friedel–Crafts reaction performed on 1-methyl-1H-pyrrole with oxalyl 
chloride/N,N-dimethylformamide and (substituted) phenylacetyl chloride/aluminum 
trichloride, followed by Wittig–Horner reaction of the obtained aroyl-pyrrolecarboxaldehydes 
6a–w with triethylphosphonoacetate and potassium carbonate (Scheme 1 a). 3-
Ethoxyphenylacetic acid, useful for the synthesis of the pyrrolealdehyde 6r, was prepared as 
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reported.344 A Suzuki coupling reaction between methyl 3-bromophenylacetate and 
phenylboronic acid in the presence of tetrakis(triphenylphosphine)palladium and sodium 
carbonate followed by alkaline hydrolysis afforded, with a simple twostep method, the 3-
biphenylacetic acid 5a,345 which was used for the synthesis of 6t (Scheme 1 b). A single-step, 
high-yielding reaction of 4-methoxyphenylacetic acid with potassium peroxymonosulfate 
(oxone) and sodium chloride led to the 3-chloro-4-methoxyphenylacetic acid 5b346 (Scheme 1 
b), which was useful in the preparation of the ethyl 3-[4-(3-chloro-4-methoxyphenylacetyl)-1-
methyl-1H-pyrrol-2-yl]-2-propenoate 7a’. Such compounds, the preparation of which failed 
with the Vilsmeier–Haack/Friedel–Crafts procedure, was obtained by acylation of ethyl (1-
methyl-1H-pyrrol-2-yl)-2-propenoate347 with aluminum trichloride and 3-chloro-4-
methoxyphenylacetyl chloride (Scheme 1 a). Ethyl 3-[4-(3-benzoylamino- and 3-
benzenesulfonylaminophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-propenoates 7y,z were 
prepared by the reaction of benzoyl chloride or benzenesulfonyl chloride with ethyl 3-[4-(3-
aminophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-propenoate 7x, previously obtained by 
reduction of the 3-nitro analogue 7n with sodium hypophosphite and potassium carbonate 
(Scheme 1 a). Alkaline hydrolysis of the ethyl pyrrole-propenoates 7a–a’ furnished the 
pyrrole-propenoic acids 8a–a’, which were in turn converted into the corresponding 
hydroxamates 4a–a’ through reaction with ethyl chloroformate and O-(2-methoxy-2-
propyl)hydroxylamine,348 followed by acid hydrolysis of the N-(1-methoxy-1-methylethoxy) 
propenamides 9a–a’ with the Amberlyst 15 ion-exchange resin (Scheme 2). The O-protected 
hydroxamates 9 were hydrolyzed without further purification as soon as they were obtained.  
 
Chemical and physical data for compounds 4a–a’ are listed in Table 1. Chemical and physical 
data for the intermediate compounds 5–8 are listed in Table 2. 
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                          Table 1. Chemical and physical data for compounds 4a–a’.
 
compound R mp, ° C 
recrystallizzation 
solvent 
% yield  
4a 2-Cl > 250 acetonitrile 58 
4b 3-Cl 162-163 benzene/acetonitrile 52 
4c 4-Cl 175-177 acetonitrile 66 
4d 2-F 188-190 benzene/acetonitrile 54 
4e 3-F 199-201 acetonitrile/benzene 57 
4f 4-F 178-179 benzene/acetonitrile 68 
4g 2-Br 180-182 benzene/acetonitrile 49 
4h 3-Br 163-165 benzene/acetonitrile 55 
4i 4-Br 153-154 benzene/acetonitrile 64 
4j 2-Me > 250 acetonitrile 52 
4k 3-Me 210-212 acetonitrile/benzene 57 
4l 4-Me >250 acetonitrile 54 
4m 2-NO2 180-182 benzene/acetonitrile 45 
4n 3-NO2 228-230 acetonitrile 58 
4o 4-NO2 118-120 benzene/acetonitrile 59 
4p 3-OMe 148-150 benzene/acetonitrile 43 
4q 4-OMe 178-180 benzene/acetonitrile 56 
4r 3-OEt 100-102 benzene 48 
4s 4-OEt 190-192 benzene/acetonitrile 44 
4t 3-Ph 117-118 benzene 42 
4u 4-Ph 199-201 benzene/acetonitrile 58 
4v 3,5-Me2 194-196 acetonitrile/ethanol 58 
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4w 3,5-F2 143-145 benzene/acetonitrile 56 
4x 3-NH2 201-202 benzene/acetonitrile 53 
4y 3-NHCOPh 222-225 benzene/acetonitrile 40 
4z 3-
NHSO2Ph 
75-77 diethyl ether 42 
4a' 3-Cl-4-
OMe 100-102 diethyl ether 55 
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                            Table 2. Chemical and physical data for compounds 5-8.
 
compound R mp, ° C 
recrystallizzation 
solvent 
% yield  
5a  141-143 benzene/cyclohexane 84 
5b  98-100 benzene/cyclohexane 90 
6a 2-Cl 101-102 benzene/cyclohexane 56 
6b 3-Cl 86-88 diethyl ether 41 
6c 4-Cl 110-111 benzene 57 
6d 2-F 89-91 cyclohexane/benzene 65 
6e 3-F 48-50 diethyl ether 70 
6f 4-F 85-87 benzene/cyclohexane 83 
6g 2-Br 94-95 benzene/cyclohexane 54 
6h 3-Br 104-105 benzene/cyclohexane 64 
6i 4-Br 128-130 benzene/cyclohexane 72 
6j 2-Me 111-112 cyclohexane 42 
6k 3-Me 54-55 cyclohexane 58 
6l 4-Me 110-111 benzene/cyclohexane 90 
6m 2-NO2 134-136 benzene 38 
6n 3-NO2 126-128 benzene/cyclohexane 87 
6o 4-NO2 135-136 benzene/cyclohexane 76 
6p 3-OMe 88-90 benzene/cyclohexane 58 
6q 4-OMe 149-151 benzene/cyclohexane 66 
6r 3-OEt 94-95 cyclohexane 42 
6s 4-OEt 125-127 benzene/cyclohexane 53 
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 6t 4-Ph 78-80 diethyl ether 41 
6u 3,5-Me2 oil  62 
6v 3,5-F2 146-147 benzene/cyclohexane 57 
7a 2-Cl 209-210 benzene/cyclohexane 42 
7b 3-Cl oil  95 
7c 4-Cl oil  73 
7d 2-F 95-97 benzene/cyclohexane 88 
7e 3-F oil  86 
7f 4-F 93-94 benzene/cyclohexane 91 
7g 2-Br 99-101 benzene/cyclohexane 75 
7h 3-Br 111-112 benzene/cyclohexane 79 
7i 4-Br 136-137 benzene/cyclohexane 89 
7j 2-Me 124-126 benzene/acetonitrile 68 
7k 3-Me 80-82 cyclohexane 77 
7l 4-Me 54-56 cyclohexane 95 
7m 2-NO2 94-96 diethyl ether 81 
7n 3-NO2 128-130 benzene/cyclohexane 87 
7o 4-NO2 129-131 benzene/cyclohexane 78 
7p 3-OMe 91-93 benzene 60 
7q 4-OMe 85-87 diethyleter 72 
7r 3-OEt 99-100 benzene/cyclohexane 67 
7s 4-OEt 73-75 cyclohexane 63 
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 7t 3-Ph oil  45 
7u 4-Ph 130-132 benzene/cyclohexane 74 
7v 3,5-Me2 oil  59 
7w 3,5-F2 154-156 benzene 63 
7x 3-NH2 oil  63 
7y 
3-
NHCOPh 
oil  53 
7z 
3-
NHSO2Ph 
oil  59 
7a' 
3-Cl-4-
OMe 
104-105 benzene/cyclohexane 67 
8a 2-Cl 210-212 benzene/cyclohexane 74 
8b 3-Cl 195-196 acetonitrile 65 
8c 4-Cl 207-209 acetonitrile 74 
8d 2-F 185-187 benzene/acetonitrile 78 
8e 3-F 105-107 benzene 67 
8f 4-F 169-171 benzene/cetonitrile 73 
8g 2-Br 210-211 benzene/acetonitrile 81 
8h 3-Br 209-210 benzene/acetonitrile 84 
8i 4-Br 178-180 benzene/acetonitrile 87 
8j 2-Me 204-205 acetonitrile 75 
8k 3-Me 160-161 acetonitrile 79 
8l 4-Me 189-190 acetonitrile 77 
8m 2-NO2 230-232 benzene/acetonitrile 68 
8n 3-NO2 260-262 acetonitrile 85 
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 8o 4-NO2 210-212 benzene/acetonitrile 76 
8p 3-OMe 150-152 benzene 69 
8q 4-OMe 174-176 benzene/acetonitrile 72 
8r 3-OEt 102-103 benzene 74 
8s 4-OEt 178-180 benzene/acetonitrile 83 
8t 3-Ph 135-136 benzene/acetonitrile 80 
8u 4-Ph 190-192 benzene/acetonitrile 73 
8v 3,5-Me2 81-83 diethyl ether 87 
8w 3,5-F2 238-239 benzene/acetonitrile 81 
8x 3-NH2 182-183 benzene 64 
8y 
3-
NHCOPh 
182-183 benzene 75 
8z 
3-
NHSO2Ph 
81-83 diethyl ether 87 
8a' 
3-Cl-4-
OMe 
239-240 acetonitrile 62 
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16.3 Experimental Section. 
Chemistry. Melting points were determined on a Büchi 530 melting point apparatus and are 
uncorrected. Infrared (IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One 
instrument. 1H NMR spectra were recorded at 200 MHz on a Bruker AC 200 spectrometer; 
chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). All compounds were routinely checked by TLC and 1H NMR.  
TLC was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light. All solvents were reagent grade and, when necessary, 
were purified and dried by standards methods. Concentration of solutions after reactions and 
extractions involved the use of a rotary evaporator operating at a reduced pressure of ca. 20 
Torr. Organic solutions were dried over anhydrous sodium sulfate. Analytical results are 
within ±0.40% of the theoretical values. A SAHA sample for biological assays was prepared 
as previously reported by us.349 All chemicals were purchased from Aldrich Chimica, Milan 
(Italy) or Lancaster Synthesis GmbH, Milan (Italy) and were of the highest purity. 
 
3-Biphenylacetic acid (5a). To a mixture of phenylboronic acid (13.4 mmol; 1.6 g) and 
methyl 3-bromophenylacetate (13.4 mmol, 3.1 g) dissolved in toluene/ethanol (70 mL/6 mL) 
an aqueous solution of 2 M sodium carbonate (28.2 mmol; 3.0 g dissolved in 14 mL of water) 
was added. After the resulting mixture was degassed for 10 min by nitrogen, 
tetrakis(triphenylphosphine)palladium (0.7 mmol, 0.8 g) was added, and the reaction was 
heated at 80 °C for 16 h. After, it was cooled until room temperature, the suspension was 
filtered and the solvent was evaporated under reduced pressure. The residue was partitioned 
between water (50 mL) and ethyl acetate (50 mL), the organic layer was separated, and the 
aqueous one was extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with 
brine (3 x 50 mL), dried, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel by eluting with ethyl acetate:chloroform 1:1. The crude methyl 
3-biphenylacetate was then dissolved in ethanol and treated with 2 N KOH (26.9 mmol, 1.5 g, 
13.5 mL). After being stirred at room temperature for 5 h, the solution was poured into water 
(100 mL), and extracted with ethyl acetate (2 x 50 mL). To the aqueous layer, a sample of 2 N 
HCl was added until the pH was 2, and the precipitate was filtered and purified by 
crystallization. 1H NMR (CDCl3) δ 3.42 (s, 2 H, CH2), 7.05 (m, 1 H, benzene H-4'), 7.17 (m, 
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1 H, benzene H-6), 7.30 (m, 5 H, benzene H-5,2',3',5',6'), 7.47 (m, 2 H, benzene H-2,4), 8.55 
(bs, 1 H, OH). Anal. (C14H12O2) C, H. 
 
3-Chloro-4-methoxyphenylacetic acid (5b). To a solution of 4-methoxyphenylacetic acid 
(12.0 mmol; 2.0 g) dissolved in acetone (20 mL) potassium peroxymonosulfate (OXONE®) 
(12.0 mmol; 7.4 g) was added, and the suspension was stirred at room temperature for 15 min. 
Afterward, sodium chloride solution (48.1 mmol; 2.8 g in 20 mL of water) was added, and the 
resulting mixture was stirred for 6 h. When the reaction was finished (TLC control: SiO2/ethyl 
acetate), the solvent was evaporated under reduced pressure, and the residue was diluted with 
water (100 mL), and extracted with ethyl acetate (3 x 50 mL). The organic layer was washed 
with sodium chloride solution (3 x 50 mL), dried, and concentrated. The residue was a solid 
that was recrystallized by cyclohexane/benzene. 1H NMR (CDCl3) δ 3.56 (s, 2 H, CH2), 3.87 
(s, 3 H, CH3), 6.88 (m, 1 H, benzene H-5), 7.14 (m, 1 H, benzene H-6), 7.30 (m, 1 H, benzene 
H-2), 9.00 (bs, 1 H, OH). Anal. (C9H9ClO3) C, H, Cl. 
 
General Procedure for the Synthesis of 4-Aroyl-1-methyl-1H-pyrrole-2-carboxaldehydes 
6a-w. Example: 4-(4'-Methylphenylacetyl)-1-methyl-1H-pyrrole-2-carboxaldehyde (6l). 
A 1,2-dichloroethane (20 mL) solution of oxalyl chloride (18.4 mmol, 1.4 mL) was added to a 
cooled (0-5 °C) solution of N,N-dimethylformamide (18.4 mmol, 1.6 mL) in 1,2-
dichloroethane (20 mL) over a period of 5-10 min. After being stirred at room temperature for 
15 min, the suspension was cooled (0-5 °C) again and treated with a solution of 1-methyl-1H-
pyrrole (18.4 mmol, 1.5 g) in 1,2-dichloroethane (20 mL). The mixture was stirred at room 
temperature for 15 min, and then was treated with aluminum trichloride (40.6 mmol, 5.4 g) 
and 4-tolylacetyl chloride (previously prepared by heating the corresponding acid (18.4 mmol, 
2.8 g) with SOCl2 (20 mL) for 1 h at 50 °C). After 3 h, the reaction mixture was poured onto 
crushed ice (100 g) containing 50% NaOH (20 mL) and stirred for 10 min. The pH of the 
solution was adjusted to 4 with 37% HCl, the organic layer was separated, and the aqueous 
one was extracted with chloroform (2 x 20 mL). The combined organic solutions were washed 
with water (3 x 50 mL), dried, and evaporated to dryness. The residual oil was purified by 
column chromatography on silica gel eluting with ethyl acetate:chloroform 1:5. The obtained 
solid was recrystallized from cyclohexane/benzene to give pure 6l. 1H NMR (CDCl3) δ 2.27 
(s, 3 H, PhCH3), 3.90 (s, 3 H, NCH3), 3.96 (s, 2 H, PhCH2CO), 7.10 (dd, 4 H, benzene H), 
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7.27 (m, 1 H, pyrrole β-proton), 7.39 (m, 1 H, pyrrole α-proton), 9.54 (s, 1 H, CHO). Anal. 
(C15H15NO2) C, H, N. 
 
General Procedure for the Synthesis of Ethyl 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-2-
propenoates 7a-w. Example: Ethyl 3-[4-(3'-methoxyphenylacetyl)-1-methyl-1H-pyrrol-2-
yl]-2-propenoate (7p). A suspension of 6p (1.7 mmol, 0.6 g) in absolute ethanol (20 mL) was 
added in one portion to a mixture of triethyl phosphonoacetate (2.1 mmol, 0.4 mL) and 
anhydrous potassium carbonate (3.5 mmol, 0.5 g). After being stirred at 70 °C for 2 h, the 
reaction mixture was cooled to room temperature, diluted with water (50 mL), and extracted 
with ethyl acetate (3 x 50 mL). The organic layer was washed with water, dried, and 
evaporated to dryness, and the solid residue was recrystallized to furnish pure 7p. 1H NMR 
(CDCl3) δ 1.36 (t, 3 H, COOCH2CH3), 3.74 (s, 3 H, NCH3), 3.81 (s, 3 H, OCH3), 4.01 (s, 2 H 
CH2CO), 4.27 (q, 2 H, COOCH2CH3), 6.25 (d, 1 H, CH=CHCO), 6.90 (m, 3 H, benzene H-
2,4,6), 7.10 (m, 1 H, pyrrole β-proton), 7.26 (m, 1 H, benzene H-5), 7.40 (m, 1 H, pyrrole α-
proton), 7.55 (d, 1 H, CH=CHCO). Anal. (C19H21NO4) C, H, N. 
 
Ethyl 3-[4-(3'-aminophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-propenoate (7x). 
Potassium carbonate (4.1 mmol, 0.6 g) and 10% palladium on carbon (20 mg) were slowly 
added to a solution of ethyl 3-[4-(3'-nitrophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-
propenoate 7n (5.8 mmol, 2.0 g) in a mixture of water (4 mL) and THF (5 mL). After being 
stirred at room temperature for 10 min, a solution of sodium hypophosphite (22.2 mmol, 2.4 
g) in water (30 mL) was added. After stirring at room temperature for 2 h, the reaction 
mixture was filtered, the organic layer was separated, and the aqueous one was extracted with 
ethyl acetate (3 x 50 mL). The combined organic solution was washed with water (2 x 100 
mL), dried, and evaporated to dryness. The residual oil was purified through column 
chromatography on silica gel by eluting with a 1:1 mixture of ethyl acetate and chloroform. 
Compound 7x was obtained as pure oil. 1H NMR (CDCl3) δ 1.30 (t, 3 H, COOCH2CH3), 3.72 
(s, 3 H, NCH3), 3.90 (s, 2 H CH2CO), 4.24 (q, 2 H, COOCH2CH3), 6.25 (d, 1 H, CH=CHCO), 
6.64 (m, 2 H, NH2), 6.70 (m, 4 H, benzene H-2,4,6 and pyrrole β-proton), 7.09 (m, 1 H, 
benzene H-5), 7.36 (m, 1 H, pyrrole α-proton), 7.49 (d, 1 H, CH=CHCO). Anal. (C18H20N2O3) 
C, H, N. 
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General Procedure for the Synthesis of Ethyl 3-[4-(3'-benzoyl- and -
benzenesulfonylaminophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-propenoates 7y,z. 
Example: Ethyl 3-[4-(3'-benzenesulfonylaminophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-
2-propenoate (7z). Benzenesulfonyl chloride (6.8 mmol, 2.1 g) and triethylamine (10.2 
mmol, 1.4 mL) were added to a solution of 3-[4-(3'-aminophenylacetyl)-1-methyl-1H-pyrrol-
2-yl]-2-propenoate (7x) (6.8 mmol, 2.1 g) in dichloromethane (20 mL). After being stirred at 
room temperature for 1 h, the reaction mixture was poured into water (50 mL), the organic 
layer was separated, and the aqueous one was extracted with chloroform (2 x 50 mL). The 
combined organic solution was washed with water (100 mL) and brine (100 mL), and was 
dried and evaporated to dryness. The residual oil was purified through column 
chromatography on silica gel by eluting with a 1:1 mixture of ethyl acetate and chloroform. 
Compound 7z was obtained as pure oil. 1H NMR (CDCl3) δ 1.28 (t, 3 H, COOCH2CH3), 3.72 
(s, 3 H, NCH3), 3.90 (s, 2 H CH2CO), 4.20 (q, 2 H, COOCH2CH3), 6.25 (d, 1 H, CH=CHCO), 
6.90-7.95 (m, 12 H, pyrrole protons, benzene protons, and CH=CHCO). Anal. (C24H24N2O5S) 
C, H, N, S. 
 
Ethyl 3-[4-(3'-chloro-4'-methoxyphenylacetyl)-1-methyl-1H-pyrrol-2-yl]-2-propenoate 
(7a'). Aluminum trichloride (15.0 mmol, 2.0 g) was slowly added to a cooled (0-5 °C) 
solution of ethyl (1-methyl-1H-pyrrol-2-yl)-2-propenoate[53] (7.5 mmol, 1.3 g) and 3-chloro-
4-methoxyphenylacetyl chloride (previously prepared by heating 5b (15.0 mmol, 3.0 g) with 
SOCl2 (20 mL) for 1 h at 50 °C) in 1,2-dicloroethane (100 mL). After being stirred at room 
temperature for 30 min, the reaction mixture was poured onto crushed ice (100 g) and the pH 
of the solution was adjusted to 4 with 37% HCl. The organic layer was separated, and the 
aqueous one was extracted with chloroform (3 x 50 mL). The combined organic solution was 
washed with water (100 mL), dried and evaporated to dryness. The residual oil was purified 
through column chromatography on silica gel by eluting with a 1:20 mixture of ethyl acetate 
and chloroform. Compound 7a' was obtained as pure solid. 1H NMR (CDCl3) δ 1.32 (t, 3 H, 
COOCH2CH3), 3.71 (s, 3 H, NCH3), 3.87 (s, 3 H, OCH3), 3.93 (s, 2 H CH2CO), 4.25 (q, 2 H, 
COOCH2CH3), 6.25 (d, 1 H, CH=CHCO), 6.88 (m, 1 H, benzene H-5), 7.03 (m, 1 H, pyrrole 
β-proton), 7.13 (m, 2 H, benzene H-6), 7.30 (m, 1 H, benzene H-2), 7.35 (m, 1 H, pyrrole α-
proton), 7.52 (d, 1 H, CH=CHCO). Anal. (C19H20ClNO4) C, H, Cl, N. 
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General Procedure for the Synthesis of 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-2-propenoic 
Acids 8a-a'. Example: 3-[4-(4'-Chlorophenylacetyl)-1H-pyrrol-2-yl)]-2-propenoic acid 
(8c). A mixture of 7c (4.3 mmol, 1.4 g), 2 N KOH (17.2 mmol, 1.0 g, 8.6 ml), and ethanol (15 
mL) was stirred at room temperature overnight. Afterward, the solution was poured into water 
(50 mL) and extracted with ethyl acetate (3 x 20 mL). A sample of 2 N HCl was added to the 
aqueous layer until the pH was 5, and the obtained precipitate was filtered and recrystallized 
from benzene/acetonitrile to give the pure compound 8c. 1H NMR (DMSO-d6) δ 3.70 (s, 3 H, 
NCH3), 3.98 (s, 2 H, CH2CO), 6.25 (d, 1 H, CH=CHCO), 7.28 (m, 6 H, benzene and pyrrole 
protons), 7.40 (d, 1 H, CH=CHCO), 12.10 (bs, 1 H, OH). Anal. (C16H14ClNO3) C, H, Cl, N. 
 
General Procedure for the Synthesis of 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-
2-propenamides 4a-a'. Example: 3-[4-(2'-Fluorophenylacetyl)-1-methyl-1H-pyrrol-2-yl)-
N-hydroxy-2-propenamide (4d). Ethyl chloroformate (1.9 mmol, 0.2 mL) and triethylamine 
(2.0 mmol, 0.3 mL) were added to a cooled (0 °C) solution of 3d (1.6 mmol, 0.5 g) in dry 
THF (10 mL), and the mixture was stirred for 10 min. The solid was filtered off, and O-(2-
methoxy-2-propyl)hydroxylamine (4.7 mmol, 0.4 mL)[54] was added to the filtrate. The 
solution was stirred for 15 min at 0 °C, then was evaporated under reduced pressure, and the 
residue was diluted in methanol (10 mL). Amberlyst® 15 ion-exchange resin (0.2 g) was 
added to the solution of the O-protected hydroxamate, and the mixture was stirred at 45 °C for 
1 h. Afterward, the reaction was filtered and the filtrate was concentrated in vacuo to give the 
crude 4d, which was purified by crystallization. 1H NMR (DMSO-d6) δ 3.78 (s, 3 H, NCH3), 
4.15 (s, 2 H, CH2CO), 6.33 (d, 1 H, CH=CHCO), 6.99 (m, 1 H, pyrrole β-proton), 7.38 (m, 5 
H, benzene protons and pyrrole α-proton), 7.85 (m, 1 H, CH=CHCO), 9.01 (bs, 1 H, NH), 
10.72 (bs, 1 H, OH). Anal. (C16H15FN2O3) C, H, F, N. 
 
16.4. Molecular modeling and docking studies. 
Homology models for the HD1-A342,243,350 and HD1-B340,341 sequences were derived by using 
the CPHmodels 2.0 Server351 with structural data from the HDAC8–TSA complex352 (PDB 
code: 1T64). The models were refined with a molecular dynamics (MD) protocol 
(Experimental Section) by using the program AMBER 8.0353,354 The Autodock355 program 
was used to explore the binding mode of derivatives 4u and 4t, the most selective derivatives 
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against HD1-B and HD1-A, respectively. In general, the docked conformations obtained with 
the two enzymes differ mainly in that the molecules are placed deeper in the HD1-A pocket, 
where they partially occupy the acetyl escape channel,356 whereas in HD1-B, the docked 
conformations adopt different 
conformations (Figure 31 and Figure 32).  
 
 
Figure 31. Derivatives 4t (orange) and 4u (cyan) 
docked into HD1-A. The enzyme is shown in tube 
representation (violet), and side chains are in gray. 
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Figure 32. Derivatives 4t (orange) and 4u (cyan) 
docked into HD1-B. The enzyme is shown in tube  
representation (yellow), and side chains are in gray. 
 
 
Binding mode of 4u.  
The Autodock lowest-energy pose for derivative 4u in HD1-A shows a deep position inside 
the catalytic channel. Inspection of the binding mode reveals several positive interactions: the 
hydroxyl oxygen atom is positioned within hydrogen-bonding distance from either the 
carbonyl oxygen atom of Ala 277 (d=2.62 M) or that of Pro 106 (d=2.73 M); the 
hydroxyamide carbonyl oxygen atom is within weak hydrogen-bonding distance from His 109 
NH (d=3.20 M); a weak hydrogen bond is present between the phenylacetyl carbonyl oxygen 
atom and the phenol group of Tyr 180 (O_O distance=3.74 M). Finally, positive hydrophobic 
interactions (<4 M) are possible between the 4-biphenyl group of 4u and the benzyl side chain 
of Tyr 180 and one of the methyl groups of Leu249. In contrast to HD1-A, the acetyl escape 
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is narrower in the HD1-B model and places the hydroxyamide portion of 4u close to the 
catalytic zinc ion (Supporting Information). This scenario reveals that the hydroxyamide 
carbonyl oxygen approaches the zinc ion at an effective chelating distance (Zn2+···O=C 
d=1.88 M) that could explain the slightly improved selectivity toward HD1-B. Along with the 
chelation, further contributing interactions can be observed: the hydroxy oxygen atom is 
positioned within a weak hydrogen-bonding distance from the carbonyl oxygen atom of Gly 
268 (d=3.87 M); the hydroxyamide nitrogen atom at a hydrogen-bonding distance from the 
carbonyl oxygen atom of Asp144 (d=2.90 M). Furthermore, positive hydrophobic interactions 
may take place between the pyrrole group of 4u and the benzyl side chain of Phe173, and 
between the 4-phenyl substituent of 4u and the side chain of Arg 238. 
Binding mode of 4t. 
Similar to 4u, the lowest-energy docked conformation of 4t is placed deep inside the HD1-A 
catalytic tunnel, and the pyrrolyl hydroxypropenamide moiety is nicely superimposed with 
that of 4u (with some slight differences), whereas the biphenyl group of 4u is swiveled ~110°. 
This rotation of the biphenyl group leads to the disruption of the previously observed 
hydrophobic interactions for 4u and creates new interactions with the Phe118 side chain. In 
contrast to 4u, the hydroxyamide group is rotated roughly 180°, and only weak hydrogen-
bond interactions are displayed between the hydroxy oxygen atom and the carbonyl oxygen 
atom of Asp149 (d=3.59 M), and between the hydroxyamide carbonyl oxygen atom and the 
amide group of His 109 (d=3.79 M). The lowest-energy docked conformation of 4t in HD1-B 
is shifted back from the catalytic channel with an overall decrease in the contributing 
favorable interactions that could explain the slight selectivity of 4t toward HD1-A. Moreover, 
comparison of the binding mode of 4t with that of 4u in the HD1-B catalytic pocket shows 
that whereas the latter is placed optimally to chelate Zn2+, the former does not show any 
effective chelating distance between the hydroxyamide group and the zinc ion (Zn···O=C 
d=2.76 M, Zn···O_N d=3.02 M). 
Docking of 4t and 4u. 
.The docking studies were performed using Autodock 3.0.5. The molecular structures of 
derivatives 4t and 4u were drawn using the PRODGR software which give directly the 
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molecule ready to be used by Autodock. The AutodockTools package was employed to 
generate the docking input files and to analyze the docking results, the same procedure as 
described in the manual was followed. All the nonpolar hydrogens and the water molecules 
were removed. The Kollmann charges were loaded for the proteins while the charges applied 
by the PRODRG program were retained in the ligand. A grid box size of 40 × 40 × 60 points 
with a spacing of 0.375 Å between the grid points was implemented and covered most of the 
catalytic channel of either enzymes. The grid was centered on the mass center of the bound 
TSA. For all the inhibitors, the single bonds including the amide bonds were treated as active 
torsional bonds. One hundred structures, ie 30 runs, were generated by using genetic 
algorithm searches. A default protocol was applied, with an initial population of 50 randomly 
placed individuals, a maximum number of 2.5 × 105 energy evaluations, and a maximum 
number of 2.7 × 104 generations. A mutation rate of 0.02 and a crossover rate of 0.8 were 
used. In a parallel docking experiment the bound TSA molecules extracted from either 
average MD equilibrated complexes were docked back. Autodock proved to reposition the 
TSA with a minimal rmsd error (rmsdTSA-HD1-A = 1.29, rmsdTSA-HD1-B = 0.95). 
 
16.5. Biological evaluation. 
The novel APHA compounds 4a–a’ (Figure 30) were evaluated for their ability to inhibit 
maize HDACs. The maize system offers the advantage that three different types of HDACs 
can be biochemically separated: class I (HD1-B) and class II (HD1-A) enzymes, and the 
plant-specific form HD2. Two short-chain fatty acids (NaB and VPA), two hydroxamic acids 
(TSA and SAHA), two cyclic tetrapeptides (TPX and HC-toxin), PAOA (a class I-selective 
inhibitor), and tubacin (an in-cell class IIb-selective inhibitor) have been reported as reference 
drugs in anti-HD2 assays. The results, expressed as the percent inhibition at a fixed dose and 
IC50 (50% inhibitory concentration) values, are reported in Table 3. In assays for HD1-B and 
HD1-A inhibition, TSA, SAHA, PAOA, tubacin, 2, and 3 were also tested for the purpose of 
comparison (Table 4). Selected compounds (3’-chloro (compound 4b) and 3’-methyl 
(compound 4k) derivatives) were tested against mouse HDAC1 in comparison with 2 and 
SAHA (Table 5). 
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Table 3. Maize HD2 Inhibitory Activity of Compounds 4a-a'a 
compound R % inhibition (at 
fixed dose, µM) IC50 ± SD (µM) 
4a 2-Cl 94.3 (24.1) 0.09 ± 0.004 
4b 3-Cl 97.2 (24.1) 0.05 ± 0.001 
4c 4-Cl 96.8 (24.1) 0.10 ± 0.005 
4d 2-F 96 (25.4) 0.13 ± 0.006 
4e 3-F 96.9 (25.4) 0.07 ± 0.003 
4f 4-F 93.9 (25.4) 0.15 ± 0.007 
4g 2-Br 91.1 (21.2) 0.18 ± 0.009 
4h 3-Br 98 (21.2) 0.08 ± 0.004 
4i 4-Br 93.7 (21.2) 0.15 ± 0.007 
4j 2-Me 95 (25.8) 0.21 ± 0.01 
4k 3-Me 96.6 (25.8) 0.06 ± 0.003 
4l 4-Me 83 (1.3) 0.23 ± 0.009 
4m 2-NO2 96 (23.4) 0.16 ± 0.005 
4n 3-NO2 97 (23.4) 0.13 ± 0.005 
4o 4-NO2 97.2 (23.4) 0.18 ± 0.005 
4p 3-OMe 96.5 (24.5) 0.07 ± 0.003 
4q 4-OMe 93.7 (24.5) 0.06 ± 0.001 
4r 3-OEt 91.2 (23.4) 0.34 ± 0.02 
4s 4-OEt 93.6 (23.4) 0.18 ± 0.005 
4t 3-Ph 95 (21.3) 0.25 ± 0.01 
4u 4-Ph 97 (21.3) 0.09 ± 0.004 
4v 3,5-Me2 97 (23.4) 0.07 ± 0.003 
4w 3,5-F2 95 (24) 0.12 ± 0.004 
4x 3-NH2 88.5 (25.5) 1.84 ± 0.07 
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4y 3-NHCOPh 94.1 (19.1) 0.10 ± 0.002 
4z 3-NHSO2Ph 94.3 (17.5) 0.09 ± 0.003 
4a' 3-Cl-4-OMe 95 (22.1) 0.08 ± 0.002 
2b  96 (29) 0.10 ± 0.004 
3c  98 (25.7) 0.05 ± 0.003 
NaB  35 (5000) NDd 
VPA   128 ± 3.8 
TSA   0.007 ± 0.0002 
SAHA   0.05 ± 0.001 
TPX   0.01 ± 0.0003 
HC-toxin   0.11 ± 0.004 
PAOA   292 ± 8.8 
tubacin  92.9 (40) 2.0 ± 0.1 
aData represent mean values of at least three separate experiments. bRef. 45.  
cRef. 46. dND, not determined. 
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Table 4. Maize HD1-B and HD1-A Inhibitory Activities of Compounds 4a-a'a 
IC50 ± SD (µM) fold selectivity 
compound R 
HD1-B HD1-A class I class II 
4a 2-Cl 0.13 ± 0.005 0.12 ± 0.005   
4b 3-Cl 0.03 ± 0.0007 0.03 ± 0.001   
4c 4-Cl 0.07 ± 0.003 0.06 ± 0.002   
4d 2-F 0.04 ± 0.001 0.02 ± 0.0005   
4e 3-F 0.04 ± 0.001 0.03 ± 0.0005   
4f 4-F 0.06 ± 0.002 0.07 ± 0.003   
4g 2-Br 0.29 ± 0.015 0.21 ± 0.011   
4h 3-Br 0.04 ± 0.001 0.03 ± 0.001   
4i 4-Br 0.06 ± 0.002 0.05 ± 0.002   
4j 2-Me 0.10 ± 0.004 0.11 ± 0.004   
4k 3-Me 0.02 ± 0.0005 0.03 ± 0.0008   
4l 4-Me NDb ND   
4m 2-NO2 0.07 ± 0.003 0.08 ± 0.003   
4n 3-NO2 0.07 ± 0.003 0.13 ± 0.004   
4o 4-NO2 0.06 ± 0.001 0.12 ± 0.005 2  
4p 3-OMe 0.05 ± 0.002 0.04 ± 0.001   
4q 4-OMe 0.06 ± 0.002 0.09 ± 0.004   
4r 3-OEt 0.15 ± 0.004 0.13 ± 0.005   
4s 4-OEt 0.06 ± 0.002 0.06 ± 0.002   
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4t 3-Ph 1.16 ± 0.07 0.32 ± 0.013  3.6 
4u 4-Ph 0.02 ± 0.0005 0.05 ± 0.002 2.5  
4v 3,5-Me2 ND ND   
4w 3,5-F2 ND ND   
4x 3-NH2 ND ND   
4y 3-NHCOPh 0.08 ± 0.004 0.05 ± 0.003   
4z 3-NHSO2Ph 0.10 ± 0.006 0.05 ± 0.003  2 
4a' 3-Cl-4-OMe 0.10 ± 0.006 0.04 ± 0.001  2.5 
2  0.15 ± 0.004 0.05 ± 0.001  3 
3  0.12 ± 0.006 0.06 ± 0.002  2 
TSA  
0.0004 ± 0.00001 0.0008 ± 0.00003 2  
SAHA  
0.03 ± 0.001 0.2 ± 0.009 6.7  
PAOA  
150 ± 4.5 756 ± 30.2 5  
tubacin  
0.98 ± 0.04 0.45 ± 0.02  2.2 
aData represent mean values of at least three separate experiments. bND, not determined. 
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Table 5. Mouse HDAC1 Inhibitory 
Activities of Compounds 4b and 4ka 
compd R IC50 ± SD (µM) 
4b 3-Cl 0.23 ± 0.01 
4k 3-Me 0.31 ± 0.01 
2b  0.51 ± 0.02 
SAHA  0.11 ± 0.004 
aData represent mean values of at least 
three separate experiments. bRef. 45. 
 
16.5.1. Anti-HD2 Activity and Structure-Activity Relationships (SARs) 
Starting from the recently reported findings about the APHA compounds,337-340 we chose the 
3-(1-methyl-4-phenylacetyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamide 2 as lead compound, 
and we introduced various substituents (ie chloro, fluorine, bromo, methyl, nitro, amino, 
benzoylamino, benzenesulfonylamino, methoxy, ethoxy, phenyl groups) at ortho, meta, and 
para positions of the benzene ring to determine the effect of such substitutions on anti-HD2 
activity (Table 3).  
Halogen and methyl substitutions at both ortho and para positions of the benzene ring of the 
pyrrole-C4 phenylacetyl moiety of 2 left unaltered (4a,c) or lowered (4d,f,g,i,j,l) the HDAC 
inhibitory activity of the new derivatives. Conversely, the 3'-chloro- (4b), 3'-fluoro- (4e), and 
3'-bromo- (4h) as well as 3'-methylsubstituted (4k) pyrroles were endowed with higher anti-
HD2 activity than 2. With the insertion of a nitro group (at whatever position of benzene ring) 
only low-active compounds (4m-o) were obtained. Differently, the introduction of a methoxy 
(but no ethoxy!) group at either 3'- or 4'-position of the benzene ring led to more potent 
compounds (4p,q) than 2, while the bulky phenyl substituent was well tolerated at para (4u) 
but it was not at meta position (4t). Reduction of 3'-nitro to 3'-amino function (from 4n to 4x) 
strongly abated the HD2 inhibiting activity of the derivative, but this activity was promptly 
restored when an amide function (4y,z) replaced the amine group (4x). 3',5'-Difluoro- (4w) 
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and 3',5'-dimethyl- (4v) as well as 3'-chloro-4'-methoxyphenyl (4a') substitutions at the 
pyrrole-C4 phenylacetyl moiety, that were designed by taking together two equal or diverse 
groups efficient in increasing the anti-HD2 activity of APHA compounds, did not 
significantly improve the inhibitory potency of the derivatives. 
16.5.2. HD1-B and HD1-A Inhibitory Effects: Class Selectivity Assessment. 
3-[1-Methyl-4-phenylacetyl- and -4-(3-phenylpropionyl)-1H-pyrrol-2-yl]-N-hydroxy-2-
propenamides 2 and 3, when tested against the maize deacetylases homologues of mammalian 
class I (HD1-B) and class II (HD1-A) HDACs, showed in both cases submicromolar 
inhibitory activities, they being more potent against HD1-A than HD1-B enzyme (class II fold 
selectivity: 2 = 3; 3 = 2) (Table 4). In order to study the inhibiting action of the new pyrrole 
compounds against these two enzymes, and to explore the effect of substituent insertion on 
HDAC class selectivity, we assayed 4a-a' against HD1-B and HD1-A, in comparison with 
TSA, SAHA, PAOA (class I-selective inhibitor), and tubacin (in cell class IIb-selective 
inhibitor) (Table 4). 
Halogen as well as methyl substitution at the 3'- (4b,e,h,k) or 4'-position (4c,f,i) of the 
pyrrole-C4 phenylacetyl moiety led to compounds with higher inhibiting activity against HD1-
B than 2, while 2'-substituted analogues were as active as (4j) or less active than (4a,g) the 
pyrrole reference, with the exception of the 2'-fluoroderivative 4d, which was 3-4 times more 
potent than 2 against HD1-B. 
Against HD1-A enzyme, a little effect of benzene ring substitution on inhibiting activity was 
observed, 4'-substituted derivatives (4c,f,i) showing the same activity and the 3'-analogues 
(4b,e,h,k) being 2-fold more potent than 2. 2'-Chloro, 2'-bromo, and 2'-methylsubstituted 
derivatives 4a,g,j were from 2 to 4 times less potent than the pyrrole reference, while again 
the 2'-fluoro analogue 4d showed an increase of two-fold in HD1-A inhibiting activity if 
compared with 2. 
To determinate the potential class selectivity of the described compounds, the IC50-HD1-A/IC50-
HD1-B ratio for class I-selectivity and the IC50-HD1-B/IC50-HD1-A ratio for class II-selectivity have 
been calculated. Only selectivity values ≥ 2 have been reported. As a result of the HD1-
B/HD1-A inhibitory trend, all the halogen- and methyl-substituted compounds did not show 
any class selectivity. Nitro-substituted compounds 4m-o displayed a opposite pattern of HD1-
B/HD1-A inhibition when it is compared with that of 2, 4m-o being more potent against 
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HD1-B than HD1-A. However, just 4o showed little class I selectivity value (class I fold 
selectivity = 2). The 3'-methoxy-, 4'-methoxy-, and 4'-ethoxyphenylacetyl compounds 4p,q,s 
were efficient HD1-B and HD1-A inhibitors, with IC50 values ranging from 40 to 90 nM, but 
lacked selectivity. The introduction of phenyl substituent at the 3'-position of the benzene ring 
(compound 4t) highly decreased the anti-HD1-B and, to a lesser extent, the anti-HD1-A 
activities of the derivative. Nevertheless, 4t showed 3.6-fold selectivity against class II 
deacetylase, while its 4'-phenyl counterpart 4u was very potent against both the enzymes and 
showed little class I selectivity ratio (class I fold selectivity = 2.5). The 3'-amide analogues 
4y,z and the 3'-chloro-4'-methoxyderivative 4a' were still endowed with interesting inhibiting 
activities, they being more active than (HD1-B) and as active as (HD1-A) the pyrrole 
reference 2. However, only 4z and 4a' showed little class II selectivity values (class II fold 
selectivity = 2 and 2.5, respectively). 
TSA and SAHA in anti-HD1-B assay were endowed with strong inhibiting activity, TSA 
being inhibitor at subnanomolar concentration (IC50 = 0.4 nM), and SAHA showing an IC50 = 
30 nM. Compared with SAHA, 3'-chloro- (4b), 2'-fluoro- (4d), 3'-bromo- (4h), 3'-methyl- 
(4k), and 4'-phenylsubstituted (4u) APHAs displayed similar inhibiting activity. 
Against HD1-A, TSA was still a very potent inhibitor (IC50 = 0.8 nM), while SAHA exhibited 
submicromolar activity (IC50 = 0.2 µM), showing 6.7-fold selectivity towards class I HDACs. 
The APHA derivatives described herein, when compared with SAHA, were all more potent in 
inhibiting HD1-A enzyme, with the sole exceptions of the 2'-bromo (4g) and the 3'-phenyl 
(4t) derivatives. 
          
16.5.3.  Anti-mouse HDAC1 Activity of Selected Compounds. 
Among the title compounds, 3'-chloro (4b) and 3'-methyl (4k) derivatives were from 2 to 7.5 
times more potent than 2 in maize system (HD2, HD1-B, and HD1-A). Thus, we tested them 
against mouse HDAC1, in comparison with 2 and SAHA (Table 5). Similarly to that obtained 
with maize HD2, 4b and 4k were 2-fold more potent than 2, and 2 or 3 times less potent than 
SAHA in inhibiting mouse HDAC1. 
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16.5.4. In Vitro Maize HD2, HD1-B, and HD1-A Enzyme Inhibition.  
Radioactively labeled chicken core histones were used as the enzyme substrate according to 
established procedures. The enzyme liberated tritiated acetic acid from the substrate, which 
was quantified by scintillation counting. IC50 values are results of triple determinations. A 50 
µL sample of maize enzyme (at 30 °C) was incubated (30 min) with 10 µL of total 
[3H]acetate-prelabeled chicken reticulocyte histones (1 mg/mL). Reaction was stopped by 
addition of 36 µL of 1 M HCl/0.4 M acetate and 800 µL of ethyl acetate. After centrifugation 
(10 000g, 5 min), an aliquot of 600 µL of the upper phase was counted for radioactivity in 3 
mL of liquid scintillation cocktail. The compounds were tested at a starting concentration of 
40 µM, and active substances were diluted further. NaB, VPA, TSA, SAHA, TPX, HC-toxin, 
PAOA, and tubacin were used as the reference compounds, and blank solvents were used as 
negative controls. 
16.5.5. Mouse HDAC1 Enzyme Assay.  
For inhibition assay, partially purified HDAC1 from mouse A20 cells (ATCC: TIB-208) 
(anion exchange chromatography, affinity chromatography was used as enzyme source. 
HDAC activity was determined as described using [3H]acetate-prelabeled chicken reticulocyte 
histones as substrate. 50 µL of mouse HDAC1 were incubated with different concentrations 
of compounds for 15 min on ice and 10 µL of total [3H]acetate-prelabeled chicken 
reticulocyte histones (4 mg/mL) were added, resulting in a concentration of 41 µM. The 
mixture was incubated at 37 °C for 1 h. The reaction was stopped by addition of 50 µL of 1 M 
HCl/0.4 M acetylacetate and 1 mL ethyl acetate. After centrifugation at 10 000g for 5 min an 
aliquot of 600 µL of the upper phase was counted for radioactivity in 3 mL liquid scintillation 
cocktail. 
16.5.6. Growth Inhibition and Cell Differentiation Assay. Cell Culture and Reagents.  
Human acute promyelocytic leukemia HL-60 cells were obtained from Interlab Cell Line 
Collection (CBA, Genoa, Italy). Cells were maintained at 37 °C under a humidified 
atmosphere of 5% CO2 in RPMI 1640 Hepes modified medium supplemented with 10% (v/v) 
heat inactivated fetal calf serum, 2 mmol/L glutamine, 100 IU/mL penicillin and 100 µg/mL 
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streptomycin. Unless indicated all chemicals and reagents (cell culture grade) were obtained 
from Sigma Chemical Co., Milan, Italy. 
16.5.7. Cell Viability and Growth Inhibition Assay.  
Cell number was determined using a Neubauer hemocytometer, and viability was assessed by 
their ability to exclude trypan blue. The stock solutions were prepared immediately before 
use. TSA and 4b were dissolved in DMSO. HL-60 exponentially growing cells (2 x 105 
cells/mL) were set at day 0 in media containing various concentrations of drugs for 96 h. The 
final concentrations of the drugs were as follows: TSA, 30 nM; 4b, 2.5, 5, 10, and 20 µM. 
The final concentration of DMSO, used as a vehicle, was the same (0.1% v/v) in all samples 
during the experiments. 
16.5.8. Cell Differentiation Assay.  
Phorbol-12-myristate-13-acetate- (PMA-) stimulated reactive oxygen species (ROS) 
production, mostly due to the activity of NADPH oxidase system, was used as a marker of 
differentiation in the human myeloid cell line HL-60. ROS metabolism was studied by a 
chemiluminescence (CL) assay as already described. Briefly, assays were performed in 
triplicate in an automatic luminometer (Autolumat LB 953, EG&G, Turku, Finland) at 25 °C 
for 120 min with cycles of five minutes each. The CL system contained 1 x 105 cells, without 
treatment (control), or treated with 0.1% DMSO (vehicle alone), or cells treated with different 
differentiating factors, 100 nmol of luminol, 150 pmol of PMA adjusted to a final volume of 
1.0 mL with KRP solution. Unstimulated activity was measured without any addition of 
stimulus. Stimulated CL was evaluated trough calculation of a CL index as follows: Area 
(expressed as counts/cell/120 min)stimulated cells/Area (expressed as counts/cell/120 min)unstimulated 
cells. 
 
Statistical Analysis.  
All results are expressed as the mean ± SEM. The group mean values were compared by 
analysis of variance (ANOVA) followed by a multiple comparison of means by the Dunnet 
test. p < 0.05 was considered significant. 
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         16.5.9. Antiproliferative and Cytodifferentiating Activities of 4b on Human Acute  
Promyelocytic Leukemia HL-60 Cells. 
Among the APHA derivatives showing the highest inhibitory values against the three maize 
enzymes (the 3'-substituted phenylacetylpyrroles 4b,e,h,k,p), we chose the 3[4-(3'-
chlorophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide 4b to test as 
antiproliferative and cytodifferentiating agent in human acute promyelocytic leukemia HL-60 
cells. 
16.5.10. Antiproliferative effect of 4b on human leukemia HL-60 cells. 
The capability of 4b to induce growth inhibition on human leukemia cell line was evaluated in 
comparison with TSA (30 nM). Figure 5A shows the effect of 4b on the growth of HL-60 
cells, cultured for 96 h with different concentrations of drug. The APHA compound 4b 
showed a significant dose-dependent inhibitory effect on the growth rate of the cell line. In 
particular, the growth curve of cells is inhibited by the presence of 2.5, 5, 10 and 20 µM of 4b 
by 15% (p < 0.05), 36% (p < 0.01), 49% (p < 0.01), and 86% (p < 0.01), with respect to 
vehicle (Figure 33a). This 4b inhibitory effect does not seem to depend on a direct cytotoxic 
action of the drug. In fact, the viability index (VI) appears significantly modified by 4b only 
at 20 µM (VI = 64%) (Figure 33b). 
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Figure 33. a) Effect of various concentrations of 
4b (in dark grey) on the growth of human 
leukemia cells cultured for 96 h in comparison 
with TSA (30 nm); data are expressed as cell 
number (mean +/- SEM, n=4); *p<0.05, 
**p<0.01. b) Cytotoxic effect in human leukemia 
cells cultured for 96 h with various concentrations 
of 4b (in dark grey); each point represents the 
mean +/- SEM (n=4); **p<0.01. 
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16.5.11. Differentiating activity of 4b on human leukemia HL-60 cells.  
The restoration of so-called respiratory burst was evaluated as fundamental functional marker 
of differentiation in human leukemia cell lines. This aspect of the phagocytes oxidative 
metabolism has been analyzed by chemiluminescence (CL) in HL-60 cells, incubated with 
different concentrations of 4b for 96 hours, and stimulated by phorbol-12-myristate-13-
acetate (PMA). In particular, the presence of PMA-induced CL seems to demonstrate an 
acquired right assembly of the NADPH oxidase system.  
Results clearly showed a dose-dependent recovery of reactive oxygen species (ROS) 
metabolism when the cells were stimulated by PMA, reaching the maximum CL activity (p < 
0.01) at 4b concentration = 20 µM (Figure 34). 
 
 
Figure 34. Concentration-dependent effect of 4b 
on the differentiation of HL-60 cells with TSA 
(30 nm) as a reference. Cells were cultured with 
various concentrations of 4b (in dark grey) for 
96 h. Differentiation-inducing activity was 
measured by chemiluminescence (CL) as 
described in the Experimental Section. Each 
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point represents the mean _SEM (n=4); 
*p<0.05; **p<0.01. 
 
 
16.5.12. Conclusions. 
A new series of aroyl-pyrrolyl hydroxyamides (compounds 4–4a’) have been described and 
are analogues of the lead compound 3-(1-methyl-4-phenylacetyl-1H-pyrrol-2-yl)-N-hydroxy-
2-propenamide (2). The phenyl ring of 2 was substituted with a wide range of electron-
donating and electron-withdrawing groups, and the effects were evaluated with three maize 
histone deacetylases: HD2, HD1-B (class I HDAC), and HD1-A (class II HDAC). HD2 
inhibition data (Table 3) shows that the insertion ofsubstituents such as halogen or methyl 
groups at the 3’ position of the benzene ring increases the inhibitory effect of the derivatives 
4b, 4e, 4h, and 4k up to 2-fold. The highest inhibiting activity was showed by the 3-[4-(3’-
chlorophenylacetyl)-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide (4b, IC50= 0.05 
mm) and its 3’-methyl analogue 4k (IC50=0.06 mm), which were more potent than VPA, HC-
toxin, and 2. Moreover, they showed the same activity as SAHA and were 7–5-fold less active 
than TSA and TPX. In assays against mouse HDAC1 in comparison with 2, 4b and 4k 
showed inhibition data in agreement with those obtained in the anti-HD2 assay. Assays for the 
inhibition of HD1-B and HD1-A (Table 4) performed with 4a–4a’ confirmed the inhibition 
trend observed with HD2 above. The introduction of various substituents at the 3’ and, to a 
lesser extent, at the 4’ positions of the benzene ring of 2 led to compounds up to 6-fold more 
active than 2 against HD1-B (with the exception of the 3’-ethoxy and 3’-phenyl compounds 
4r and 4t), whereas their anti-HD1-A activity remained the same as 2. The 3- and 2-fold 
selectivity ratios toward class II (HD1-A) enzymes displayed by 2 and 3, respectively, was 
lost by the insertion of substituents at the benzene ring; exceptions include the 3’-phenyl 
(compound 4t), 3’-benzenesulfonamido (compound 4z), and the 3’-chloro-4’-methoxy 
(compound 4a’) derivatives, which showed selectivity ratios from 2 to 3.6 in favor of class II. 
Two compounds, the 4-nitro and the 4-phenyl derivatives 4o and 4u displayed an opposite 
pattern of HD1-B/HD1-A inhibition, as both are slightly more potent against HD1-B than 
HD1-A. Molecular modeling studies based on HD1-B and HD1-A homology models have 
been performed to gather insight on the observed inhibition differences. In tests with human 
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acute promyelocytic leucemia HL-60 cells, 4b showed interesting, dose-dependent 
antiproliferative and cytodifferentiation properties. 
 
17. Second lead optimization. 
In parallel with the study of the influence of Pyrrole C4-phenylacetyl substitution on Histone 
Deacetylase inhibition we applied a different approach on the 1 structure to discover novel 
leads, using structure-based drug design and docking procedures. Particularly, we designed 
two isomers of 1, 3-(2-benzoyl-1-methyl-1H-pyrrol-5-yl)-N-hydroxy-2-propenamide 3 and 3-
(2-benzoyl-1-methyl-1H-pyrrol-4-yl)-Nhydroxy-2-propenamide 4, and we performed 
computational studies to predict their HDAC inhibiting activity. 
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In the chemical structure of the APHA lead compound 1, virtual rotation of N-methylpyrrole 
ring between benzoyl and N-hydroxy-2-propenamide moieties allowed us to design two 
isomers of 1, 3-(2-benzoyl-1-methyl-1H-pyrrol-5-yl)-N-hydroxy-2-propenamide 3 and 3-(2-
benzoyl-1-methyl-1H-pyrrol-4-yl)-N-hydroxy-2-propenamide 4. Extensive binding mode 
analyses were undertaken to see if the HDAC1 enzyme inhibitory potency would be 
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influenced by the above different rearrangement of benzoyl and N-hydroxypropenamide 
substituents on the pyrrole ring. 
Initially, binding mode analyses of 3 and 4 into the modeled HDAC1 structure were 
investigated using a semiautomatic dock (SAD) procedure, analogous to that reported for 1. In 
parallel experiments, docking studies were performed on 3 and 4 structures by the mean of the 
DOCK 4.0.2 and Autodock 3.0.5 programs. The results of the automatic docking procedures 
(DOCK and Autodock) were energy rescored by a single point minimization by the 
MACROMODEL molecular mechanics program, using the AMBER all atom force fields and 
point charges calculated with the MOZYME routine as implemented in the MOPAC2000 
program. From docking studies three bound conformations for both 3 and 4 were obtained, 
and their associated HDAC inhibitory potencies, expressed as pKi values, were predicted 
using our in house refined VALIDATE scoring function model. In Table 6 the pKi prediction 
values for APHA isomers 3 and 4 compared with their experimental pIC50 values (see below) 
are reported. For comparison purpose, 1, TSA, and SAHA pKi prediction values are also 
shown. Among the minimized ligand/HDAC1 complexes, the most stable ones were those 
proposed by Autodock (Table 7). Similarly as previously observed, DOCK and Autodock 
results were in good agreement each other and with those obtained by the SAD procedure 
(Table 8). To compare the docked molecules (1, 3, 4, TSA, and SAHA), their binding 
conformations obtained by Autodock are depicted in Figure 35. 
  
Table 6. VALIDATE and Autodock Predicted Anti-HDAC1 pKi 
Compared with Experimental pIC50 Values of APHA Isomers 1, 
3, 4, and TSA, and SAHA. 
 
a Predicted from X-ray experimental data. 
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Table 7. Minimized Complex Steric Energies (kJ/mol) 
(AMBER force field) Relative to APHA Isomers 3 and 4 
Obtained by DOCK, Autodock, and SAD Procedures into the 
Modeled HDAC1. For Direct Comparison the Same Values 
for 1, TSA, and SAHA Are Reported. 
 
 
Table 8. Comparison of Docking Studies Performed on 3 and 
4. Values Are the Root Mean Square Deviations (RMSDs) for 
All Non-H Atoms. For Direct Comparison, the Same Values 
for 1, TSA, and SAHA Are Reported. 
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  Table 9. Antimaize HD2 and Antimouse HDAC1 Activities of 
  Compounds 3 and 4a. 
    
                                    a Data represent mean values of at least three separate experiments. 
                                    b Percent of inhibition at 30 µM. 
 
 
Figure 35. Stereoview of superimposition of the Autodock docked conformations 
of 1 (magenta), 3 (green), 4 (red), TSA (yellow), and SAHA (cyan). The gray ball 
represents the mean position of the zinc ion. HDAC1 pocket and nonessential 
hydrogen atoms are not shown for the sake of clarity. 
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Figure 36. Autodock binding mode of APHA isomers 3 (bottom) and 4 (top). 
Inhibitors are drawn in ball-and-stick. For the sake of clarity, only a 3 Å core of 
the HDAC1 with essential hydrogen atoms is displayed. Residue numbering is 
reported for description without correction relative to the real HDAC1 sequence. 
 
By comparing the docking studies performed on 3 and 4, it is possible to observe that docking 
studies highly agree each other, displaying clustered binding conformations for either isomer 
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3 or 4 (Figure 36). These data agree with our previous findings that low active compounds 
(i.e., isomer 1) bind the deacetylase core in a lousy way and probably with a not fully defined 
binding conformation. On the other hand, in this study we found that the pyrrole ring rotation 
between benzoyl and N-hydroxy-2-propenamide moieties critically affects the binding mode 
of APHA isomers. In fact (Figure 36), while the N-hydroxy-2-propenamide tail maintains a 
similar conformation for either isomer 3 or 4, the N-methylpyrrole and benzoyl moieties are 
clearly disposed in different ways (compare left side with right side of  the  Figure 36). 
         17.1. Antiproliferative and Cytodifferentiating Effects of 4 on Friend Murine Erythroleu-
kemia  (MEL) Cells. 
In addition to in vitro enzyme assays, the capability of 4 to induce antiproliferative and 
cytodifferentiating effects in vivo on Friend MEL cells were evaluated. Figure 36A shows the 
effect of 4 on the growth of MEL cells, cultured for 48 h. Such compounds showed significant 
dose-dependent inhibitory effect on the growth rate of cell line (p < 0.01). Moreover, after 48 
h the inhibitor was not cytotoxic at the tested concentrations (data not shown). In MEL cells, 
benzidine staining reveals the  aemoglobin accumulation rate, which is related to the 
activation of the cell line differentiation process. The results (Figure 36B) clearly indicate a 
dose-dependent increase of  aemoglobin synthesis for 4 at the tested doses. 
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Figure 36. Antiproliferative and cytodifferentiating 
effects of 4 on MEL cell line. (A) Effects of 4 on cell 
growth of MEL cells, cultured for 48 h. Data are 
expressed as area under the curve (AUC) (mean ( SEM, 
n ) 4); *, p < 0.05; **, p < 0.01. (B) Effects of 4 on 
differentiation of MEL cells. The cells were cultured 
with various concentrations of drug for 48 h. Each point 
is the mean ( SEM (n ) 4); **, p < 0.01. 
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18. Third lead optimization. 
As the predicted pKi values were in the submicromolar range, we synthesized and tested 3 and 
4 against both maize HD2 and mouse HDAC1 enzymes.  
Furthermore we performed various chemical modifications (as the introduction of different 
substituents on the benzene ring and the  replacement of the benzene ring with a bulkier aromatic 
one) on these two APHAs isomers in order to improve prototypes enzyme inhibiting activity . 
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Figure 37. APHA (Aroyl pyrrolil hydroxyamides) isomers 
derivatives. 
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18.1. Chemistry. 
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Scheme 1. 
A: BF3X Et2O, RCOCl, CH2Cl2, r.t., three days; b: 1) DMF, (COCl)2, (CH2)2Cl2, 0°C, 1 
h; 2) NaOH 50%, 15 min.; c: (EtO)2POCH2COOEt, anhydrous K2CO3, EtOH, 80°C, 2 h; 
d: KOH 2N, EtOH, overnight; e: 1) ClCOOEt, Et3N, anhydrous THF, 0°C, 15 min.; 2) 
CH3OC(CH3)2ONH2, anhydrous THF, 0°C, 1 h; 3) Amberlist 15, MeOH, r.t., 1 h. 
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Chemical and physical data for compounds 1a-j and 1’a-j are listed in Table 10,11. Chemical 
and physical data for the intermediate compounds 5–8 are listed in Table 12, 13. 
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 Table 10. 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R Melting point (°C) 
recrystallization 
solvent Yield (%) 
1a Ph 88-89 Benzene/acetonitrile 84.6 
1b 2’-Cl-Ph oil Benzene/acetonitrile 77.9 
1c 3’-Cl-Ph 100-101 Acetonitrile 85.3 
1d 4’-Cl-Ph 132-133 Acetonitrile 98.0 
1e 2’-CH3-Ph 114-115 Benzene 77.3 
1f 3’-CH3-Ph 125-126 Benzene/acetonitrile 65.9 
1g 4’-CH3-Ph 151-152 Benzene/acetonitrile 90.1 
1h 1-naphthyl oil Benzene/acetonitrile 98.2 
1i 2-naphthyl 126-127 Benzene/acetonitrile 78.4 
1j 4-biphenyl 150-151 Acetonitrile 93.0 
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  Table 11. 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
Compound R Melting point (°C) 
recrystallization 
solvent Yield (%) 
1’a Ph 144-145 Benzene 68.3 
1’b 2’-Cl-Ph 146-148 Benzene 94.8 
1’c 3’-Cl-Ph 164-165 Benzene/acetonitrile 89.1 
1’d 4’-Cl-Ph 165-166 Benzene/acetonitrile 88.9 
1’e 2’-CH3-Ph 218-220 Benzene/acetonitrile 97.8 
1’f 3’-CH3-Ph 168-169 Benzene/acetonitrile 98.1 
1’g 4’-CH3-Ph 168-169 Benzene/acetonitrile 98.9 
1’h 1-naphthyl 140-141 Benzene 87.8 
1’i 2-naphthyl 205-206 Benzene/acetonitrile 78.8 
1’j 4-biphenyl 184-186 Acetonitrile 97.9 
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Compound R Melting Point (°C) 
Recrystallizzation 
solvent Yield (%) 
2a Ph 97-99 Cyclohexane 68.7 
2b 2’-Cl-Ph Oil - 64 
2c 3’-Cl-Ph Oil - 67 
2d 4’-Cl-Ph Oil - 65.6 
2e 2’-CH3-Ph 120-122 Cyclohexane 62 
2f 3’-CH3-Ph Oil - 69.5 
2g 4’-CH3-Ph 130-132 Cyclohexane/benzene 71 
2h 1-naphthyl 116-118 Cyclohexane 63.8 
2i 2-naphthyl 114-116 Cyclohexane 66.3 
2j 4-biphenyl 81-83 Cyclohexane 63.4 
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     Table 13. 
         
 
Compound R Z Melting point (°C) 
recrystallization 
solvent Yield (%) 
3a Ph CHO 88-89 Cyclohexane 84.6 
3b 2’-Cl-Ph CHO oil - 77.9 
3c 3’-Cl-Ph CHO 100-101 Cyclohexane 85.3 
3d 4’-Cl-Ph CHO 132-133 Cyclohexane/benzene 98.0 
3e 2’-CH3-Ph CHO 114-115 Cyclohexane/benzene 77.3 
3f 3’-CH3-Ph CHO 125-126 Cyclohexane 65.9 
3g 4’-CH3-Ph CHO 151-152 Cyclohexane/benzene 90.1 
3h 1-naphthyl CHO oil - 98.2 
3i 2-naphthyl CHO 126-127 Cyclohexane/benzene 78.4 
3j 4-biphenyl CHO 150-151 Cyclohexane/benzene 99.5 
4a Ph CH=CHCOOEt 222-223 Benzene/acetonitrile 91.8 
4b 2’-Cl-Ph CH=CHCOOEt 163-164 Cyclohexane/benzene 93.0 
4c 3’-Cl-Ph CH=CHCOOEt 158-159 Benzene 89.6 
4d 4’-Cl-Ph CH=CHCOOEt 127-128 Benzene 87.3 
4e 2’-CH3-Ph CH=CHCOOEt oil - 68.7 
4f 3’-CH3-Ph CH=CHCOOEt 112-113 Cyclohexane 84.9 
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4g 4’-CH3-Ph CH=CHCOOEt 129-130 Cyclohexane/benzene 95.3 
4h 1-naphthyl CH=CHCOOEt oil - 89.5 
4i 2-naphthyl CH=CHCOOEt 110-111 Cyclohexane 93.8 
4j 4-biphenyl CH=CHCOOEt 157-158 Cyclohexane/benzene 77.8 
5a Ph CH=CHCOOH 188-189 Benzene 84.0 
5b 2’-Cl-Ph CH=CHCOOH 158-160 Acetonitrile 95.2 
5c 3’-Cl-Ph CH=CHCOOH 180-181 Acetonitrile 88.8 
5d 4’-Cl-Ph CH=CHCOOH 201-202 Acetonitrile 89.6 
5e 2’-CH3-Ph CH=CHCOOH 188-189 Acetonitrile 77.1 
5f 3’-CH3-Ph CH=CHCOOH 162-163 Acetonitrile 98.3 
5g 4’-CH3-Ph CH=CHCOOH 180-181 Acetonitrile 88.9 
5h 1-naphthyl CH=CHCOOH 199-200 Benzene 81.0 
5i 2-naphthyl CH=CHCOOH 237-238 Benzene/acetonitrile 87.9 
5j 4-biphenyl CH=CHCOOH 239-240 Benzene/acetonitrile 83.3 
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  Table 14. 
Compound R Z Melting point (°C) 
recrystallization 
solvent Yield (%) 
3’a Ph CHO olio - 75.0 
3’b 2’-Cl-Ph CHO 123-125 cyclohexane 79.3 
3’c 3’-Cl-Ph CHO 115-116 Cyclohexane/benzene 87.4 
3’d 4’-Cl-Ph CHO 148-149 Cyclohexane/benzene 94.1 
3’e 2’-CH3-Ph CHO oil - 84.2 
3’f 3’-CH3-Ph CHO oil - 82.9 
3’g 4’-CH3-Ph CHO 148-149 Cyclohexane/benzene 95.2 
3’h 1-naphthyl CHO oil - 98.0 
3’i 2-naphthyl CHO 145-146 cyclohexane 82.7 
3’j 4-biphenyl CHO 148-149 Cyclohexane/benzene 97.0 
4’a Ph CH=CHCOOEt 178-179 Benzene 71.5 
4’b 2’-Cl-Ph CH=CHCOOEt 143-145 Cyclohexane/benzene 94.6 
4’c 3’-Cl-Ph CH=CHCOOEt 155-156 Benzene 84.2 
4’d 4’-Cl-Ph CH=CHCOOEt 135 Benzene 86.9 
4’e 2’-CH3-Ph CH=CHCOOEt oil - 75.9 
4’f 3’-CH3-Ph CH=CHCOOEt 109-110 Cyclohexane/benzene 89.2 
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4’g 4’-CH3-Ph CH=CHCOOEt 135-136 Cyclohexane/benzene 97.0 
4’h 1-naphthyl CH=CHCOOEt oil - 92.7 
4’i 2-naphthyl CH=CHCOOEt 100-101 cyclohexane 91.0 
4’j 4-biphenyl CH=CHCOOEt 146-147 Cyclohexane/benzene 87.2 
5’a Ph CH=CHCOOH 209-210 Benzene/acetonitrile 92.3 
5’b 2’-Cl-Ph CH=CHCOOH 193-195 Benzene/acetonitrile 98.8 
5’c 3’-Cl-Ph CH=CHCOOH 185-186 Acetonitrile 85.9 
5’d 4’-Cl-Ph CH=CHCOOH 228-229 Acetonitrile 91.5 
5’e 2’-CH3-Ph CH=CHCOOH 201-202 Benzene/acetonitrile 78.9 
5’f 3’-CH3-Ph CH=CHCOOH 159-160 Acetonitrile 98.7 
5’g 4’-CH3-Ph CH=CHCOOH 159-160 Acetonitrile 98.7 
5’h 1-naphthyl CH=CHCOOH 206-207 Acetonitrile 79.5 
5’i 2-naphthyl CH=CHCOOH 231-232 Benzene/acetonitrile 85..0 
5’j 4-biphenyl CH=CHCOOH 242-243 Benzene/acetonitrile 78.8 
 
 
18.3. Experimental Section. 
General procedure for the synthesis of 2-aroyl-1-methyl-1H-pyrroles (2a-j). 
Example: 2-(2’-chlorobenzoyl)-1-methyl-1H-pyrrole (2d). 
1-methyl-1H-pyrrole (24.65 mmol; 2.2 ml) was added to a solution of  2-
chlorobenzoylchloride (49.3 mmol; 6.32 ml) and BF3.Oet (49.3 mmol; 6.19 ml) in 
dichloromethane (100ml). After being stirred at room temperature for three days, water was 
slowly added to the reaction mixture. The organic layer was separated, and the aqueous one 
was extracted with chloroform (2 x 50 mL). The combined organic solutions were washed 
with water, dried, and evaporated to dryness. The residual oil (alpha+beta isomers) was 
chromatographed on silica gel eluting with ethyl acetate: n-hexane 1:10 to give as first eluate 
the pure desidered compound 2d. 1H NMR (CDCl3) δ 4.08 (s, 3H, N-CH3), 6.10 (m, 1H, 
pyrrole H-4), 6.46 (d, 1H, pyrrole H-3), 6.93 (d, 1H, pyrrole H-5), 7.3-7.42 (m, 4H, benzene 
H-2-5). 
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General procedure for the synthesis of 5-aroyl-1-methyl-1H-pyrrole-2-carboxaldehyde 
(3a-j) and 5-aroyl-1-methyl-1H-pyrrole-3-carboxaldehyde (3’a-j). 
Example: 2-Benzoyl-1-methyl-1H-pyrrole-5-carboxaldehyde (3a) and 2-Benzoyl-1-
methyl-1H-pyrrole-4-carboxaldehyde (3’a). 
A solution of oxalyl chloride (0.06 mol, 5.2 mL) in 1,2-dichloroethane was added to a cooled 
(0-5 °C) solution of N,Ndimethylformamide (0.06 mol, 4.6 mL) in 1,2-dichloroethane (50 
mL) over a period of 5-10 min. After being stirred at room temperature for 15 min, the 
suspension was cooled (0-5 °C) again and treated with a solution of 2-benzoyl-1-methyl-1H-
pyrrole (0.06 mol, 11.1 g) in 1,2-dichloroethane (50 mL). The mixture was stirred at room 
temperature for 1 h and then was poured onto crushed ice (200 g) containing 50% NaOH (50 
mL) and stirred for 10 min. The pH of the solution was adjusted to 4 with 37% HCl, the 
organic layer was separated, and the aqueous one was extracted with chloroform (2 x 50 mL). 
The combined organic solutions were washed with water, dried, and evaporated to dryness. 
The residual oil was chromatographed on silica gel eluting with ethyl acetate:chloroform 1:10. 
The first eluates were collected and evaporated to afford 3a as a pure solid; further elution 
gave 3a’ as a pure solid. 3a: yield: 44%; mp: 90-91 °C, recrystallization solvent: cyclohexane; 
1H NMR (CDCl3) δ 4.23 (s, 3 H, CH3), 6.62 (m, 1 H, pyrrole β-proton), 6.87 (m, 1 H, pyrrole 
β-proton), 7.44 (m, 3 H, benzene H-3,4,5), 7.78 (m, 2 H, benzene H-2,6), 9.77 (s, 1 H, CHO). 
3’a: yield: 56%; mp: 108-109 °C, recrystallization solvent: cyclohexane; 1H NMR (CDCl3) δ 
4.04 (s, 3 H, CH3), 7.12 (d, 1 H, pyrrole β-proton), 7.47 (m, 4 H, pyrrole α-proton and 
benzene H-3,4,5), 7.76 (m, 2 H, benzene H-2,6), 9.74 (s, 1 H, CHO). 
 
General Procedure for the Synthesis of Ethyl 3-[(5-aroyl)-1H-1-methyl-2-pyrrolyl]-
propenoates and 3-[(5-aroyl)-1H-1-methyl-3-pyrrolyl)]-propenoates.  
Example: Ethyl 3-[5-(2-naphthoyl)-1H-1-methyl-2-pyrrolyl)-propenoates (4i) and Ethyl 
3-[5-(2-naphthoyl)-1H-1-methyl-3-pyrrolyl)-propenoates (4’i).    
A suspension of 3i or 3’I (1.03 mmol, 0.27 g) in absolute ethanol (20 mL) was added in one 
portion to a mixture of triethyl phosphonoacetate (1.2 eq, 1.24 mmol, 0.25 ml) and anhydrous 
potassium carbonate (2 eq, 2.06 mmol, 0.28 g). After stirring at 70 °C for 2 h, the reaction 
mixture was cooled to room temperature, diluted with water (50 mL) and extracted with ethyl 
acetate (3 x 30 mL). The organic layer was washed with water, dryed with sodium sulfate and 
evaporated to dryness, the solid residue was recrystallized by cyclohexane to furnish pure 4i 
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Yield: 93.8 %, mp: 110-111°C. 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 1.35 (m, 3H, 
CH2CH3), δ 4.10 (s, 3H, N-CH3), 4.28 (m, 3H, CH2CH3), 6.41 (d, 1H, CH=CHCOOEt), 6.65 
(d, 1H, pyrrole H-3), 6.76 (d, 1H, d, 1H, pyrrole H-4), 7.57 (m, 2H, naphthalene H-6,7), 7.71 
(d, 1H, CH=CHCOOEt), 7.90 (m, 4H, naphthalene H-3,4,5,8), 8.31 (s, 1H, naphthalene H-1) 
or 4’a Yield: 91 %, mp: 100-101°C. NMR (CDCl3, 400 MHz, δ; ppm) δ 1.28 (m, 3H, 
CH2CH3), δ 4.06 (s, 3H, N-CH3), 4.21 (m, 3H, CH2CH3), 6.10 (d, 1H, CH=CHCOOEt), 6.96 
(d, 1H, pyrrole H-4), 7.15 (s, 1H, pyrrole H-2), 7.53-7.61 (m, 3H, CH=CHCOOEt, 
naphthalene H-6,7), 7.87-7.97 (m, 4H, naphthalene H-3,4,5,8), 8.32 (s, 1H, naphthalene H-1). 
 
General Procedure for the Synthesis of 3-[(5-aroyl)-1H-1-methyl-2-pyrrolyl)]-propenoic 
and 3-[(5-aroyl)-1H-1-methyl-3-pyrrolyl)]-propenoic acids.  
Example. 3-[5-(3’-methyl)-1H-1-methyl-2-pyrrolyl)]-propenoic acid (5f) and Ethyl 3-[5-
(2-naphthoyl)-1H-1-methyl-3-pyrrolyl)]-propenoic acid (5’f).  
A mixture of 4f or 4f’ (3.13 mmol, 0.93 g), 2 N KOH (4 eq, 12.52 mmol, 0.70 g, 6.26 ml 
H2O) and ethanol (15 mL) was stirred at room temperature overnight. Then the solution was 
poured into water (50 mL) and extracted with ethyl acetate (3 x 20 mL). To the aqueous layer 
2 N HCl was added until the pH was 5, and the precipitate was filtered and recrystallized by 
acetonitrile to give pure compound 5f Yield: 98.3 %, mp: 162-163 °C. NMR (DMSO-d6, 400 
MHz, δ; ppm) δ 2.42 (s, 3H, CH3), 4.08 (s, 3H, N-CH3), 6.40 (d, 1H, CH=CHCOOH), 6.70 
(m, 2H, pyrrole H-3,4) 7.35 (m, 2H, benzene H-3,4), 7.60 (m, 2H, benzene H-2,6), 7.79 (d, 
1H, CH=CHCOOEt), 12 (s, 1H, COOH) or 5f’ Yield: 98.7%, mp: 159-160°C. NMR (DMSO-
d6, 400 MHz, δ; ppm) δ 2.37 (s, 3H, CH3), 3.90 (s, 3H, N-CH3), 6.15 (d, 1H, CH=CHCOOH), 
6.99 (s, 1H, pyrrole H-4), 7.34-7.43 (m, 3H: benzene H-3,4, CH=CHCOOEt), 7.53 (m, 2H, 
benzene H-2,6), 7.67 (s, 1H, pyrrole H-2), 12 (s, 1H, COOH). 
 
General Procedure for the Synthesis of 3-[(5-aroyl)-1H-1-methyl-2-pyrrolyl)]-N-
hydroxy-2-propenamide and 3-[5-aroyl)-1H-1-methyl-3-pyrrolyl)]- N-hydroxy-2-
propenamide.  
Example. 3-[5-(4-biphenylcarbonyl)-1H-1-methyl-2-pyrrolyl)]-N-hydroxy-2-
propenamide (1j) and 3-[5-(4-biphenylcarbonyl)-1H-1-methyl-2-pyrrolyl)]-N-hydroxy-2-
propenamide (1’j). 
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Ethyl chloroformate (1.2 eq, 1.88 mmol, 0.18 ml) and triethylamine (1.3 eq, 2.04 mmol, 0.28 
ml) were added to a cooled (0 °C) solution of 5j or 5’j (1.57 mmol, 0.50 g) in dry THF (10 
mL), and the mixture was stirred for 10 min. The solid was filtered off. To the filtrate was 
added O-(2-methoxypropyl)-hydroxylamine (3 eq, 4.71 mmol, 0.35 ml). The solution was 
stirred for 15 minutes at 0°C, then the mixture was evaporated under reduced pressure, the 
residue was eluted in methanol (10 ml) and to the solution of protected hydroxamate was 
added Amberlist 15 (157 mg) and the mixture was stirred at 45°C for 1 h. The resin was 
filtered and the filtrate was concentrated in vacuo to give compound 1j recrystallized from 
acetonitrile. Yield: 93%,  mp: 150-151°C. NMR (DMSO-d6, 400 MHz, δ; ppm) δ 3.98 (s, 3H, 
N-CH3), 6.45 (d, 1H, CH=CHCONHOH), 6.63 (d, 1H, pyrrole, H-3), 6.72 (d, 1H, pyrrole, H-
4), 7.41-7.51 (m, 3H: CH=CHCOOEt, biphenyl H-3,5),  7.74 (d, 2H,  biphenyl H-2,6), 7.81 
(s, 5H, biphenyl H-2’-6’), 9 (s, 1H, NHOH), 10.75 (s, 1H, NHOH).  
 
18.4. Biological evaluation. 
In anti-HD2 assay, 8a and 9a were 16- and 76-times more effective in inhibiting the enzyme 
than 1a, 9a being as potent as SAHA and 7-times less active than TSA. 
Biological data related to HD2 also underlined as in 2,5 isomers (8b-g) the introduction of 
chloro or methyl groups was well tolerated in para but not in orto position; furthermore meta 
substitution improved HD2 inhibiting activity (8c: IC50 (HD2)=0.09 µM).  
 
 
N
CH3O
R CONHOH
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N
CH3O
R CONHOH
 
                  
                 Table 15. Inhibiting activity of the compounds 1a-j. 
 
 
 
 
 
 
 
 
 
 
 
Data represent mean values of at least three separate experiments. 
 
 
                
 
 
IC50  (µM) Compound R 
zmHD2 zmHD1-B zmHD1-A 
1a Ph 0.23 0.176 0.093 
1b 2’-Cl-Ph 0.32 1.59 0.682 
1c 3’-Cl-Ph 0.09 1.04 0.104 
1d 4’-Cl-Ph 0.239 0.445 0.131 
1e 2’-CH3-Ph 0.312 0.413 0.309 
1f 3’-CH3-Ph 0.189 0.225 0.104 
1g 4’-CH3-Ph 0.192 0.391 0.093 
1h 1-naphthyl 0.131 0.046 0.264 
1i 2-naphthyl 0.668 0.56 0.812 
1j 4-biphenyl 2.8 2.2 2.76 
1 none 3.8  NDb NDb 
sodium valproate 128  - - 
TSA 0.0072  0.0004 0.0008 
SAHA 0.05  0.028 0.178 
trapoxin 0.01  - - 
HC-toxin 0.11  - - 
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                  Table 16. Inhibiting activity of the compounds 1’a-j. 
 
 
 
 
 
 
 
 
 
 
 
 
                  Data represent mean values of at least three separate experiments. 
 
 
 
IC50  (µM) Compound R 
zmHD2 zmHD1-B zmHD1-A 
1’a Ph 0.05 0.152 0.02 
1’b 2’-Cl-Ph 0.198 0.32 0.116 
1’c 3’-Cl-Ph 0.178 0.24 0.053 
1’d 4’-Cl-Ph 0.161 0.17 0.075 
1’e 2’-CH3-Ph 0.061 0.133 0.011 
1’f 3’-CH3-Ph 0.101 0.166 0.021 
1’g 4’-CH3-Ph 0.146 0.068 0.168 
1’h 1-naphthyl 0.013 0.012 0.075 
1’i 2-naphthyl 0.049 0.089 0.043 
1’j 4-biphenyl 0.048 0.031 0.146 
1 none 3.8  NDb NDb 
sodium valproate 128  - - 
TSA 0.0072  0.0004 0.0008 
SAHA 0.05  0.028 0.178 
trapoxin 0.01  - - 
HC-toxin 0.11  - - 
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In this series inhibiting activity decreased with the replacement of the phenyl ring with 2-
naphthyl (1i) or biphenyl (1j) groups while 1-naphthyl derivative (1h) was 1.8 and 29-fold 
respectively more potent than 1a and 1. 
2,4 isomers showed a different trend on HD2: only methyl substitution in orto (1’e: IC50 
HD2=0.061 µM) kept biological activity while all chloro derivatives (1’b-d) were less active 
than lead 1’a.  
As in 2,5 series, 1-naphthylic derivative 1h was 4.6 fold more efficient than lead (1h: IC50 
HD2=0.013 µM); 2-naphthyl and biphenyl groups didn’t affect inhibitory potency. 
The two isomers 1a, 1’a were tested also on HD1-B (homologue of class I HDACs) and HD1-
A (homologue of class II HDACs) to underline a possible class selectivity: both were 
selective towards class II, being 1’a 7-fold more potent on HD1-A than HD1-B (IC50 (HD1-
B)=0.152 µM; IC50(HD1-A)=0.021 µM).   
Biological screening on HD1-B showed as in 2,5 series choro/methyl substitutions (in all 
positions) and replacement with 2-naphthyl or biphenyl groups led to an inhibiting activity 
decrease; whereas 1h (1-naphthyl derivative) was 3.8 times more potent than 1a on this 
enzyme. 
In 2,4 series, chloro and methyl insertion in para position respectively kept or improves 
biological activity (1’d: IC50 (HD1-B)=0.17 µM; 1’g: IC50 (HD1-B)=0.068 µM). 1-naphthyl 
(1’h), 2-naphthyl (1’i) and biphenyl (1’j) derivatives were all more potent than 1’a: 1’h IC50 
(HD1-B)=0.012 µM. 
Finally enzymatic screening on HD1-A showed as in 2,5 series all compounds were less or as 
active (1c,f,g: respectively meta-Cl, meta-CH3, para-CH3 derivatives) as lead 1a. 
In 2,4 series, methyl was well tolerated in orto and meta position (orto- CH3 derivative 1’e 
was 2-fold more potent than lead 1’a); chloro substitution and big aromatic groups caused an 
inhibiting activity decrease. 
In conclusion we can underline these SAR features: 
(i) in 2,5 series, insertion of chloro or methyl groups was well tolerated in meta and para 
positions in all the enzymatic screening (HD2, HD1-B, HD1-A); orto substitution caused an 
inhibiting activity decrease. 2-naphthyl (1i) and 4-biphenyl (1l) derivatives were always less 
active than lead 1a, while 1-naphthyl compound 1h was more active on HD2 and HD1-B and 
less active on HD1-A. 
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(ii) in 2,4 series, insertion of a methyl group was favourable only in orto position (1’e); meta 
and para substitutions (1’f,g) led to less active derivative with the exception of para-methyl 
compound 1’g on HD1-B. 
Chlorine in all positions (1’b-d) caused a decrease of inhibiting activity. 
With regard to 1/2 naphthyl and biphenyl derivatives (1’h-l), biological data showed that 1-
naphthyl 1’h was more active than lead 1’a on HD2 and HD1-B but not on HD1-A; 2-naphtyl 
and biphenyl derivatives (1’i,l) were more active than lead only on HD1-B.  
(iii) about class selectivity, the best selective compounds were 1c (2,5 series; 3-Cl derivative; 
IC50 (HD1-B)=1.04 µM; IC50(HD1-A)=0.1 µM) and 1’e (2,4 series; 2- CH3 derivative; IC50 
(HD1-B)=0.133 µM; IC50(HD1-A)=0.011 µM) respectively 10 and 11 fold more potent on 
class II than class I.  
18.5. Modification of the connection unit and aromatic spacer. 
Another development of the our HDAC inhibitors was the replacement of the connection unit 
and aromatic spacer common to all synthesized derivatives, in fact we have substituted the 
ketone (C.U) with the amidic function and the pyrrole (aromatic spacer) with the benzene 
ring, so obtaining the new acylaminocinnamyl N-hydroxyamides.  
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   Figure 38.  Rational design. 
 
Then we synthesized a new class of compounds having a cinnamyl-hydroxamate (HS plus 
EIG) function linked to 2-, 3-, or 4-acylamino moiety (CAP plus CU) (compounds 1-3, Fig. 
(39)), and the new derivatives were tested against three maize enzymes with deacetylase 
activity, ie HD2, HD1-B (homologue of mammalian class I HDACs), and HD1-A 
(homologue of mammalian class II HDACs). 
 Cinnamyl-hydroxyamides bearing acylamino substituents at the C2 position of the benzene 
ring (compounds 1a-g) showed very low HDAC inhibiting activities, with IC50 values in the 
high micromolar range. By shifting the same acylamino groups from C2 to C3 (compounds 
2a-g) as well as C4 (compounds 3a-f) position of the benzene ring, a number of highly potent 
HDAC inhibitors have been obtained.  
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Figure 39. 2-Acylaminocinnamyl-N-hydroxyamides 1, 3-acylaminocinnamyl-N-
hydroxyamides 2, and 4-acylaminocinnamyl-N-hydroxyamides 3. 
   
18.6. Chemistry. 
Ethyl 2-, 3-, and 4-aminocinnamates 4-6 were treated with the appropriate acyl chloride in the 
presence of triethylamine to afford the amido-esters 7a-g, 8a-g, and 9a-g, which were in turn 
hydrolyzed in alkaline medium to the corresponding carboxylic acids 10a-g, 11a-g, and 12a-f. 
Strangely, the hydrolysis under basic conditions (NaOH, KOH, LiOH) of the ethyl 4-(4-
biphenylcarbonylamino)cinnamate 9g failed to give the corresponding cinnamic acid. Further 
conversion of 10-12 into the desired hydroxamates 1-3 has been accomplished by a one-pot, 
three step procedure involving (i) the formation of mixed anhydrides between 10-12 and ethyl 
chloroformate in the presence of triethylamine, (ii) the reaction of such activated anhydrides 
with O-(2-methoxy-2-propyl)hydroxylamine, and (iii) acidic hydrolysis of the O-(2-methoxy-
2-propyl)hydroxamates with the Amberlyst® 15 ion-exchange resin (Scheme 1). All 
compounds were purified by crystallization. 
Chemical and physical data of compounds 1-3 are listed in Table 17. Chemical and physical 
data of the intermediate compounds 7-12 are reported in Table 18. 
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Scheme 1. a(a) RCOCl, (C2H5)3N, CH2Cl2, room temp. (b) LiOH, H2O, room temp. (c) 
ClCOOC2H5, (C2H5)3N, THF, 0 °C. (d) NH2OC(CH3)2OCH3, room temp. (e) Amberlyst 
15, CH3OH, room temp. 
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                         Table 17. Chemical and physical properties of compounds 1-3. 
 
compd R mp, °C recrystall. solvent yield, % 
1a Ph 170-172 benzene 53 
1b PhCH2 158-160 benzene 55 
1c PhCH2CH2 150-151 benzene 54 
1d PhCH=CH 128-130 benzene 47 
1e 1-naphthyl 195-196 MeOH 65 
1f 2-naphthyl 128-130 benzene 67 
1g 4-biphenyl 124-125 benzene 48 
2a Ph 213-214 THF 51 
2b PhCH2 183-184 THF 50 
2c PhCH2CH2 179-180 THF 56 
2d PhCH=CH 86-87 Et2O 45 
2e 1-naphthyl 191-192 MeOH 61 
2f 2-naphthyl 182-183 MeOH 59 
2g 4-biphenyl 213-214 MeOH 53 
3a Ph 212-213 THF 54 
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3b PhCH2 198-199 THF 55 
3c PhCH2CH2 204-205 THF 51 
3d PhCH=CH 218-220 THF 49 
3e 1-naphthyl 210-211 MeOH 63 
3f 2-naphthyl 223-224 MeOH 58 
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           Table 18. Chemical and physical properties of compounds 7-12. 
compd R X mp, °C recrystall. solvent yield, % 
7a Ph COOC2H5 137-139 toluene 73 
7b PhCH2 COOC2H5 123-124 toluene 58 
7c PhCH2CH2 COOC2H5 119-120 toluene 72 
7d PhCH=CH COOC2H5 114-116 toluene 60 
7e 1-naphthyl COOC2H5 182-183 toluene 75 
7f 2-naphthyl COOC2H5 168-169 toluene 78 
7g 4-biphenyl COOC2H5 173-174 toluene 71 
8a Ph COOC2H5 110-111 CH2Cl2/n-hexane 75 
8b PhCH2 COOC2H5 97-98 CH2Cl2/n-hexane 83 
8c PhCH2CH2 COOC2H5 90-92 CH2Cl2/n-hexane 80 
8d PhCH=CH COOC2H5 94-95 CH2Cl2/n-hexane 68 
8e 1-naphthyl COOC2H5 155-156 toluene 81 
8f 2-naphthyl COOC2H5 115-116 toluene 83 
8g 4-biphenyl COOC2H5 174-175 toluene 69 
9a 
9b 
9c 
9d 
9e 
Ph 
PhCH2 
PhCH2CH2 
PhCH=CH 
1-naphthyl 
COOC2H5 
COOC2H5 
COOC2H5 
COOC2H5 
COOC2H5 
144-146 
158-160 
124-126 
153-155 
169-170 
CH2Cl2/n-hexane 
CH2Cl2/n-hexane 
CH2Cl2/n-hexane 
CH2Cl2/n-hexane 
toluene 
71 
78 
77 
68 
80 
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9f 2-naphthyl COOC2H5 161-162 toluene 85 
9g 4-biphenyl COOC2H5 246-248 toluene 78 
10a Ph COOH 185-186 MeOH 75 
10b PhCH2 COOH 207-208 MeOH 79 
10c PhCH2CH2 COOH 235-236 MeOH 78 
10d PhCH=CH COOH 265-266 MeOH 65 
10e 1-naphthyl COOH 166-168 EtOH 83 
10f 2-naphthyl COOH 146-147 EtOH 79 
10g 4-biphenyl COOH 270-271 MeOH 75 
11a Ph COOH 230-231 MeOH 74 
11b PhCH2 COOH 207-209 MeOH 80 
11c PhCH2CH2 COOH 196-198 MeOH 81 
11d PhCH=CH COOH >280 MeOH 71 
11e 1-naphthyl COOH >280 EtOH 87 
11f 2-naphthyl COOH 236-237 EtOH 77 
11g 4-biphenyl COOH >280 MeOH 74 
12a Ph COOH 252-254 MeOH 78 
12b PhCH2 COOH >280 MeOH 83 
12c PhCH2CH2 COOH >280 MeOH 76 
12d PhCH=CH COOH 260-262 MeOH 67 
12e 1-naphthyl COOH 248-249 MeOH 91 
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12f 2-naphthyl COOH >280 MeOH 84 
 
 18.6. Experimental section. 
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus and are 
uncorrected. Infrared (IR) spectra (KBr) were recorded on a Perkin- Elmer Spectrum One 
instrument. 1H NMR spectra were recorded at 200 MHz on a Bruker AC 200 spectrometer; 
chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). All compounds were routinely checked by TLC and 1H NMR. 
Mass spectra (MS) were obtained on a JEOL JMS-HX 110 spectrometer. TLC was performed 
on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 F254) with spots 
visualized by UV light. All solvents were reagent grade and, when necessary, were purified 
and dried by standards methods. Concentration of solutions after reactions and extraction 
involved the use of a rotary evaporator operating at a reduced pressure of ca. 20 Torr. Organic 
solutions were dried over anhydrous sodium sulfate. Analytical results are within –0.40 and 
+0.40% of the theoretical values. All chemicals were purchased from Aldrich Chimica, Milan 
(Italy) or Lancaster Synthesis GmbH, Milan (Italy) and were of the highest purity. 
 
General procedure for the synthesis of ethyl 3-(2-acylaminophenyl)-2-propenoates 7a-g, 
ethyl 3-(3-acylaminophenyl)-2-propenoates 8a-g, and 4-(4-acylaminophenyl)-2-
propenoates 9a-g. Example: Ethyl 3-[4-(3-phenylpropionyl)aminophenyl]-2-propenoate 
(9c). 3-Phenylpropionyl chloride (3.7 mmol, 0.5 mL) and triethylamine (7.7 mmol, 1.1 mL) 
were added to a solution of ethyl 3-(4-aminophenyl)-2-propenoate hydrochloride 6 (3.1 mmol, 
0.7 g) in dry dichloromethane (20 mL) at 0 °C under nitrogen atmosphere. After stirring at 
room temperature for 4 h, the reaction mixture was poured into water (50 mL), the organic 
layer was separated, and the aqueous one was extracted with chloroform (2 x 50 mL). The 
combined organic solution was washed with water (100 mL) and brine (100 mL), and was 
dried and evaporated to dryness. The residual solid was purified by crystallization from 
dichloromethane/n-hexane to yield pure 9c. 1H NMR (CDCl3) δ 1.31-1.34 (t, 3 H, 
COOCH2CH3), 2.66-2.70 (t, 2 H, PhCH2CH2CO), 3.02-3.06 (t, 2 H, PhCH2CH2CO), 4.22-
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4.27 (q, 2 H, COOCH2CH3), 6.32-6.36 (d, 1 H, CH=CHCO), 7.21-7.23 (m, 2 H, benzene H-
2,6), 7.27-7.29 (m, 2 H, benzene H-3,5), 7.42-7.50 (m, 5 H, benzene H-2'-6'), 7.59-7.63 (d, 1 
H, CH=CHCO). Low resolution MS (EI+) m/z 324 (M+). 
 
General procedure for the synthesis of 3-(2-acylaminophenyl)-2-propenoic acids 10a-g, 
3-(3-acylaminophenyl)-2-propenoic acids 11a-g, and 3-(4-acylaminophenyl)-2-propenoic 
acids 12a-f. Example: 3-[2-(3-Phenyl-2-propenoylamino)phenyl]-2-propenoic acid (10d). 
A mixture of ethyl 3-[2-(3-phenyl-2-propenoylamino)phenyl]-2-propenoate (7d) (2.0 mmol, 
0.6 g), lithium hydroxide hydrate (4.0 mmol, 0.17 g), and ethanol (15 mL) was stirred at room 
temperature. After 24 h, 2 N HCl was added to the mixture until the pH was 5, and the 
obtained solid was filtered and recrystallized from methanol to yield pure 10d. 1H NMR 
(DMSO-d6) δ 6.47-6.51 (d, 1H, CH=CHCOOH), 6.92-6.96 (d, 1H, CH=CHCONH), 7.23-
7.27 (m, 1 H, benzene H-5), 7.40-7.46 (m, 3 H, benzene H-4,6,4'), 7.51-7.57 (m, 2 H, benzene 
H-3',5'), 7.61-7.64 (m, 3 H, benzene H-3,2',6'), 7.73-7.77 (d, 1H, CH=CHCOOH), 7.80-7.82 
(d, 1 H, CH=CHCONH), 12.50 (bs, 1H, COOH exchangeable with D2O). Low resolution MS 
(EI+) m/z 294 (M+). 
 
General procedure for the synthesis of 3-(2-acylaminophenyl)-N-hydroxy-2-
propenamides 1a-g, 3-(3-acylaminophenyl)-N-hydroxy-2-propenamides 2a-g, and 3-(4-
acylaminophenyl)-N-hydroxy-2-propenamides 3a-f. Example: 3-[4-(2-
Naphthoylamino)phenyl]-N-hydroxy-2-propenamide (3f). Ethyl chloroformate (2.9 mmol, 
0.3 mL) and triethylamine (3.1 mmol, 0.4 mL) were added to a cooled (0 °C) solution of 3-[4-
(2-naphthoylamino)phenyl[-2-propenoic acid 12f (1.5 mmol, 0.5 g) in dry THF (10 mL), and 
the mixture was stirred for 10 min. The solid was filtered off, and O-(2-methoxy-2-
propyl)hydroxylamine (4.71 mmol, 0.35 mL) was added to the filtrate. The solution was 
stirred for 15 min at 0 °C, then was evaporated under reduced pressure, and the residue was 
diluted in methanol (10 mL). Amberlyst® 15 ion-exchange resin (0.16 g) was added to the 
solution of the O-protected hydroxamate, and the mixture was stirred at room temperature for 
1 h. After, the reaction was filtered and the filtrate was concentrated in vacuo to give the 
crude 3f which was purified by crystallization. 1H NMR (DMSO-d6) δ 6.39-6.43 (d, 1 H, 
CH=CHCO), 7.42-7.46 (d, 1 H, CH=CHCO), 7.57-7.62 (m, 5 H, benzene H-2,6 and 
naphthalene H-5-7), 7.75-7.76 (d, 1 H, naphthalene H-8), 7.85-7.87 (d, 2 H, benzene H-3,5), 
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8.00-8.02 (m, 1 H, naphthalene H-4), 8.06-8.08 (d, 1 H, naphthalene H-3), 8.16-8.18 (m, 1 H, 
naphthalene H-1), 9.03 (bs, 1 H, OH exchangeable with D2O), 10.74 (s, 2 H, NH 
exchangeable with D2O). Low resolution MS (EI+) m/z 333 (M+). 
 
18.7. Biological evaluation, results and discussion. 
          
     Table 19. HD2 inhibitory activity of compounds 1-3a 
compound R % inhbtn (fixed dose, µM) 
IC50 ± SD 
(µM) 
1a Ph 43.9 (27.2) 33.6 ± 1344 
1b PhCH2 58 (26) 14.5 ± 725 
1c PhCH2CH2 28.4 (24.8) 48.2 ± 1928 
1d PhCH=CH 72.5 (25) 8.1 ± 405 
1e 1-naphthyl 32 (23.1) 41.6 ± 2080 
1f 2-naphthyl 48.6 (23.1) 24.8 ± 744 
1g 4-biphenyl 54.2 (21.4) 19.3 ± 965 
2a Ph 94.7 (27.2) 0.130 ± 3.9 
2b PhCH2 97.4 (25.9) 0.085 ± 4.2 
2c PhCH2CH2 96.8 (24.8) 0.090 ± 2.7 
2d PhCH=CH 95.2 (24.9) 0.092 ± 2.8 
2e 1-naphthyl 96.2 (23.1) 0.112 ± 3.4 
2f 2-naphthyl 96.3 (23.1) 0.102 ± 4.1 
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2g 4-biphenyl 89.2 (21.4) 0.096 ± 4.8 
3a Ph 93.7 (27.2) 0.168 ± 6.7 
3b PhCH2 97.3 (26) 0.065 ± 3.2 
3c PhCH2CH2 98 (24.8) 0.011 ± 0.5 
3d PhCH=CH 94.3 (24.9) 0.077 ± 3.1 
3e 1-naphthyl 96.4 (23.1) 0.69 ± 2.8 
3f 2-naphthyl 96.3 (23.1) 0.84 ± 3.4 
sodium butyrate  35 (5000) - 
sodium valproate   128 ± 3800 
TSA   0.007.2 ± 0.2 
SAHA   0.050 ± 1.5 
trapoxin   0.010 ± 0.3 
HC-toxin   0.110 ± 4.4 
aData represent mean values of at least three separate experiments 
 
  Table 20. HD1-B and HD1-A inhibitory activity of compounds 1-3a 
IC50 ± SD (µM) class selectivity compd R 
HD1-B HD1-A class I class II 
1a Ph 32.2 ± 1610 34.1 ± 1364   
1b PhCH2 23.2 ± 696 23.0± 920   
1c PhCH2CH2 42.0 ± 1680 NIb   
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1d PhCH=CH 13.0 ± 520 11.5 ± 690   
1e 1-naphthyl 52.0 ± 2080 17.8 ± 1068  2.9 
1f 2-naphthyl 22.0 ± 1100 26.1± 1044   
1g 4-biphenyl 23.2 ± 1160 14.1 ± 423  1.6 
2a Ph 0.302 ± 15.1 0.070 ± 3.5  4.3 
2b PhCH2 0.192 ± 9.6 0.081 ± 3.2  2.4 
2c PhCH2CH2 0.114 ± 3.4 0.094 ± 3.8   
2d PhCH=CH 0.232 ± 13.9 0.152 ± 6.1   
2e 1-naphthyl 0.216 ± 8.6 0.102 ± 5.1  2.1 
2f 2-naphthyl 0.168 ± 5.0 0.090 ± 4.5  1.9 
2g 4-biphenyl 0.206 ± 10.3 0.120 ± 3.6  1.7 
3a Ph 0.239 ± 7.1 0.130 ± 6.5  1.8 
3b PhCH2 0.092 ± 2.8 0.072 ± 3.6   
3c PhCH2CH2 0.102 ± 6.1 0.076 ± 3.0   
3d PhCH=CH 0.126 ± 5.0 0.101 ± 5.0   
3e 1-naphthyl 0.115 ± 4.6 0.059 ± 2.9  1.9 
3f 2-naphthyl 0.036 ± 1.4 0.042 ± 1.3   
TSA  0.0004 ± 0.01 0.0008 ± 0.03 2  
SAHA  0.030 ± 1.0 0.200 ± 9.0 6.7  
aData represent mean values of at least three separate experiments. bNI, no 
inhibition. 
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Compounds 1-3 have been evaluated for their inhibiting activities against three maize HDAC 
enzymes, namely HD2, HD1-B, and HD1-A. In the anti-HD2 assay, the percent of inhibition 
displayed by 1-3 at a fixed dose (ranged from 20 to 30 µM, see Table 18) and their IC50 (50% 
inhibitory concentration) values in comparison with those of two short-chain fatty acids 
(sodium butyrate and sodium valproate), two hydroxamic acids (TSA and SAHA), and two 
cyclic tetrapeptides (trapoxin and HC-toxin) as reference drugs have been reported (Table 18).  
Table 19 shows the inhibiting effect (IC50 values) of 1-3 against HD1-B and HD1-A enzymes 
in comparison with TSA and SAHA, and the resulting fold-selectivity values (for class I 
HDACs: IC50-HD1-A/IC50-HD1-B ratio; for class II HDACs: IC50-HD1-B/IC50-HD1-A ratio) have been 
assessed. From both anti-HD2 and –HD1-B/–HD1-A assays, inhibitory data clearly showed 
that the 2-acylaminocinnamyl-N-hydroxyamides 1a-g are endowed with poor deacetylase 
inhibiting activity, their IC50 values being in the range 8.1-52.0 µM. The most potent 
compound is the 2-cinnamoylamino derivative 1d, its IC50 values being 8.1, 13.0, and 11.5 
µM against HD2, HD1-B, and HD1-A respectively.  
Instead, the 3-acylamino- and the 4-acylamino-isomers 2 and 3 were very efficient in HDAC 
inhibition with inhibitory values in the nanomolar range. In particular, against HD2 the 3-
acylamino-substituted compounds 2a-g showed IC50 values from 85 to 130 nM. The less 
active derivative was the 3-benzoylamino 2a (IC50 = 130 nM). By insertion of one or two 
carbon atom units between the benzene ring and the carbonyl group of the 2a benzoyl portion, 
as well as by replacement of the benzene ring with bulkier aromatic groups (1-naphthyl, 2-
naphthyl, 4-biphenyl), highly potent compounds have been obtained (2b-g; IC50 values: 85-
112 nM). The activities of 2a-g against HD1-B and HD1-A enzymes were still in the 
nanomolar range (IC50 values = 70-302 nM), but while in the anti-HD1-B assay the same 
structure-activity relationships (SARs) as those described in the anti-HD2 assay have been 
observed, against HD1-A the 3-benzoylamino derivative 2a was the most potent (IC50 = 70 
nM) and the most class II-selective (class II selectivity ratio: 4.3) compound among all the 
synthesized cinnamyl-hydroxyamides 1-3. Molecular modeling and docking studies with 3D-
QSAR models of HD1-B and HD1-A enzymes have been undertaken, also to provide an 
explanation for the 2a activity data. 
Against HD2, the 4-substituted series (compounds 3a-f) resembled the same SAR profile as 
the 3-substituted counterparts, the 4-benzoylamino derivative 3a and the 4-(3-
phenylpropionylamino) derivative 3c being, respectively, the least and the most potent 
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compound (3a: IC50 = 168 nM; 3c: IC50 = 11 nM) of the series. In the anti-HD1-B and -HD1-
A assays, again the 4-benzoylamino derivative 3a was the less active compound, whilst the 4-
(2-naphthoylamino)cinnamyl-N-hydroxyamide 3f showed the highest inhibitory activity, with 
IC50-HD1-B = 36 nM and IC50-HD1-A = 42 nM. 
18.8. Conclusions. 
A new series of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides 1-3 have been prepared, 
and their anti-HDAC (against maize HD2, HD1-B, and HD1-A enzymes) activities have been 
assessed. Cinnamyl-hydroxyamides bearing acylamino substituents at the C2 position of the 
benzene ring (compounds 1a-g) showed very low HDAC inhibiting activities, with IC50 
values in the high micromolar range. By shifting the same acylamino groups from C2 to C3 
(compounds 2a-g) as well as C4 (compounds 3a-f) position of the benzene ring, a number of 
highly potent HDAC inhibitors have been obtained.  
As a rule, the introduction of a benzoylamino moiety both at C3 or C4 position led to 3- and 
4-benzoylaminocinnamyl-N-hydroxyamides (2a and 3a) with IC50 values in the range 130-
302 nM (with the exception of the activity of 2a against HD1-A, IC50 = 70 nM). The insertion 
of 1-2 carbon atom units between the benzene and the carbonyl group of the benzoyl portion, 
as well as the replacement of the benzene with the bulkier 1-naphthyl, 2-naphthyl, or 4-
biphenyl moiety increased up to 15-times the HDAC inhibitory activity of the derivatives 
(compare 3a, IC50-HD2 = 168 nM, with 3c, IC50-HD2 = 11 nM).  
In the anti-HD2 assay 3c (IC50 = 11 nM) was the most potent compound, being >11600-, 4.5-, 
and 10-fold more potent than sodium valproate, SAHA, and HC-toxin, respectively, and 
showing the same activity as trapoxin and slightly lower (1.5-fold) activity than TSA. HD1-B 
and HD1-A assays have been performed to screen the inhibitory action of 1-3 against 
mammalian class I (HD1-B) and class II (HD1-A) HDAC homologous enzymes. From the 
corresponding IC50 data, a selectivity ratio has been calculated. In general, compounds 1-3 
showed no or little selectivity towards the class II homologue HD1-A, the most selective 
being 2a with class II selectivity ratio = 4.3. SAHA and, to a lesser extent, TSA were both 
class I selective (class I selectivity ratios: SAHA, 6.7; TSA, 2). About the inhibitory potency, 
the 4-(2-naphthoylamino)cinnamyl-N-hydroxyamide 3f showed the highest inhibiting effect 
against the two enzymes. Even though it was 90- (HD1-B) and 52-fold (HD1-A) less potent 
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than TSA, 3f showed the same activity as SAHA against HD1-B, and was 4.8-fold more 
potent than SAHA against HD1-A.  
Selected 2 and 3 compounds will be evaluated to determine their antiproliferative and 
cytodifferentiating activities on human acute promyelocytic leukemia HL-60 cells. 
18.9. Optimizzation’s study  of 3b. 
The 4-acylaminocinnamyl-N-hydroxyamides series resulted the most potent against the HD1-
B and HD1-A  enzymes, in particular the compound 3b. That induced us to effect chemical 
manipulations on such derivatives. Then we made stiff 3b and then we studied the branching 
effect at methylene group between the benzene ring and the carbonilic group. Afterwards, on 
the MS-275’s stuctural basis, we replaced the idroxammic function (EIG) with a 2-
aminoanilide function. Furthermore we replaced the cinnamylic benzene ring with an 
heteroaromatic ring, that is with the  pyridin ring. At last we introduced on the acylic moiety 
bulky groupas 1 and 2-naphthyl groups, for improving the interactions between the CAP 
group and the rhyme of  enzyme’s tubular pocket. 
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Figure 40. Optimizzation’s study of 3b. 
 
 
 
 
 
 
Design, synthesis and biological validation of epigenetic modulators of histone/protein deacetylation and 
methylation. 
 
 163
 18.10. Chemistry. 
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H2N
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HCl x
2a-k X= OEt
3a-k  X= OH
Y= OCOOEt
Y= NHC(CH3)2OCH3
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b
c
d
e
f
1a-k  
 
Scheme 1. a) SnCl2 X 2H2O, HCl, EtOH. b) RCOCl, (C2H5)3N, CH2Cl2, room temp. c) 
LiOH, H2O, room temp. d) ClCOOC2H5, (C2H5)3N, THF, 0 °C. e) NH2OC(CH3)2OCH3, 
room temp. f) Amberlyst 15, CH3OH, room temp. 
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Ar = phenyl, 1,2-naphtyl  
 
Scheme 2.  a) n-BuLi 2.5 M, Et2NH, THF, -78°C, b) alkyl bromide or iodide, -78°C. 
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Scheme 3.  a) MeONa, MeOH, THF, 70°C, 5 h. 
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Scheme 4.  a) Et3N, BOP reagent, DMF, r.t.,  b) 1,2-phenylendiamine, DMF, r.t. 
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Table 21. Chemical and physical data of compound 1a-k. 
 Compound R m.p. (°C) Recrystallization solvent Yield (%) 
1a 
 
103-105 Benzene 65.7 
1b 
 
95-97 Benzene 68.4 
1c 
 
133-135 Benzene 67.3 
1d 
 
128-130 Benzene 59.8 
1e 
 
180-182 Benzene/acetonitrile 61.0 
1f 
 
179-181 Benzene/acetonitrile 63.8 
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 1g 
 
162-164 Benzene/acetonitrile 67.6 
1h 
 
110-112 Benzene 58.3 
1i 
OCH3  
146-148 Benzene/acetonitrile 54.9 
1j 
 
238-240 Acetonitrile/methanol 61.3 
1k 
 
182-184 Acetonitrile 59.2 
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         Table 22. Chemical and physical data of compound 2a-k.   
 
Compound R m.p. (°C) Recrystallization solvent Yield (%) 
2a 
 
144-146 Cyclohexane/benzene 85.0 
2b 
 
105-107 Cyclohexane 78.4 
2c 
 
114-116 Cyclohexane 87.3 
2d 
 
109-111 Cyclohexane 88.2 
2e 
 
135-137 Cyclohexane/benzene 79.6 
2f 
 
125-127 Cyclohexane/benzene 82.8 
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2g 
 
95-97 Cyclohexane 83.6 
2h 
 
114-116 Cyclohexane/benzene 77.5 
2i 
OCH3  
133-135 Cyclohexane/benzene 78.7 
2j 
 
151-153 Cyclohexane/benzene 73.4 
2k 
 
143-145 Cyclohexane/benzene 83.4 
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         Table 23. Chemical and physical data of compound 3a-k. 
 
Compound R m.p. (°C) Recrystallization solvent Yield (%) 
3a 
 
>250 Acetonitrile/methanol 86.7 
3b 
 
>250 Acetonitrile/methanol 95.7 
3c 
 
224-226 Acetonitrile/methanol 94.5 
3d 
 
210-212 Acetonitrile/methanol 88.6 
3e 
 
186-188 Acetonitrile 89.4 
3f 
 
187-189 Acetonitrile 83.8 
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3g 
 
162-164 Benzene/acetonitrile 89.0 
3h 
 
171-173 Benzene/acetonitrile 82.3 
3i 
OCH3  
198-200 Benzene/acetonitrile 85.7 
3j 
 
>250 Acetonitrile/methanol 81. 
3k 
 
168-170 Benzene/acetonitrile 83.4 
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           Table 24. Chemical and physical data of compound 4c-k. 
 
Compound R m.p. (°C) Recrystallization solvent Yield (%) 
4c 
 
228-230 Acetonitrile/methanol 87.0 
4d 
 
200-202 Acetonitrile/methanol 78.5 
4e 
 
206-208 Acetonitrile/methanol 76.9 
4f 
 
205-207 Acetonitrile/methanol 73.4 
4g 
 
240-242 Methanol 74.6 
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4h 
 
240-242 Methanol 72.8 
4i 
OCH3  
180-182 Benzene/acetonitrile 75.7 
4j 
 
>250 Methanol 77.4 
4k 
 
244-246 Methanol 78.5 
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18.11. Experimental section. 
Synthesis of Ethyl 3-(4-aminophenyl)-2-propenoate. 
To a solution of ethyl 4-nitrocynnamate (18.08 mmol, 4g) in ethanol (30 mL) stannous 
chloride dihydrate (64 mmol, 14.44 g) was added. Then concentrated HCl was dropwise 
added and the resulting suspension was stirred overnight. The precipitate salt was filtered, 
washed with ether and dryed to afford the pure amine hydrochloride. 
 
General procedure for the synthesis of ethyl 3-(4-acylaminophenyl)-2-propenoates 2a-k. 
Example: Ethyl 3-[4-(2-phenylbutyryl)aminophenyl]-2-propenoate (2d). 3-Phenylbutyryl 
chloride (6.1 mmol, 1 g) and triethylamine (15.22 mmol, 2.12 mL) were added to a solution of 
ethyl 3-(4-aminophenyl)-2-propenoate hydrochloride  (6.1 mmol, 1.39 g) in dry 
dichloromethane (20 mL) at 0 °C under nitrogen atmosphere. After stirring at room 
temperature for 4 h, the reaction mixture was poured into water (50 mL), the organic layer 
was separated, and the aqueous one was extracted with chloroform (2 x 50 mL). The 
combined organic solution was washed with water (100 mL) and brine (100 mL), and was 
dried and evaporated to dryness. The residual solid was purified by crystallization from 
dichloromethane/n-hexane to yield pure 2d. 1H NMR (CDCl3) δ 0.93 (m, 3H, CH2CH3), 1.32 
(m, 3H, OCH2CH3), 1.85-2.25 (m, 2H, CH2CH3), 3.40 (m, 3H, PhCHCO), 4.25 (OCH2CH3), 
6.34 (d, 1H, PhCH=CHCOOEt), 7.26-7.49 (m, 9H, benzene protons), 7.60 (d, 1H, 
PhCH=CHCOOEt). 
 
General procedure for the synthesis of 3-(4-acylaminophenyl)-2-propenoic acids 3a-k. 
Example: 3-[4-(2-Phenyl-pent-4-en-oylamino)phenyl]-2-propenoic acid (3h). 
A mixture of ethyl 3-[4-(2-Phenyl-pent-4-enoylamino)phenyl]-2-propenoate (2h) (0.57 mmol, 
0.20 g), lithium hydroxide hydrate (1.14 mmol, 0.048 g), and tetrahydrofuran (15 mL) was 
stirred at room temperature. After 24 h, 2 N HCl was added to the mixture until the pH was 5, 
and the obtained solid was filtered and recrystallized to yield pure 3h. 1H NMR (DMSO-d6) δ 
2.48-2.76 ( m, 2H, CH2CH=CH2), 3.50 (m, 1H, PhCHCO), 5.00 (m, 2H, CH2CH=CH2), 5.72 
(m, 1H, CH2CH=CH2), 6.35 (d, 1H, PhCH=CHCOOEt), 7.31-7.60 (m, 10 H, benzene protons 
and PhCH=CHCOOEt), 10.30 (s, 1H, CONHPh). 
 
Ph.D. program: “Small Molecules as Epigenetic Modulators” 
 
 174
 
General procedure for the synthesis of 3-(4-acylaminophenyl)-N-hydroxy-2-
propenamides 1a-k. Example: 3-[4-(2,3-Diphenyl-propionylamino)-phenyl]- N-hydroxy-
2-propenamide (1k). 
Ethyl chloroformate (1.26 mmol, 0.12 mL) and triethylamine (1.37 mmol, 0.19 mL) were 
added to a cooled (0 °C) solution of 3-[4-(2,3-Diphenyl-propionylamino)-phenyl]-2-
propenoic acid 3k (1.05 mmol, 0.42 g) in dry THF (10 mL), and the mixture was stirred for 
10 min. The solid was filtered off, and O-(2-methoxy-2-propyl)hydroxylamine (3.15 mmol, 
0.23 mL)  was added to the filtrate. The solution was stirred for 15 min at 0 °C, then was 
evaporated under reduced pressure, and the residue was diluted in methanol (10 mL). 
Amberlyst® 15 ion-exchange resin (42 mg) was added to the solution of the O-protected 
hydroxamate, and the mixture was stirred at room temperature for 1 h. After, the reaction was 
filtered and the filtrate was concentrated in vacuo to give the crude 1k which was purified by 
crystallization. 1H NMR (DMSO-d6) δ 3.05 (m, 1H, PhCH2), 3.60 (m, 1H, PhCH2), 3.75 (m, 
1H, PhCHCO), 6.36 (d, 1H, PhCH=CHCOOEt), 7.15-7.70 (m, 15H, benzene protons and 
PhCH=CHCOOEt), 9.00 (s, 1H, OH), 10.23 (s, 1H, CONHPh), 10.85 (s, 1H, NHOH). 
 
General procedure for the synthesis of N-(2-Amino-phenyl)-3-[4-(acylamino)-phenyl]-2-
propenamide 4c-k. Example: N-(2-Amino-phenyl)-3-[4-(2-naphthalen-2-yl-
butyrylamino)-phenyl]-2-propenamide (4f). 
To a solution of 3-[4-(2-naphthalen-2-yl-butyrylamino)-phenyl]-2-propenoic acid (3f) (0.55 
mmol, 0.20 g) in anhydrous dimethylformamide (5mL) triethylamine (2.2 mmol) and BOP 
reagent (0.66 mmol, 0.29 g) were added under nitrogen atmosphere. The resulting mixture 
was stirred for 30 min at room temperature. The reaction was quenced by water, extracted 
with ethyl acetate (3 x 30 mL), then the organic layers were dryed with sodium sulfate and 
concentrated to afford a solid that was chromatographed by SiO2 eluting with 
acetate/chloroform 1:1. The pure product 4f was obtained as a yellow solid. 1H NMR 
(DMSO-d6) δ 0.90 (m, 3H, CH2CH3), 1.75-2.25 (m, 2H, CH2CH3), 3.77 (m, 1H, 2-napht-
CHCO), 6.56-6.74 (m, 4H, 2-aminoanilide C3-5 and PhCH=CHCONHPh), 7.30 (d, 1H, 2-
aminoanilide C6), 7.44-7.89 (m, 12H, 2-naphthalene and benzene protons and 
PhCH=CHCONHPh), 9.29 (s, 1H, PhCH=CHCONHPh), 10.33 (s, 1H, 2-napht-CHCONH).  
 
Design, synthesis and biological validation of epigenetic modulators of histone/protein deacetylation and 
methylation. 
 
 175
General procedure for the synthesis of the α-alkyl-arylacetic acids. Example: 3-Methyl-
2-phenyl-butyric acid. 
A solution of diethylamine (16.16 mmol, 1.68 mL) in anhydrous tetrahydrofuran (10 mL) was 
dropwise added to a solution of n-butyllithium 2.5 M in hexane (32.32 mmol, 12.93 mL) 
cooled at -78°C and under nitrogen atmosphere. The resulting solution was stirred at 0°C for 
30 min, then cooled again at -78°C and a solution of phenylacetic acid in tetrahydrofuran (10 
mL) was dropwise added under nitrogen atmosphere. The mixture was stirred at 0°C for 
others 30 min, afterwards it was cooled at -78°C and a solution of 2-iodopropane (16.16 
mmol, 1.613 mL) was slowly added. The reaction was left stirring at room temperature 
overnight, was quenced by water (50 mL) and the aqueous layer was extracted with ethyl 
acetate (3 x 30 mL), acidified with concentrated HCl and extracted again with ethyl acetate (3 
x 30 mL). The organic layers was washed with NaCl solution (3 x 30 mL). dryed with sodium 
sulfate and concentrated to afford an oil that was purified by chromatography eluting with 
ethyl acetate/ chloroform 1:5. The pure product was obtained as a white solid. 
 
General procedure for the synthesis of the α-methoxy-phenylacetic acid. 
To a cooled at 0°C solution of sodium methoxide (63.48 mmol, 1.46 g Na) in methanol (20 
mL) a solution of α-chloro-phenylacetyl chloride (7.93 mmol, 1.25 mL) in tetrahydrofuran 
(10 mL) was slowly added. The mixture was stirred at 70°C for 5 h, then the solvent was 
evaporated, the residue was eluted with water (50 mL) and extracted with ethyl acetate (3 x 30 
mL), the aqueous layer was acidified and extracted again with ethyl acetate (3 x 30 mL). The 
organic layers was dryed and concentrated to afford the pure product that slowly solidify. 
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19. Biological evaluation. 
  
Table 25.  HD1-B, HD1-A and mouse HDAC1 inhibiting activity of compounds 1a-k. 
 
 IC50 (µM)  Compound R 
zm- HD1-B zm-HD1-A mouse-HDAC1 
1a 
 
0.064 0.132 0.198 
1b 
 
0.065 0.196 0.334 
1c 
 
0.033 0.057 0.102 
1c (2) 
 
0.056 0.073 0.258 
1c (1) 
 
0.170 0.125 0.406 
1d 
 
0.028 0.068 0.055 
1d (2) 
 
0.040 0.070 0.045 
1d (1) 
 
0.101 0.063 0.328 
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1e 
 
0.058 0.042 0.620 
1f 
 
0.062 0.069 0.560 
1g 
 
0.187 0.057 0.296 
1h 
 
0.126 0.057 0.115 
1i 
OCH3  
0.083 0.140 0.150 
1j 
 
0.162 0.055 0.128 
1k 
 
0.133 0.074 0.083 
lead  
compound  
0.092  0.072  - 
SAHA - 0.030  0.200  - 
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Compounds 1a-k have been evaluated for their inhibiting activities against two maize HDAC 
enzymes, HD1-B, HD1-A and for the first time against the mouse HDAC1. As reference we 
used the lead compound and SAHA. 
The results showed that all alkylic groups are well tolerated but the best branching is resulted 
by the methyl and ethyl groups, introduced in the compound 1c and 1d, respectively, that 
endowed with most potency, comparable with SAHA. All derivatives 1a-k have a chiral 
center, then on the basis of good results obtained we have separated two enantiomers R-(-) 
and S-(+) of raceme 1c and 1d, with the aim to have a different activity beetween two 
enantiomers. The inibitory activity of the enantiomers 1c(1) and 1d(1), that are the 
enantiomers R-(-), are better than the inibitory activity of 1c(2) and 1d(2). This result is more 
evident analysing the biological assays below reported. 
 
19.1. Granulocytic Differentiation on human U937 leukemia Cells. 
The most potent derivatives, 1c, 1c(1), 1c(2), 1d, 1d(1), 1d(2), 1g, 4c, 4d, 4g, 4e, 4f were 
assayed on human U937 leukemia cells to value the granulocytic differentiating capacity. We 
considered as reference SAHA and MS-275. The results are represented in the following 
figure 41 and 42. 
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Figure 41 (a). Differentiation of the human U937 leukemia Cells 
(30 hours) by HDAC inhibitors (idroxammates derivatives). 
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Figure 41 (b). Differentiation of the human U937 leukemia Cells 
(30 hours) by HDAC inhibitors (idroxammates derivatives). 
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Figure 42 (a). Differentiation of the  human U937 leukemia Cells 
(30 hours) by HDAC inhibitors (2-aminoanilides  derivatives). 
 
Ph.D. program: “Small Molecules as Epigenetic Modulators” 
 
 182
 
0,00
10,00
20,00
30,00
40,00
50,00
60,00
%
C MS SAHA 4e 4f
 
Figure 42 (b). Differentiation of the  human U937 leukemia Cells 
(30 hours) by HDAC inhibitors (2-aminoanilides  derivatives). 
 
 
Granulocytic differentiation of human leukemia U937 cells was determined by CD11c 
expression level upon 30 h of stimulation with selected compounds. To this end, cell cultures 
were treated with compounds at 5 µM concentration together with SAHA and MS-275 as the 
reference drugs, and after 30 h, the percent values of CD11c positive PI negative cells were 
determined. 
 
Granulocytic Differentiation on U937 Cells. Granulocytic differentiation was carried out as 
previously described.66 Briefly, U937 cells were harvested and resuspended in 10 µL of 
phycoerythrine-conjugated CD11c (CD11c-PE). Control samples were incubated with 10 µL 
of PE conjugated mouse IgG1, incubated for 30 min at 4 °C in the dark, washed in PBS, and 
resuspended in 500 µL of PBS containing PI (0.25 íg/mL). Samples were analyzed by FACS 
with Cell Quest technology (Becton Dickinson). PI positive cells have been excluded from the 
analysis. 
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19.2. Effects on human U937 leukemia cells cycle. 
The derivatives 1c, 1c(1), 1c(2), 1d, 1d(1), 1d(2), 1g, 4c, 4d, 4g, 4e, 4f were tested against the 
human U937 leukemia cells to estimate the antiproliferative effect considering cell cycle 
arrest in the phases G1, G2, M and the pro-apoptotic effect. 
The results of these assays are showed in the below figure 43 and 44. 
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Figure 43 (a). Effect  on human U937 leukemia Cells cycle (24 hours) by 
HDAC inhibitors (idroxammates derivatives). 
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Figure 43 (b). Effect  on human U937 leukemia Cells cycle (24 hours) by 
HDAC inhibitors (idroxammates derivatives). 
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Figure 44 (a). Effect  on human U937 leukemia Cells cycle (24 hours) by 
HDAC inhibitors (2-aminoanilides  derivatives). 
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Figure 44 (b). Effect  on human U937 leukemia Cells cycle (24 hours) by 
HDAC inhibitors (2-aminoanilides  derivatives). 
 
 
To evaluate the effects of HDAC inhibitors on cell cycle and apoptosis in the human leukemia 
U937 cell line, cell cultures were treated with 5 µM concentration of selected derivatives in 
comparison with SAHA (5 µM) and MS-275 (5 µM), and after 24 h the cell cycle analysis 
was determined. Apoptosis, measured as caspase 3 cleavage (data not shown) and 
AnnexinV/propidium iodide (PI) double staining by FACS analyses, was checked after 24 h 
of treatment with selected compounds used at 5 µM. 
 
Cell Cycle Analysis on U937 Cells. Cells (2.5 x 105) were collected and resuspended in 500 
µL of hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 50 µg/mL of propidium 
iodide (PI), and RNAse A). Cells were incubated in the dark for 30 min. Samples were 
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acquired on a FACS-Calibur flow cytometer using the Cell Quest software (Becton 
Dickinson) and analyzed with standard procedures using the Cell Quest software (Becton 
Dickinson) and the ModFit LT version 3 Software (Verity). All of the experiments were 
performed three times. 
 
19.3. p21 Induction and α-Tubulin Acetylation. 
Taking the cyclin dependent kinase inhibitor p21WAF1/CIP1 (p21) induction as well as the 
acetylation extents of α-tubulin as markers of HDACi activity in U937 cells, we performed 
Western blot analyses to test the activity of selected derivatives. 
 
 
 
      Figure  45.  p21 oncosuppressor expression by HDAC inhibition. 
 
 
                Figure 46.  α-tubulin acetylation. 
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Taking the cyclin dependent kinase inhibitor p21WAF1/CIP1 (p21) induction as well as the 
acetylation extents of α-tubulin as markers of HDACi activity in U937 cells, we performed 
Western blot analyses to test the activity of selected HDAC inhibitors. Figure 46 shows that 
1d (2), but not 1d (1), increased the p21 expression more than MS-275 and SAHA. No 
compound induced α-tubulin acetylation. α-tubulin acetylation is a functional test for the 
evaluation of HDAC6 activity, a class IIb HDAC, whereas p21 induction represents  a feature 
of HDAC class I inhibitors. 
 
20. HMT inhibitors design.  
In 2004, a series of dyes and dye-like compounds were evaluated as small molecule 
modulators of PRMT and HKMT activity. In this screen, AMI-1 has been described as the 
first specific PRMT inhibitor, and AMI-5 was one of the most potent, though less selective, 
compound (Figure 47).357 Recently, the fungal metabolite chaetocin was identified and 
characterized as first specific inhibitor of the HKMT SU(VAR)3-9 (figure 47).358 
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Figure 47. PRMT inhibitors and HKMT SU(VAR)3-9 specific inhibitor. 
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As a part of our medicinal chemistry project aimed to discover new entities as small molecule 
modulators of epigenetic targets, we chose the AMI-5 chemical structure as a template and 
designed a new series of simplified analogues starting from a pharmacophore hypothesis. In 
this hypothesis, we identified the presence of two o-bromo- or o,o-dibromophenol moieties as 
crucial for having anti-methyltransferase activity, and inserted a hydrophobic spacer between 
the above fragments (figure 48). 
 
 
 
Figure 48. Rational design for development of HMT inhibitors. 
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 20.1. Chemistry. 
 
R1
HO
CHO
R1
R1
R1
HO
O
CH3
RO
O
CH3
RO
CHO
R1
R1
HO
RO
OH
OR
R2
R2
a or b c
d
2a-h 3c-k', 1j, k, v, w.
  SPACER
(KETONE)
  SPACER
(KETONE)
1c-m'
3a, b
1a, b
d
c'
 
Scheme 1. a: NaH, CH3OCH2Br, THF, O°C, 30 min; b: K2CO3, CH3I, CH3CN, 80°C; c: 
ketone, Ba(OH)2 X 8H2O, r. t., 2h; c’: CH3COCH3, Ba(OH)2 X 8H2O, r. t., 2h d: HCl 3N, 
MeOH, 70°C, 3h. 
 
R1
HO
CHO
R1
HO
O OH
OH
R2
a
1o, 1p  
  
Scheme 2. a: 2,4-pentanedione, B2O3, B(OBu)3, BuNH2, AcOEt, 80°C. 
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Scheme 3. a: NaH, CH3OCH2Br, THF, O°C, 30 min. b: LDA, DMF, THF, -80°C, 30 
min. 
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Scheme 4. a: NaH, CH3OCH2Br, THF, O°C; b: KOH 2N, MeOH;  c: 1) TEA, ClCOOEt, THF,   
0°C, 2) diamine, THF, 0°C; d: HCl 3N, MeOH, 50°C. 
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Scheme 5. a: SOCl2, 70°C; b: TEA, 1,3 or 1,4-phenylendiamine, THF, 0°C; c: BBr3, 
CH2Cl2, -78°C.    
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Scheme 6. a: TEA, opportune acylic dichloride, THF, 0°C. 
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HO
R
O
CH3
 
 
 
      Table 26. Chemical and physical data of the compounds 1a-b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds R 
Melting 
Point (°C) 
Recrystallizzation 
solvent Yield (%) 
1a 3-Br 100-102 Ethanol 94.0 
1b 3,5-di-Br 142-144 Ethanol 93.0 
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R1 R2
SPACER
 
 
   Table 27. Chemical and physical data of the compound 1c-x’. 
 
Compounds R1, R2 Spacer 
Melting 
Point (°C) 
Recrystalliz. 
solvent 
Yield 
(%) 
1c Bis-3-Br-4-OH 
O
 248-250       methanol 84.5 
1d Bis-3,5-di-Br-4-OH 
O
 274-276       methanol 92.5 
1e 3-Br-4-OH, 3,5-di-Br-4-OH 
O
 240-242       methanol 86.0 
1f Bis-3-Br 
O
 118-120 methanol 97.3 
1g Bis-4-OH 
O
 246-248 methanol 100.0 
1h Bis-2-Br-4-OH 
O
 >250 methanol 78.1 
1i Bis-2,6-di-Br-4-OH 
O
 >250 methanol 82.8 
1j Bis-3-Br-4-OCH3 
O
 170-172 methanol 93.7 
1k Bis-3,5-di-Br-4-OCH3 
O
 218-220 methanol 89.4 
1l Bis-3-NO2-4-OH 
O
 239-241 methanol 87.8 
1m Bis-3-F-4-OH 
O
 240-242 methanol 95.0 
1n Bis-3,5-di-CH3-4-OH 
O
 229-231 methanol 91.6 
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1o Bis-3-Br-4-OH 
O OH
 238-240 methanol 45.0 
1p Bis-3,5-di-Br-4-OH 
O OH
 244-246 methanol 26.0 
1q Bis-3-Br-4-OH 
O O
 
130-132 methanol 67.5 
1r Bis-3,5-di-Br-4-OH 
O O
 
146-148 methanol 59.6 
1s Bis-3-Br-4-OH 
O
 
151-153 methanol 96.5 
1t Bis-3,5-di-Br-4-OH 
O
 
198-200 methanol 92.4 
1u Bis-4-OH 
O
 
>250 methanol 98.3 
1v Bis-3-Br-4-OCH3 
O
 
156-158 methanol 89.4 
1w Bis-3,5-di-Br-4-OCH3 
O
 
200-202 methanol 78.0 
1x Bis-3-Br-4-OH 
O
O
 
220-222 methanol 86.0 
1y Bis-3,5-di-Br-4-OH 
O
O
>250 methanol 76.7 
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1z Bis-4-OH 
O
O
 
>250 methanol 88.2 
1a’ Bis-3-Br-4-OH 
S
O
 
168-170 methanol 86.0 
1b’ Bis-3,5-di-Br-4-OH 
S
O
 
230-232 methanol 76.8 
1c’ Bis-3-Br-4-OH 
N
O
CH3  
>250 methanol 75.4 
1d’ Bis-3,5-di-Br-4-OH N
O
CH3  
>250 methanol 73.8 
1e’ 3,5-di-Br-4-OH, 3-Br-4-OH N
O
CH3  
>250 methanol 86.0 
1f’ Bis-3-Br-4-OH 
N
O
Bz  
>250 methanol 68.5 
1g’ Bis-3,5-di-Br-4-OH N
O
Bz
>250 methanol 56.7 
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1h’ Bis-3-Br-4-OH 
OO
>250 methanol 79.8 
1i’ Bis-3,5-di-Br-4-OH 
OO
>250 methanol 64.7 
1j’ Bis-4-OH 
OO
>250 methanol 75.6 
1k’ Bis-3-Br-4-OH 
O
O
>250 methanol 77.4 
1l’ Bis-3,5-di-Br-4-OH 
O
O
>250 methanol 68.0 
1m’ Bis-4-OH 
O
O
>250 methanol 78.0 
1n’ Bis-3,5-di-Br-4-OH 
O
N
H
H
N
O  
>250 methanol 98.7 
1o’ Bis-3,5-di-Br-4-OH 
O
N
H
N
H
O
238-240 methanol 96.5 
1p’ Bis-3,5-di-Br-4-OH 
O
N
H
H
N
O
 
246-248 methanol 89.0 
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1q’ Bis-3,5-di-Br-4-OH NH
O
N
H
O
>250 methanol 88.6 
1r’ Bis-3,5-di-Br-4-OH 
H
N
N
H
O
O >250 methanol 75.4 
1s’ Bis-3,5-di-Br-4-OH O
O
N
H
H
N
 
>250 methanol 78.3 
1t’ Bis-3,5-di-Br-4-OH 
O
N
H
N
H
O
 
230-232 methanol 66.5 
1u’ Bis-3,5-di-Br-4-OH 
H
NN
H
O
O  
215-217 methanol 75.7 
1v’ Bis-3,5-di-Br-4-OH NH
O
N
H
O
198-200 methanol 84.6 
1w’ Bis-3,5-di-Br-4-OH 
O
N
H
O
N
H
196-198 methanol 92.3 
1x’ Bis-3,5-di-Br-4-OH 
O
N
H
O
H
N >250 methanol 90.1 
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R
 
 
      Table 28. Chemical and physical data of the compound 3a-b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
 
 
 
       
 
Compounds R Melting Point (°C) 
Recrystallization 
solvent Yield (%) 
3a 3-Br 115-117 cyclohex/benz 96.0 
3b 3,5-di-Br 112-114 cyclohex/benz 82.7 
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R1 R2
SPACER
 
 
Table 29. Chemical and physical data of the compound 3c-p’. 
 
Compounds R1 R2 Spacer 
Melting 
Point (°C) 
Recrystalliz. 
solvent 
Yield 
(%) 
3c Bis-3-Br-4-OCH2OCH3 
O
 121-123 methanol 90.3 
3d Bis-3,5-di-Br-4-OCH2OCH3 
O
 140-142 methanol 88.2 
3g Bis-4-OCH2OCH3 
O
 84-86 cyclohex/benz 95.0 
3h Bis-2-Br-4- OCH2OCH3 
O
 133-135 methanol 74.0 
3i Bis-2,6-di-Br-4-OCH2OCH3 
O
 138-140 methanol 76.7 
3l Bis-3-NO2-4- OCH2OCH3 
O
 154-156 methanol 83.5 
3m Bis-3-F-4- OCH2OCH3 
O
 90-92 methanol 95.0 
3n 
Bis-3,5-di-
CH3-4- 
OCH2OCH3 
O
 101-103 methanol 93.0 
 3q Bis-3-Br-4- OCH2OCH3 
O O
 
78-80 cyclohexane 64.0 
3r Bis-3,5-di-Br-4-OCH2OCH3 
O O
90-92 cyclohexane 60.3 
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3s Bis-3-Br-4- OCH2OCH3 
O
 
116-118 methanol 93.2 
3t Bis-3,5-di-Br-4-OCH2OCH3 
O
 
155-157 methanol 86.8 
3u Bis-4-OCH2OCH3 
O
 
171-173 methanol 95.4 
3v Bis-3-Br-4- OCH2OCH3 O
O
 
162-164 methanol 87.6 
3w Bis-3,5-di-Br-4-OCH2OCH3 
O
O
 
164-166 methanol 84.0 
3x 
Bis-4-
OCH2OCH3 
O
O
 
174-176 methanol 95.6 
3y Bis-3-Br-4- OCH2OCH3 S
O
 
150-152 methanol 93.7 
3z Bis-3,5-di-Br-4-OCH2OCH3 S
O
 
162-164 methanol 88.5 
3a’ Bis-3-Br-4- OCH2OCH3 N
O
CH3  
184-186 methanol 96.4 
3b’ Bis-3,5-di-Br-4-OCH2OCH3 N
O
CH3
166-168 methanol 86.8 
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3c’ 
3,5-di-Br-4- 
OCH2OCH3,  
3-Br-4- 
OCH2OCH3 
N
O
CH3  
182-184 methanol 84.3 
3d’ Bis-3-Br-4- OCH2OCH3 N
O
Bz  
164-166 methanol 75.7 
3e’ Bis-3,5-di-Br-4-OCH2OCH3 N
O
Bz  
178-180 methanol 64.5 
3f’ Bis-3-Br-4- OCH2OCH3 
OO
 
174-176 methanol 73.0 
3g’ Bis-3,5-di-Br-4-OCH2OCH3 
OO
 
179-181 methanol 76.7 
3h’ Bis-4-OCH2OCH3 
OO
 
166-168 methanol 79.8 
3i’ Bis-3-Br-4- OCH2OCH3 
O
O
 
182-184 methanol 67.4 
3j’ Bis-3,5-di-Br-4-OCH2OCH3 
O
O
189-191 methanol 62.3 
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3k’ Bis-4-OCH2OCH3 
O
O
 
197-199 methanol 76.7 
3l’ Bis-3,5-di-Br-4-OCH2OCH3 
O
N
H
H
N
O  
174-176 methanol 96.5 
3m’ Bis-3,5-di-Br-4-OCH2OCH3 
O
N
H
N
H
O
 
150-152 methanol 94.3 
3n’ Bis-3,5-di-Br-4-OCH2OCH3 
O
N
H
H
N
O
126-128 methanol 89.0 
3o’ Bis-3,5-di-Br-4-OCH3 NH
O
N
H
O
 
248-250 methanol 92.0 
3p’ Bis-3,5-di-Br-4-OCH3 
H
N
N
H
O
O
 
>250 methanol 76.4 
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      Table 30. Chemical and physical data of the compound 2a-h. 
 
 
 
20.2. Experimental Section. 
Chemistry. Melting points were determined on a Büchi 530 melting point apparatus and are 
uncorrected. Infrared (IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One 
instrument. 1H NMR spectra were recorded at 200 MHz on a Bruker AC 200 spectrometer; 
chemical shifts are reported in δ (ppm) units relative to the internal reference 
tetramethylsilane (Me4Si). All compounds were routinely checked by TLC and 1H NMR. 
TLC was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light. All solvents were reagent grade and, when necessary, 
were purified and dried by standards methods. Concentration of solutions after reactions and 
extractions involved the use of a rotary evaporator operating at a reduced pressure of ca. 20 
Torr. Organic solutions were dried over anhydrous sodium sulfate. Analytical results are 
within ±0.40% of the theoretical values.  
Compounds R 
Melting 
Point (°C) 
Recrystallizzation 
solvent Yield (%) 
2a 3-Br 72-74 cyclohexane 98.0 
2b 3,5-di-Br 66-68 cyclohexane 94.0 
2c 2-Br 62-64 cyclohexane 89.4 
2d 2,6-di-Br 96-98 cyclohexane 25.6 
2e H oil - 100.0 
2f 3,5-di-CH3 oil - 100.0 
2g 3-F oil - 96.7 
2h 3-NO2 95-97 cyclohexane 98.0 
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All chemicals were purchased from Aldrich Chimica, Milan (Italy) or Lancaster Synthesis 
GmbH, Milan (Italy) and were of the highest purity. 
 
General Procedure for the Synthesis of 4-(Methoxymethoxy)benzaldehydes (2a-h) and of 
1,3-dibromo-5-(methoxymethoxy)benzene. Example: 3,5-Dibromo-4-
(methoxymethoxy)benzaldehyde (1b). 
To a suspension of sodium hydride in mineral oil 60% (14.3 mmol, 572 mg) in anhydrous 
tetrahydrofuran (20 mL) at 0 °C (ice bath), 3,5-dibromo-4-hydroxybenzaldehyde (7.15 mmol, 
2 g) was slowly added and the resulting mixture was stirred for 30 min. Then, a solution of 
bromomethyl(methyl)ether (14.3 mmol, 1.17 mL ) in anhydrous tetrahydrofuran (5 mL) was 
added dropwise at 0 °C, and the mixture was stirred for further 30 min. The reaction was 
quenced with water (30 mL) and extracted with diethyl ether (3 × 50 mL). The organic phases 
were washed with 2 N sodium hydroxide (3 × 50 mL) and sodium chloride (3 × 50 mL), and 
dried with sodium sulfate. The residual oil was purified by column chromatography on silica 
gel by eluting with a 1:5 mixture of ethyl acetate and chloroform to furnish the pure product 
2b as a solid. 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 9.86 (s, 1H), 8.04 (s, 2H), 5.28 (s, 2H), 
3.72 (s, 3H). 
 
Synthesis of 2,6-dibromo-4-(methoxymethoxy)benzaldehyde (2d). 
A 2 M solution of lithium diisopropylamide (LDA) in heptane/THF/ethylbenzene (14.87 
mmol, 7.43 mL) was added dropwise (ca. 15 min) to a solution of 1,3-dibromo-5-
(methoxymethoxy)benzene  (7.43 mmol, 2.2 g) in anhydrous THF (20 mL) cooled to –80 °C. 
The resultant solution was stirred for 15 min, then anhydrous N,N-dimethylformamide (DMF, 
14.87 mmol, 1.15 mL) was slowly added. The mixture was stirred for additional 30 min and 
then the reaction was quenched with water (30 mL) and extracted with diethyl ether (3 × 50 
mL). The collected organic phases were washed with sodium chloride (3 × 50 mL) and dried 
with sodium sulfate. Evaporation of solvent afforded a mixture of 1,4-dibromo-6-
(methoxymethoxy)benzaldehyde  and 2,6-dibromo-4-(methoxymethoxy)benzaldehyde (2d), 
which were separated by column chromatography on silica gel by eluting with ethyl acetate:n-
hexane 1:10. For 2d: 1H NMR (CDCl3, 400 MHz, δ; ppm) δ 10.22 (s, 1H), 7.34 (s, 2H), 5.22 
(s, 2H), 3.49 (s, 3H). 
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General Procedure for the Synthesis of the compounds 3a-k’. Example: 1,5-Bis-(4-
(methoxymethoxy)-3-nitrophenyl)penta-1,4-dien-3-one (3l). 
To a suspension of barium hydroxide octahydrate (6.62 mmol, 2.08 g) in methanol (20 mL) 2-
propanone (1.65 mmol, 0.12 mL) was added, and the mixture was stirred for 5 min. Then a 
solution of 4-(methoxymethoxy)-3-nitrobenzaldehyde 2h (3.31 mmol, 0.7 g) in methanol (10 
mL) was added, and the resultant mixture was stirred for 2 h at room temperature. The 
precipitate was filtered, washed with water, and dried to afford the pure product 3l. 1H NMR 
(DMSO-d6, 400 MHz, δ; ppm) δ 8.32 (s, 2H), 8.03 (d, 2H), 7.77 (d, 2H), 7.47 (d, 2H), 7.34 
(d, 2H), 5.42 (s, 4H), 3.49 (s, 6H). 
 
General Procedure for the Synthesis of the compounds 1a-m’.  Example: 3,5-Bis-(3-
bromo-4-hydroxy-benzylidene)-1-methyl-piperidin-4-one (1c’).  
A 3 N hydrochloric acid solution (5mL) was added to a solution of 3,5-Bis-(3-bromo-4-
methoxymethoxy-benzylidene)-1-methyl-piperidin-4-one 3a’ (0.53 mmol, 0.3 g) in methanol 
(5 mL), and the resulting mixture was refluxed for 3 h. The reaction was cooled at room 
temperature, then the precipitate was filtered, washed with water and dried to afford the pure 
product 1c’. 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 11.22 (s, 2H), 7.73 (d, 4H), 7.39 (s, 
2H), 7.13 (s, 2H), 4.60 (s, 4H), 2.98 (s, 3H). 
 
Synthesis of 3,5-di-Br-4-methoxymethoxybenzoic acid. 
To a suspension of sodium hydride in mineral oil 60% ( 9.67 mmol, 0.387 g) in anhydrous 
tetrahydrofuran (20 ml) cooled to 0°C slowly methyl-3,5-dibromo-4-hydroxy-benzoate ( 6.45 
mmol, 2 g) was added and resulting mixture was stirred for 30 min. Then a solution of 
bromomethylmethylether (9.67 mmol, 0.79 mL) in anhydrous tetrahydrofuran (5 ml) was 
added dropwise at 0°C and the mixture was stirred for 30 min. The reaction was quenced by 
water (30 ml) and extracted with diethyl ether (3x50 ml). The organic layers were washed 
with a solution of sodium hydroxide 2N (3x50 ml) before and with a solution of sodium 
chloride (3x50 ml) and finally dried with sodium sulfate. The crude product was eluted with 
methanol and hydrolyzed with 2N KOH ( 12.43 mmol, 0.697 g) to afford the pure product as 
a white solid. 
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General procedure for the synthesis of  the N,N’-[bis-(3,5-di-Br-4-methoxymethoxy-
alkylen-benzamides)] (3l’-n’). Example: synthesis of N,N’-[bis-(3,5-di-Br-4-
methoxymethoxy-ethylen-benzamide)] (3l’). 
Ethyl chloroformate (2.93 mmol, 0.28 mL) and triethylamine (3.17 mmol, 0.45 mL) were 
added to a cooled (0°C) solution of 3,5-di-Br-4-methoxymethoxybenzoic acid (2.44 mmol, 
0.83 g) in dry THF (10 mL), and the mixture was stirred for 10 min. The solid was filtered 
off, and ethylendiamine (1.22 mmol, 0.082 mL) was added to the filtrate. The solution was 
stirred for 15 min at 0°C, evaporated under decreased pressure to afford pure product 3l as a 
white solid. 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 8.55 (s, 2H), 8.09 (s, 4H), 5.18 (s, 4H), 
3.59 (s, 6H), 3.36 (s, 4H). 
 
General procedure for the synthesis of the N,N’-[bis-(3,5-di-Br-4-hydroxy-alkylen-
benzamides)] (1l’-n’).  Example: synthesis of N,N’-[bis-(3,5-di-Br-4- hydroxy-propylen-
benzamide)] (1m’). 
To a solution of N,N’-[bis-(3,5-di-Br-4-methoxymethoxy-propylen-benzamide)] (3m’)(0.70 
mmol, 0.5 g) in methanol (10 mL) 3N HCl solution was added and the resulting mixture was 
stirred at 60°C for 1h. The solvent was evaporated and the solid residue was washed with 
water and dried to furnish the pure product 1m’. 1H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 
10.5 (s, 2H), 8.55 (s, 2H), 8.00 (s, 4H), 3.31 (s, 4H). 
 
General procedure for the synthesis of  the N,N’- phenylen-[bis-(3,5-di-Br-4-methoxy-
benzamides)] (3o’, 3p’). Example: synthesis of N,N’-1,3-phenylen-[bis-(3,5-di-Br-4- 
methoxy-benzamide)] (3o’). 
3,5-di-Br-4-methoxybenzoic acid (2.58 mmol, 0.8 g) was eluted with thionyl chloride and 
refluxed for 1h. Then the solution was concentrated on vacuum, eluted with tetrahydrofuran 
(10 mL) and added dropwise to a cooled (0°C) solution of 1,3-phenylendiamine (1.29 mmol, 
0.139 g), triethylamine (3.87 mmol, 0.54 mL) and the resulting mixture was stirred for 30 
min. The suspension was concentrated on vacuum, eluted with water (50 mL) and the 
precipitated solid was filtered and finally dried to afford pure 3o’. 1H NMR (DMSO-d6, 400 
MHz, δ; ppm) δ 10.70 (s, 2H), 10.24 (s, 2H), 8.25 (s, 1H), 8.19 (s, 4H), 7.45 (d, 2H), 7.30 (m, 
1H), 3.70 (s, 6H). 
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General procedure for the synthesis of  the N,N’- phenylen [bis-(3,5-di-Br-4-hydroxy- 
benzamides)] (1o’, 1p’). Example: synthesis of N,N’-1,3-phenylen-[bis-(3,5-di-Br-4- 
methoxy-benzamide)] (1o’). 
To a suspension of diether 3o’( 0.29 mmol, 0.2 g) in methylene chloride (5 mL) cooled at -
78°C a BBr3 solution in methylene chloride (5 mL) was slowly added. The reaction mixture, 
which immediately became clear, was allowed to warm to room temperature and was stirred 
for 5h. Water (30 mL) was added to quench the reaction. The off-solid that formed was 
removed by filtration to afford diphenol 1o’ as a white solid. 1H NMR (DMSO-d6, 400 MHz, 
δ; ppm) δ 10.70 (s, 2H), 10.24 (s, 2H), 8.25 (s, 1H), 8.19 (s, 4H), 7.45 (d, 2H), 7.30 (m, 1H). 
 
General procedure for the synthesis of  the compounds 1s’-x’. Example: synthesis of  
N,N'-Bis-(3,5-dibromo-4-hydroxy-phenyl)-isophthalamide 1w’. 
To a cooled (0°C) solution of 4-Amino-2,6-dibromo-phenol (3.75 mmol, 1g) and  
triethylamine (5.61 mmol, 0.78 mL) in tetrahydrofuran (10 mL) isophtaloyl dichloride (1.87 
mmol, 0.38g), eluted in tetrahydrofuran (10 mL), was slowly added. The reaction mixture was 
stirred for 1h, then the solvent was distilled on vacuum and the solid residue was washed with 
HCl 2N, then with water (50 mL) and at last dried to afford pure product 1w’. 1H NMR 
(DMSO-d6, 400 MHz, δ; ppm) δ 11.0 (s, 2H), 10.39 (s, 2H), 8.50 (s, 1H), 8.10 (d, 2H), 7.98 
(s, 4H), 7.67 (m, 1H). 
 
Synthesis of  the 1,7-Bis-(3-bromo-4-hydroxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one 
(1o) and 1,7-Bis-(3,5-di-bromo-4-hydroxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one 
(1p). Example: synthesis of  1,7-Bis-(3,5-di-bromo-4-hydroxy-phenyl)-5-hydroxy-hepta-
1,4,6-trien-3-one (1p). 
2,4-pentanedione (4.97 mmol, 0.51 mL) and boric anhydride (3.48 mmol, 0.24 g) were 
dissolved in EtOAc (15 mL). The solution was stirred at 70°C for 30 min. 3-bromo-4-
hydroxybenzaldehyde (9.95 mmol, 2 g) and tributyl borate (9.95 mmol, 2.68 mL) were added. 
After stirring for 30 min, butylamine (7.45 mmol, 0.73 mL) dissolved in 4 mL of EtOAc was 
added dropwise over 15 min. The stirring continued for 5 h at 85°C. The mixture was then 
hydrolyzed by adding 1 N HCl (8 mL) and stirring for 30 min at 60°C. The organic layer was 
separated, and the aqueous layer was extracted with EtOAc. The combined organic layers 
were washed until neutral and dried over anhydrous sodium sulfate. The solvent was removed 
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in vacuo, and the crude product was purified by column chromatography eluting with hexane-
EtOAc 1:1 to give the pure product (1o) as an orange solid. 1H NMR (DMSO-d6, 400 MHz, δ; 
ppm) δ 10.48 (s, 2H), 7.96 (s, 4H), 7.49 (d, 2H), 6.95 (d, 2H), 6.00 (s, 1H). 
 
20.3. Biological evaluation. 
Compounds 1a-x’ were tested against RmtA, an arginine methyltransferase from Aspergillus 
nidulans with significant sequence homology to human PRMT1 and specific for methylation 
at Arg3 of H4.13 Histones H4 were used as substrate. The results have been reported as 
percent of inhibition at a fixed dose and IC50 (50% inhibitory concentration) values (Table 
30). 
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                Table 30. Inhibiting activity of the new HMT inhibitors against RmtA.a 
 
Compounds R1, R2 Spacer RmtA (µM) 
1a 3-Br - 
No 
inhibition at 
73 µM 
1b 3,5-di-Br - 
No 
inhibition at 
73 µM 
1c Bis-3-Br-4-OH 
O
 162 
1d Bis-3,5-di-Br-4-OH 
O
 69 
1e 
3-Br-4-OH, 
3,5-di-Br-4-
OH 
O
 40 
1f Bis-3-Br 
O
 
Inactive up 
to 90 µM 
1g Bis-4-OH 
O
 
Inactive up 
to 90 µM 
1h Bis-2-Br-4-OH 
O
 114 
1i Bis-2,6-di-Br-4-OH 
O
 215 
1j Bis-3-Br-4-OCH3 
O
 
Inactive up 
to 90 µM 
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 1k Bis-3,5-di-Br-4-OCH3 
O
 
Inactive up 
to 90 µM 
1l Bis-3-NO2-4-OH 
O
 249 
1m Bis-3-F-4-OH
O
 
No 
inhibition at 
28.3 µM 
1n Bis-3,5-di-CH3-4-OH 
O
 206 
1o Bis-3-Br-4-OH 
O OH
  
1p Bis-3,5-di-Br-4-OH 
O OH
 48 µM 
1q Bis-3-Br-4-OH 
O O
 
no inhib. at   
91,8 µM 
1r Bis-3,5-di-Br-4-OH 
O O
 
no inhib. 
at 13,0 µM 
1s Bis-3-Br-4-OH 
O
 
90 µM 
1t Bis-3,5-di-Br-4-OH 
O
 
14 µM 
1u Bis-4-OH 
O
 
no inhib. at 
27,7 µM 
1v Bis-3-Br-4-OCH3 
O
Inactive up 
to 90 µM 
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1w Bis-3,5-di-Br-4-OCH3 
O
 
Inactive up 
to 90 µM 
1x Bis-3-Br-4-OH 
O
O
 
132 µM 
1y Bis-3,5-di-Br-4-OH 
O
O
 
29 µM 
1z Bis-4-OH 
O
O
 
no inhib. at 
27,5 µM 
1a’ Bis-3-Br-4-OH 
S
O
 
No 
inhibition at 
17.7 µM 
1b’ Bis-3,5-di-Br-4-OH 
S
O
 
45 µM 
1c’ Bis-3-Br-4-OH N
O
CH3  
no inhib. 
at 17,7 µM 
1d’ Bis-3,5-di-Br-4-OH N
O
CH3  
39 µM 
1e’ 
3,5-di-Br-4-
OH, 3-Br-4-
OH N
O
CH3
no inhib. at 
15,2 µM 
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1f’ Bis-3-Br-4-OH N
O
Bz  
No 
inhibition at 
15.4 µM 
1g’ Bis-3,5-di-Br-4-OH N
O
Bz  
210 µM 
1h’ Bis-3-Br-4-OH 
OO
 
59 µM 
1i’ Bis-3,5-di-Br-4-OH 
OO
 
10 µM 
1j’ Bis-4-OH 
OO
 
no inhib. at 
22,9 µM 
1k’ Bis-3-Br-4-OH 
O
O
 
47 µM 
1l’ Bis-3,5-di-Br-4-OH 
O
O
 
37 µM 
1m’ Bis-4-OH 
O
O
 
no inhib. at 
22,9 µM 
1n’ Bis-3,5-di-Br-4-OH 
O
N
H
H
N
O
no inhib. at 
13,8 µM 
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1o’ Bis-3,5-di-Br-4-OH 
O
N
H
N
H
O
 
no inhib. 
at 13.6 µM 
1p’ Bis-3,5-di-Br-4-OH 
O
N
H
H
N
O  
616 µM 
1q’ Bis-3,5-di-Br-4-OH NH
O
N
H
O
 
no inhib. at 
13,8 µM 
1r’ Bis-3,5-di-Br-4-OH 
H
N
N
H
O
O
 
no inhib. at 
13,8 µM 
1s’ Bis-3,5-di-Br-4-OH O
O
N
H
H
N
 
32,6 µM 
1t’ Bis-3,5-di-Br-4-OH 
O
N
H
N
H
O
 
no inhib. at 
14,2 µM 
1u’ Bis-3,5-di-Br-4-OH 
H
NN
H
O
O  
no inhib. at 
13,8 µM 
1v’ Bis-3,5-di-Br-4-OH NH
O
N
H
O
 
no inhib. at 
13,8 µM 
1w’ Bis-3,5-di-Br-4-OH 
O
N
H
O
N
H  
13,8 µM 
1x’ Bis-3,5-di-Br-4-OH 
O
N
H
O
H
N
 
no inhib. at 
12,8 µM 
 aData represent mean values of at least three separate experiments. 
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RmtA from A. nidulans showed high homology to human PRMT1 and is specific for Arg3 of 
H4 methylation. To acquire information on their effect and selectivity on human PRMTs and 
HKMTs, compounds 1a-x’ have been tested at 100 µM against human recombinant PRMT1 
using the Saccharomyces cerevisiae RNA-binding protein Npl3p as a substrate, against 
human recombinant CARM1/PRMT4 using poly(A)binding protein 1 (PABP1) as a substrate, 
and against the lysine methyltransferase SET7 with histones H3 as a substrate (Figure 49 and 
50).  
 
Top panels. 
 
Figure 49 (a). Fluorographs. Inhibition assay against PRMT1, CARM1, SET7 at 100 µM 
concentration of each of the compounds. 
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Figure 49 (b). Fluorographs. Inhibition assay against PRMT1, CARM1, SET7 at 100  µM 
concentration of each of the compounds. 
 
 
 
Figure 49 (c). Fluorographs. Inhibition assay against PRMT1, CARM1, SET7 at 100  
µM concentration of each of the compounds. 
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               Bottom panel. 
 
 
Figure 50. Grafic depiction. Inhibition assay expressed in percentual   
decrease of the enzyme activity  at 100 µM concentration of each of the 
compounds. 
 
 
 
20.3.1. Preparation of GST-RmtA Fusion Proteins.  
The coding sequence of RmtA was cloned into a pGEX-5X-1 expression vector (Amersham 
Pharmacia Biotech). RmtA-Protein was expressed in BL21 cells in LB-medium. 250 mL 
cultures with an A600 of 0.4 were induced with a final concentration of 1mM IPTG and grown 
for 4h at 37 °C. After centrifugation of cells at 4000g, the pellet was resuspended in 6 mL of 
GST-binding buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7.3) containing one protease inhibitor tablet (Complete, Roche, Mannheim, Germany) for 50 
mL of buffer. For cell lysis, lysozyme was added at a final concentration of 5 mg/mL binding 
buffer and cells were passed through a french press with pressure setting of 1000 psi. The 
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resulting lysate was centrifuged at 20000g for 10 min at 4 °C. GST fusion protein was 
purified from soluble extracts by binding to a GST-HiTrap column (Amersham Pharmacia 
Biotech). Proteins were eluted with 50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0 and 
assayed for histone methyltransferase activity. 
20.3.2. RmtA Inhibitory assay.  
For inhibition assays, affinity purified GST-RmtA fusion proteins were used as enzyme 
source. HMT activities were assayed using chicken erythrocyte core histones as substrate. 500 
ng of GST-RmtA fusion proteins were incubated with different concentrations of compounds 
for 15 min at room temperature and 20 µg of chicken core histones and 0.55 µCi of [3H]-S-
adenosyl-L-methionine (SAM) were added. This mixture was incubated for 30 min at 30 °C. 
Reaction was stopped by TCA precipitation (25% final concentration) and samples were kept 
on ice for 20 min. Whole sample volumes were collected onto glass fibre filter (Whatman 
GF/F) preincubated with 25% TCA. Filters were washed three times with 3 mL of 25% TCA 
and then three times with 1 mL of ethanol. After drying the filters for 10 min at 70 °C, 
radioactivity was measured by liquid scintillation spectrophotometry (3 mL scintillation 
cocktail). 
20.3.3. PRMT1, CARM1/PRMT4, and SET7 Inhibitory Assay.  
In vitro methylation reactions have been described in detail previously.359 Briefly, all 
methylation reactions were carried out in the presence of S-adenosyl-L-[methyl-
3H]methionine([3H]AdoMet, 79 Ci/mmol from a 12.6 µM stock solution in dilute HCl/ethanol 
9:1, pH 2.0–2.5, Amersham Biosciences) and PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4, pH 7.4). To determine the specificity of the small molecules, 
compounds were incubated with GST-PRMT1 and Npl3p, GST-PRMT4 and PABP1, GST-
SET7 and histone H3, respectively. Substrates (0.5 µg) were incubated with recombinant 
enzymes (0.2 µg) in the presence of 0.5 µM [3H]AdoMet and 100 µM concentration of each 
of the compound for 90 min at 30 °C in a final volume of 30 µL PBS. Reactions were run on 
a 10% SDS-PAGE, transferred to a PVDF membrane, sprayed with EnhanceTM, and exposed 
to film overnight. The fluorographs are shown in the top panels, and the quantification of the 
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methylation levels is depicted in the bottom panel. Reactions were performed in the presence 
of Me2SO at 3.3% v/v.  
 
20.4. Docking study of the compounds 1c, 1d and 1k. 
In order to elucidate the binding possibilities of selected HMT inhibitors, compounds 1c 
(PRMTs-selective), 1d (no selective), and 1k (CARM1-selective) were docked (Autodock 
program)360 into the crystal structures of PRMT1361 and SET7,362 and into the modeled 
structures of RmtA and CARM1. The analysis of the Autodock-proposed binding modes for 
1c, 1d, 1k revealed that the compounds are able to bind in the S-adenosylmethionine (SAM) 
or in the Arg/Lys substrate binding sites (Figure 51).  
 
 
Figure 51. Compounds 1c (magenta), 1d (blue), and 1k (green) docked into PRMT1 (A), 
CARM1 (B) and SET7 (C). The Arg/Lys and SAM binding sites are represented in red and 
yellow, respectively. The enzymes residues within 5.0 Å from the substrates are reported in 
white wire. For the sake of clarity hydrogen atoms are not displayed. 
 
The 1c, 1d, 1k inhibition constants (pKis) calculated by the Autodock internal scoring 
function largely agree with the experimental values. Although the absolute values are by far 
overestimated, the overall inhibition selectivity trend is respected. Thus, 1c was calculated to 
be more active against PRMTs (PRMT1, CARM1, and RmtA) than against SET7, 1d was 
predicted to be no selective, and 1k was predicted to be slightly selective for CARM1. 
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20.4.1. Molecular Docking.  
All the tested molecules were built, starting from ASCII text, using the stand alone version of 
PRODRG, in conjunction with the GROMACS suite. The docking studies were performed by 
means of the Autodock 3.0.5 program using a grid spacing of 0.375 Å and 39 × 50 × 56 
number of points that embraced both the SAM and Arg/Lys binding sites. The grid was 
centred on the mass centre of the experimental bound SAM and Arg substrates. The GA-LS 
method was adopted using the default setting except for the maximum number of energy 
evaluations that was set to 2500000. Autodock generated 100 possible binding conformations 
for each molecule that were clustered using a tolerance of 2.0 Å. The AutoDockTool (ADT) 
graphical interface was used to prepare the enzyme PDBQS file. The protein atom charges as 
calculated during the complex minimization were retained for the docking calculations. To 
analyze the docking results the ADT was used and the Chimera 1.2176 program was used to 
produce the images. 
20.5. Results and discussion. 
As depicted in Figure 49 and 50 the 1,5-bis(3-bromo-4-hydroxyphenyl)penta-1,4-dien-3-one 
1c was highly efficient and selective in inhibiting PRMTs, while it was ineffective against the 
HKMT SET7. The introduction of further bromine atoms at 5,5' or just at the 5 position 
(compound 1d or 1e) increased the inhibiting power of the derivatives but abated the 
selectivity. By shifting the bromine from C3- to C2-benzene position an inactive compound 
(1h) was obtained. Nevertheless, the introduction of bromine atoms at both 2,6 and 2',6' 
positions gave a further molecule (1i) which was highly active and selective against PRMTs. 
The 1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one 1g and the 1,5-bis(3-bromophenyl)penta-
1,4-dien-3-one 1f were ineffective in inhibiting all the tested HMTs. The replacement of the 
4-hydroxy group of 1c with the 4-methoxy one (compound 1j) gave similar results. 
Interestingly, the bis(3,5-dibromo-4- methoxy) analogue 1k behaved as a very potent and 
selective CARM1/PRMT4 inhibitor (84% inhibition). The replacement of 3-bromo with 3,5-
dimethyl or 3-fluoro substituent (compounds 1n and 1m) furnished inactive derivatives, while 
the 1,5-bis(3-nitro-4-hydroxyphenyl) penta-1,4-dien-3-one 1l showed high activity and 
selectivity against CARM1/PRMT4 (80% inhibition). Finally, the monomer 4-(3,5-dibromo-
4-hydroxyphenyl)but-3-en-2-one 1b failed in inhibiting all the tested enzymes. 
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After this study we replaced the “ketonic spacer group” with others to evaluate its importance 
in the pharmacophore model. 
All the ketonic spacer groups, except N-benzyl-4-piperidone, were tolerated, but the most 
functional were represented by cyclohexanone (compound 1t) and 1,3-diacetylbenzene 
(compound 1i’), both bis 3,5-di-bromo substituted. These compounds were the most potent 
against RmtA, in fact endowed with IC50 : 14 µM (1t) and 10 µM (1i’), but also against 
PRMT1, PRMT4 (CARM 1) and SET7, yet didn’ t show enzyme selectivity. 
So we reported the first synthetic HMT (PRMT1, CARM1 and SET7) inhibitors obtaining the 
satisfactory results, yet further synthetic and biological studies are underway on both the 
pharmacophore motif and the linker moiety that connects the two phenyl rings. 
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